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Polyketides are a class of secondary metabolites that are notable for their 
chemical diversity and therapeutic relevance. They are biosynthesized by polyketide 
synthases (PKSs) megasynthase enzymes in an assembly-line fashion. Though the 
molecular architectures of polyketides are complex, their biological precursors are 
chemically simple. Thus, understanding this powerful biosynthetic machinery is of 
interest for synthetic biology and biocatalytic applications. This dissertation presents 
three projects that decipher underlying mechanistic features and explore biocatalytic 
applications of PKSs.  
In modular PKSs, one module corresponds to one round of keto-elongation 
followed by modification through the action of β-carbon processing domains. The first 
project employs a system wherein a single module is used in vitro to generate small, 
chiral PKS products (triketide lactones). Although triketide lactones are a common output 
for PKS enzymology assays, usually they are only observed in trace quantities. In this 
study, we performed a number of strategies to scale up the production of triketide 
lactones to facilitate their use as chiral building blocks for chemical synthesis. In this 
process, we also gained new insights regarding the interacting kinetics and selectivities of 
the domains in an in vitro environment. 
 ix 
The second project focused on the ketoreductase (KR) domain, which sets the 
majority of the stereogenic centers within a polyketide, and thus has obvious potential for 
biocatalytic applications. This project employs a structure-activity relationship (SAR)-
type approach to dissecting stereocontrol. The SAR results, in concert with 
crystallographic data inspired two rational mutations that were sufficient to reverse the 
stereoselectivity of a representative KR. Thus, we were able to employ a rational 
approach to engineering stereocontrol. 
The final project also focuses on the KR domain, however from a subclass of 
PKSs termed trans-acyltranferase (AT) PKSs. In contrast to the canonical cis-AT PKSs, 
the trans-AT PKSs have more varied modular organizations and architectures. One of 
these peculiar organizations one termed a “split” bimodule, wherein domains within a 
module are present on different polypeptides. Structural characterization of a KR from a 
split bimodule revealed features that may correspond to interpeptide interactions that 
afford communication between the two polypeptides of the split bimodule. Additionally, 
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Chapter 1: Introduction 
OVERVIEW 
This dissertation describes three projects related to the overarching theme of 
dissecting mechanistic features of modular polyketide synthases (PKSs) and, in turn, 
harnessing PKSs for biocatalytic applications. The first project examines a miniaturized 
model system that generates small, chiral PKS fragments, termed triketide lactones 
(Chapter 2).[1] The second project focuses on the mechanistic details of an individual 
domain, the ketoreductase domain, which sets two stereogenic centers during an 
enzymatic reduction (Chapter 3). The third project also focuses on the ketoreductase 
domain, however in the context of an unusual (and largely uncharacterized) class of 
modular polyketide synthases, the trans-ATs (Chapter 4). An additional project 
unrelated to the main doctoral work is described in Chapter 5.[2] 
POLYKETIDE SECONDARY METABOLITES AND POLYKETIDE SYNTHASES 
Polyketides comprise a diverse class of natural products with varied and 
intriguing carbon skeletons that are known for their pharmaceutical relevance.[3,4] 
Although (in most cases) their exact physiological roles are unknown, it is believed that 
they frequently function as pigments, virulence factors, signaling molecules, or as a form 
of defense against competing organisms.[3] Regardless of their evolutionary function, 
polyketides have been fruitful for drug discovery efforts: the “hit rate” for polyketide 
natural products has been estimated to be ~0.3%, which is far superior to the typical “hit 
rate” of <0.001% for a standard synthetic compound library.[4] As medicinal entities, they 
are primarily used as antibiotics, antifungals, immunosuppressants, antitumoral agents, 




Figure 1.1 Selected pharmaceutically relevant polyketides. 
Due to the stereochemical complexity of many polyketides, members of this class 
of natural products have historically been vibrant targets for developing and showcasing 






























































polyketide, erythromycin A “looks at the present time quite hopelessly complex, 
particularly in view of its plethora of asymmetric centers.”[10] In a pioneering effort, his 
group reported the first enantioselective total synthesis of the macrolide in 1981.[11] 
Nonetheless, Woodward’s comment illustrates the inspirational role of polyketide 
scaffolds in the development of asymmetric C-C bond formation strategies. In stark 
contrast to their molecular complexity, the biological precursors of polyketides are 
remarkably simple: they are typically acetate or propionate-derived building blocks. 
Polyketides are biosynthesized by polyketide synthases (PKSs), which are multidomain 
megasynthases that assemble polyketides in an assembly-line fashion. PKSs select an 
extender unit (typically malonyl- or methylmalonyl-CoA) with an acyltranferase (AT) 
domain, which then undergoes a decarboxylative Claisen-like condensation through the 
action of a ketosynthase (KS) domain. Subsequently, the keto group may be processed by 
optional β-carbon processing domains which include: 1) the ketoreductase (KR), which 
reduces the keto group to a hydroxy moiety, 2) the dehydratase (DH), which can 
dehydrate the hydroxy moiety to form an olefin, and 3) the enoylreductase (ER), which 
results in a fully saturated carbon backbone. Finally, the polyketide is either cyclized or 
hydrolyzed through the action of a thioesterase (TE) domain. Throughout this process, 
the elongating chain is anchored on acyl carrier proteins (ACPs), which are tethered to 
the intermediate through an 18Å phosphopantetheinyl prosthetic group.i Following the 
action of the PKS, the carbon scaffold is usually decorated by post-PKS tailoring 
enzymes (i.e. oxidations, glycoylations, etc.)[3,12–14] A useful attribute of modular 
polyketide synthases is the principle of “colinearity,” or the one-to-one correspondence 
                                                
i Additionally, some polyketides contain a methyltransferase (MT) domain, which can introduce α 
branching when malonyl-CoA is used as the extender unit. 
4 
between gene sequence and metabolite structure.ii This relationship affords a priori 
predictions of the metabolite structures via their enzyme architectures (i.e. the domains 
present within the module;[3,12] consider 6-dEB biosynthesis,[13] Figure 1.2). Thus the 
colinearity principle has obvious implications for the rational reprogramming of their 
biosynthetic pathways for synthetic biology purposes. 
 
Figure 1.2  Biosynthetic pathway for 6-deoxyerythronolide B (6-dEB), the agylcone 
precursor to the polyketide antibiotic, erythromycin.  
MECHANISTIC FEATURES OF PKS CATALYTIC DOMAINS 
The colinearity principle can be taken one step further: in addition to predicting 
the connectivity and degree of reductive processing that the metabolite undergoes, 
examination of the protein sequence often provides “fingerprints,” or diagnostic residues 
that correlate to enzymatic selectivities (including stereochemical outcomes; Scheme 
1.1).[14] The first stereospecific step in PKS biosynthesis is often through the selection of 
                                                
ii This review discusses modular type I polyketides. Other subtypes of polyketides exist, including type II 
polyketides (where the domains are present on separate polypeptides[109,110]), and type III polyketides 
(which lack ACPs and instead have CoA-linked intermediates).[111,112] 











































Module 1 Module 2 Module 3
Module 4















the extender unit by the AT domain. The AT domain possesses an ~240 residue catalytic 
subdomain with an α/β hydrolase fold. Its active site consists of a serine, activated by a 
histidine and a backbone carbonyl.[14] The mechanism for extender unit selection is 
through formation of an acyl-enzyme intermediate that will either be transthioesterified 
with the next ACP or hydrolyzed. Specificity arises from the respective rates of formation 
of the acyl-enzyme intermediate and the rate of transthioesterification to the ACP; the 
remaining “incorrect” extender units are then edited by AT domains’ hydrolytic 
activity.[15] Whether the AT is selective for malonyl or methylmalonyl-CoA can be 
determined by a fingerprint found ~90-100 residues C-terminal of the active site serine (a 
YASH motif for methylmalonyl-CoA and a HAFH motif for malonyl-CoA;[16] other 
motifs have been correlated to more unusual extender units, however they are less 
robust[17,18]). For AT domains that accept methylmalonyl-CoA, there is an exclusive 
preference for the 2S isomer.[19] The current model for substrate selection of the 2S isomer 
is one in which the C2 methyl forms favorable hydrophobic interactions with the tyrosine 
while being sterically accommodated by the serine. The 2R isomer is precluded by steric 




Scheme 1.1  Summary of the introduction of stereochemistry by PKSs. 
Following extender unit selection, the KS domain (when α-substitution is present) 
catalyzes the next stereospecific step. KSs have a thiolase fold,[21] and they catalyze the 
decarboxylative condensation of ACP-linked extender units. The KS active site consists 
of two histidines and a cysteine (to which the acyl group is covalently attached). Once the 
decarboxylation occurs, the nascent enolate performs a nucleophilic attack on the 
cysteine-linked thioester electrophile.[14] During the condensation process, there is an 







































































intermediate with a D-configured methyl group.[22] Often KSs serve as “gatekeeping” 
domains and prevent the condensation of incorrect polyketide intermediates.[23,24] 
 
 
Figure 1.3  Conserved fingerprints correlating to KR stereochemical outcome. Residues 
correlating with ß–hydroxy stereochemistry are shown in magenta (the LDD 
motif correlates to D-ß-hydroxyls and the conserved W correlates to L-ß-
hydroxyls). Residues are correlated with α-stereochemistry are shown in 
cyan.[25] 
The domain that confers the most stereochemical complexity in PKS systems is 
the KR domain, as they can set two sp3-stereogenic centers in a single reduction. 
Accordingly, KRs are some of the most thoroughly studied of the domains embedded 
within PKSs, and they possess some of the most robust predictive sequence fingerprints. 
KRs are a member of the short chain dehydrogenase/reductase (SDR) superfamily, and 
they are comprised of two domains, which each have a Rossman fold: an N-terminal 
structural subdomain and a C-terminal catalytic one. The catalytic subdomain harbors a 
conserved dinucleotide-binding site with consensus sequence TGGTGxLG.[26] KRs are 
classified as B-type KRs (which generate D-ß-hydroxyls), A-type KRs (which generate L-
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ß-hydroxyls),[27,28] or C-type KRs (which are reductase-incompetent).[29]iii A conserved 
tryptophan correlates to the A-type stereochemical outcome, whereas a leucine-aspartate-
aspartate (LDD motif) correlates to the B-type stereochemical outcome.[27,28] Furthermore, 
KRs that generate products with a D-α-methyl are denoted with “1” and KRs that 
generate products with an L-α-methyl are denoted as “2”; sequence motifs are also 
correlated with these stereochemical outcomes (Figure 1.3).[29] Mechanistically, KRs 
undergo reduction by NADPH with a catalytic tyrosine (which acts as a general acid) and 
a serine that aids in the stabilization of negative character on the ß oxygen during the 
reduction process.[26] 
KRs are also the best characterized of the PKS domains structurally, with ten PKS 
KR crystal structures to date (eight published).[25,30–35] Structural characterization has 
revealed that all KRs bind the NADPH cofactor in the same orientation (transferring the 
4-pro-S-hydride[36]). Thus, stereoselectivity arises from the orientation of the ß-keto 
intermediate in the KR active site. To date, there are no crystal structures of KRs where a 
substrate mimic is bound; thus all evidence for interactions between various active-site 
residues and substrates come from modeling[37] and mutagenesis studies.[32,38–40] However, 
several features have been hypothesized to influence stereocontrol. Although the exact 
role of the conserved typtophan in A-type KRs is unknown, in B-type KRs it is believed 
that the last aspartate in the LDD motif hydrogen bonds with the first amide after the 
thioester in the phosphopantetheinyl arm of the ACP, guiding the diketide to expose its si 
face to the cofactor.[25,26,34] Supporting this hypothesis, in the related SDR enzyme (an 
acetoacetyl-CoA reductase, PhaB from Ralstonia eutropha H16) such an interaction is 
                                                
iii Because during the course of biosynthesis, the Cahn-Ingold-Prelog R and S priorities of reduced 
intermediates can change, when discussing polyketide intermediates the D/L system is used. When 
discussing small molecule substrates (such as N-acetyl cysteamine β−keto thioesters), the more common 
Cahn-Ingold-Prelog system is appropriate, and is used accordingly. 
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observed between bound acetoacetyl-CoA and a homologous aspartate.[41] Additionally, 
mutagenesis experiments have implicated several residues surrounding the active 
site.[32,38,42,43]  
 
Scheme 1.2 A)  Model of KR stereocontrol with the natural substrate, the 
phosphopantethienyl arm of the ACP. B) Model of KR sterecontrol on 
substrate analogs. Reproduced with permission.[26] 
One of the more mysterious aspects of KRs is the mechanism by which they set 
α-stereocenters. KRs can be classified into non-epimerizing and epimerizing KRs 
(denoted by “1” and “2,” respectively, vide supra).[25] Early isotope-labeling studies with 
DEBS indicated that while the hydrogens geminal to D-methyl groups were propionate-
derived, the hydrogens geminal to L-methyl groups were derived from water. Subsequent 
experiments confirming this finding were performed through the incubation of DEBS1-
TE with deuterium-labeled 2S-methylmalonyl-CoA.[22] As spontaneous epimerization 
from water was determined to be too slow, and no other short-chain dehydrogenase 
enzymes are known to catalyze epimerization, it was initially hypothesized that this 
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reaction was mediated by the KS. However, in vitro reconstitution experiments did not 
link the KS to epimerization events,[44,45]  and subsequent experimental results with KR 
domains both in vitro and in vivo have established their intrinsic epimerase activity.[46,47] 
To date, the molecular basis for epimerization remains somewhat elusive, as sequence 
and structural analysis does not reveal any residues that are clearly identifiable as a 
general base.[25] However, recent studies in vivo demonstrate that epimerization can be 
influenced by the modular context of the KR.[47] A hypothesis presented by Weissman 
and coworkers to explain this phenomenon is that, perhaps, epimerase activity is 
mediated by controlling access of water to the KR active site.[47] For racemic small 
molecule substrate mimics (such as β-keto N-acetyl cysteamine thioesters), KRs are 
believed to undergo a process equivalent to dynamic kinetic resolution, wherein the KR 
stereospecifically binds and stereoselectively reduces one epimer of the racemic substrate 
(Scheme 1.2).[32,38,42] 
Geometric isomerism is introduced by the DH domain, which undergoes a syn-
coplanar elimination of the KR-installed β-hydroxy group to yield an olefin.[48–50] 
Consequently, olefins with trans configurations result from the dehydration of D-ß-
hydroxyls, whereas olefins with cis configurations result from L-ß-hydroxyls.[49,50] When 
α-substitution is present, the KRs associated with modules with harboring DHs are 
exclusively anti-selective (i.e. B1 or A2).[49] The DH domain possesses a double hot-dog 
fold, and has two catalytic active site residues: a histidine and an aspartatic acid. The 
aspartatic acid (found in the HPALLD motif) has been hypothesized to act as a general 
acid, donating a proton to the ß-hydroxy group. The catalytic histidine (found in the 
HxxxGxxxP motif) acts as a general base, abstracting the α-proton.[48,50] The active sites 
of syn- and anti-selective DH domains are remarkably similar, and indeed, some DH 
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domains perform two sequential dehydrations, one conferring cis geometry and the other 
conferring trans geometry (see Chapter 4).[51]  
Interestingly, as the DH domain performs general acid/general base-catalyzed 
chemistry, the double hot dog fold has diverged in function to perform isomerizations. 
Enzymes that are essentially structurally identical to DHs, termed enoyl isomerases (EIs), 
have been shown to shift a double bond from the α, β position to the γ, δ position.[52–55] 
Additionally, DH-like domains termed pyran synthases (PSs) have been shown to 
catalyze cyclization.[56] DH-like domains have also been hypothesized to catalyze polyene 
geometric isomerization (see Chapter 4). In general, DH-like domains that have evolved 
to perform isomerizations typically possess a sequence motif wherein the catalytic 
aspartic acid is replaced with an asparagine, or, less commonly, a histidine.[53,56,57] 
Examples of DHs that possess both pyran synthase activity and dehydratase activity also 
exist.[57,58] 
The ER domain belongs to the medium-chain dehydrogenase/reductase (MDR) 
superfamily.[14] When α substitution is present, ER domains can confer either D- or L-
methyl group stereochemistry. In ERs that have α substitution, when a diagnostic 
tyrosine residue is present, the ER confers an L-methyl configuration, whereas if this 
diagnostic tyrosine residue is absent the ER confers a D-methyl configuration.[59,60] In 
general, ER domains are less well studied than the other β-carbon processing domains; to 
date, only one structure of an embedded PKS ER has been solved. [33] 
The elongating polyketide chain is terminated through the action of a TE domain. 
TE domains consist of an α/β hydrolase catalytic core, which has a serine-hisitidine-
aspartate catalytic triad, akin to the active site found in serine proteases.[14,61] Typically, 
thioesterases catalyze cyclization (e.g. in the case of the macrolides, such as 
erythromycin, Figure 1.2). However, some TEs catalyze hydrolysis, yielding a linear 
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polyketide product.[14,61] Understanding how TE domains mediate regio- and 
stereospecificity is an area of active investigation.[61] The best studied of the TEs is the 
DEBS TE, which has been shown to have hydrolytic activity toward a broad range of 
thioester substrates, but has a strict stereochemical preference for cyclization. In DEBS 
TE, the stereochemical configuration at the nucleophilic hydroxyl and corresponding α-
methyl position must be the same as the “natural” hexaketide intermediate (i.e., the 
stereochemistry conferred by the B2-type KR in module one).[62–64] This stereospecificity 
appears to be general among macrolactonizing TEs,[65] which has consequences for the 
rational reprogramming of polyketides through “domain swaps,” such as switching KR 
types within modules of the PKSs. Additionally, the hydrolytic activity towards unnatural 
small molecule substrates has consequences for PKSs utility in biocatalytic endeavors 
(see Chapter 2).[1,65–68] 
PKSS AS A PLATFORM FOR SYNTHETIC BIOLOGY 
As commented in a recent review by Keasling and coworkers,[69] there is a notable 
gap between the promise and reality of PKSs as a synthetic biology platform. This is in 
no small part due to the protein-protein interactions that mediate the collaborative action 
between polypeptides[14,20] that are disrupted during a “domain swap” approach. 
Additionally, (as alluded to previously) the interacting selectivities of downstream 
domains within the module can sometimes hinder the incorporation of varied structural 
elements, such as introducing different stereochemistries.[20] Although the notion of using 
a “molecular lego” type approach is intellectually attractive, these attributes render this 




Figure 1.4  Examples of PKS systems used for synthetic biology applications. A) 
Incorporation of fluorine into DEBS-derived triketide lactones.[70] B) 
Generation of a focused library of aureothin analogs through a 
mutasynthetic approach (reproduced with permission). [71] C) Introduction of 
an alkyne for further modifications in erythromycin (reproduced with 
permission).[72] 
Swaps of individual domains have had some limited success.  Early examples of 
were reported by Menzella and co-workers, who established that this approach can be 
applied to generate small, chiral PKS fragments (termed triketide lactones) with varying 
degrees of reduction and stereoisomeric configurations.[73,74] Other examples include 
applying a “mutasynthetic” approach, wherein the domains are swapped within the 
synthase to generate chemical diversity through altered specificity of the entire 
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metabolite’s biosynthetic pathway. This mutasynthetic approach has some limited 
success in the spinosin,[75] erythromycin,[76] and aureothin[77] pathways, particularly when 
the loading module’s specificity is altered. Other strategies include either relying on a 
degree of intrinsic promiscuity[72,78] or applying a directed evolution approach to altering 
specificity,[79,80] which has been employed successfully to introducing new chemical 
functionality (e.g. introducing alkynes[72,79] or fluorine[70,81] into PKS scaffolds) through 
new extender units via relaxed or altered specificity of the AT domain. However, 
frequently these architectural disruptions to the PKS only serve to either abolish or 
significantly diminish enzymatic activity. These examples of successful synthetic biology 
incorporations to yield either libraries of compounds[71] or novel functionalities[70,72] 
within polyketide scaffolds, however elegant, are somewhat limited in scope. In addition 
to more global “synthetic biology” approaches to engineering a pathway overall, using 
individual domains or modules for in vitro biocatalytic applications also has promise for 
further harnessing the potential of these remarkable enzymes.  
MODTESS AS A BIOCATALYTIC PLAFORM FOR GENERATION OF CHIRAL BUILDING 
BLOCKS 
Despite the proven track record of polyketide scaffolds as lead compounds, their 
molecular complexity often hampers their development as drug targets. Many 
pharmaceutical companies have phased out screening complex natural products due to 
difficulties accessing sufficient quantities for clinical trials.[4,82] A prominent example of 
such limitations is the bryostatins, a family of 20 marine natural products that were 
originally isolated from the bryozoan Bugula nertina.[83] These structurally complex 
compounds exhibit exceptional biological activity against cancer as well as neurological 
activity with promise for treating Alzheimer’s disease.[84–88] Unfortunately, their low 
abundance (approximately 1 gram per ton of bryozoan[89]) remains an insurmountable 
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hurdle to their development. Unlike most polyketide drugs (such as erythromycin or 
rapamycin) that are fermented, culturing the strain that produces the bryostations remains 
elusive and the pathway is intractable to heterologous expression. Indeed, with the 
exception of eribulin, all polyketide drugs to date are prepared by semi-synthesis or 
fermentation.[82] An attractive approach for the construction of polyketide scaffolds would 
be generating small, chiral polyketide chiral synthons that could be then used to generate 







Figure 1.5 A) Schematic of in vivo formation of a triketide lactone by DEBS1TE.[93] B) 
In vitro formation of a triketide lactone by priming a ModTE construct with 
a diketide priming unit.[1,49] 
Triketide lactones are the enzymatic products for a several miniaturized 
polyketide synthase model systems both in vitro[94] and in vivo (Figure 1.5).[95] Early 
seminal work by Khosla and coworkers demonstrated that DEBS1 could be used as a 
platform for the generation of one of these compounds (Figure 1.5).[95] Building on this 
result, Leadlay and coworkers demonstrated the in vivo efficiency of DEBS1 as a catalyst 
for triketide lactone formation resulted in much higher titers when it was fused the 
thioesterase domain.[93] Since these early reports, miniaturizing PKSs to simple bimodular 
17 
or modular-TE constructs and using triketide lactone output has been a useful in vitro 
strategy to interrogate enzymatic selectivity.[45,94] However, in addition to their utility as a 
model system, they could serve as intriguing chiral building blocks.[1] Indeed, one could 
envision generating a library of all 16 stereochemical combinations of triketide lactone as 
a library as synthons for the construction of polyketide architectures (Figure 1.6). 
However, typically for enzymology readouts, detection of these compounds is at the trace 
level (e.g. requiring techniques such as mass spectrometry or radio-thin layer 
chromatography for detection).[94] Thus, developing such molecules requires scaling up 
this reactivity to a preparative level. In Chapter 2, efforts to develop a model ModTE 
biocatalytic platform for the generation of triketide lactones are described.[1] 
Building on this and other work, Sherman and coworkers recently expanded the 
use of ModTE catalyze the formation of entire macrolides (pikromycin and pikromycin 
derivatives). This work involved a hybrid of chemical synthesis and biocatalysis, wherein 
pentaketide intermediates were generated through synthetic chemistry, and extension and 
macrolactonization were performed by the ModTE construct.[68,96,97] The application of 
ModTEs for these purposes beyond small molecules such as triketides demonstrates that 
ModTE constructs are versatile biocatalytic agents that can be applied in various ways to 








THE KETOREDUCTASE DOMAIN: BIOCATALYTIC APPLICATIONS AND IMPLICATIONS 
FOR ENZYME ENGINEERING 
While the collaborative action of interacting domains in PKSs is crucial for 
generating varied chemical architectures, there is still much to decipher regarding 
mechanistic aspects of each individual domain. Additionally, as well as harnessing the 
collaborative action of PKS domains, individual domains can be developed for their 
biocatalytic applications. Of all the β-carbon processing domains, KR domains have 
particular promise for development as biocatalysts.[26] PKS KRs fall within the more 
general class of enzymes, oxidoreductases. Oxidoreductases, and in particular 
ketoreductases, are applied in a number of industrial manufacturing processes.[98–100] 
Indeed, the introduction of an asymmetric hydroxyl functionality is performed by a 
ketoreductase in a number of drug manufacturing processes (including the blockbuster 
drugs atorvastin, montelukast, duloxetine, phenylephrine, ezetimibe, and crizotinib) 
(Scheme 1.3).[100] Because many PKS KRs set both the stereochemistry of the β-hydroxyl 
as well as the α-methyl group, they are particularly attractive for such applications. 
Further establishing their biocatalytic potential, KRs have been shown to have a 
somewhat high degree of substrate promiscuity. Early work by Leadlay and coworkers 
established that in addition to reducing small molecule analogs (such as β-keto N-acetyl 
cysteamine substrates), KRs possessed activity toward decalone substrates.[101] Additional 
studies established that NADPH turnover is observed when KRs from the mycolactone, 
erthryomycin, and tylosin pathways are incubated with a panel of commercially available 
keto compounds (including 3-heptanone, cyclooctanone, ethylvinyl ketone, dicyclohexyl 




Scheme 1.3  Examples of ketoreductases applied in the synthesis of pharmaceutical 
intermediates. A) Intermediate in the production of the drug 
rambatroban. B) Intermediate in the production of motolukast.[99] 
Activity toward (9R, S)-trans-1-decalone was later used as an output for a 
saturation mutagenesis study, which explored the role of altering residues surrounding the 
active site, and those mutations’ impacts on stereochemical outcomes. Leadlay and 
coworkers also generated homology models from other SDR enzymes, which guided 
rational mutagenesis experiments.[38] Through these experiments, Leadlay and coworkers 
determined that EryKR1 (a B2 type enzyme) could be made A2 selective with as few as 
three mutations to residues surrounding the active site.[39] These experiments, then, 
suggest that subtle perturbations to the active site environment mediate stereocontrol with 
small molecule mimics. Later mutagenesis efforts were guided by the crystal structures, 
especially those of AmpKR2[43] and AmpKR11.[32] In the case of AmpKR2, two residues 
(G55T and Q364H) were sufficient to reverse the diastereoselectivity and increase the 
efficiency (~4 fold increase in kcat/Km), resulting in a robust A2 type enzyme.[32]  
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Figure 1.7 Library of diketide building blocks generated by 11 isolated KRs, indicating 
their biocatalytic utility. Reproduced with permission.[104] 
The facility with which the A2 stereoisomer apparently forms when the enzyme is 
altered through mutagenesis is interesting in light of many KRs activities towards 
substrates that deviate significantly from the natural substrates. Leadlay and coworkers 
demonstrated that EryKR2, an A1 type enzyme that naturally accepts a triketide 
intermediate, has very poor activity towards diketide intermediates (the natural substrate 
for EryKR2 is a triketide; however δ-hydroxy thioester small molecule substrate mimics 
spontaneously cyclize in solution and are thus not feasible for in vitro assays). What little 
activity was observed as the A2 anti product.[42] A later, expansive study investigated the 
selectivity of eleven ketoreductases to interrogate their reactivity with five different 
diketide S-NAC thioesters[104] (Figure 1.7). This study indicated that KRs frequently 
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maintain their natural stereocontrol when presented with truncated substrates. In general, 
KRs that appear early in the synthase (and thus reduce smaller intermediates) tended to 
retain their stereocontrol; conversely, KRs found later in the biosynthetic pathways 
tended to have looser substrate selectivity and poorer activity toward diketide substrates. 
Presumably, this is because KRs found later in biosynthetic pathways have enlarged 
active sites, which are evolved to accommodate larger PKS substrates. 
The A2 stereoisomer is often the major product when the KR does not encounter 
α-branching in its natural context. For example, MycKRA, which is an A type KR and 
naturally reduces an unsubstituted keto moiety, preferentially formed the A2 anti product 
over the A1 syn product when presented with diketides with α-stereochemistry.[104] 
Interestingly MycKRB, which is a B type KR from the same pathway (mycolactone), 
when presented with diketides bearing α-stereochemistry also preferentially forms the 
anti A2 product as the major product, with the anti B1 product as the minor product (the 
syn isomers are not observed).[102] Additionally, an odd phenomenon, wherein TylKR1, a 
naturally B1-type KR switched substrate selectivity when the diketide substrate was 
truncated by one methyl group, from a 2-methyl-3-oxopentyl-S-NAC to a 2-methyl-3-
oxobutyl-S-NAC thioester, was also observed.[104] This apparent “substrate-dependent 
enatioselectivity” was further interrogated by Müller and coworkers, who explored the 
selectivity of TylKR1 using a panel of S-NAC and oxo-esters. Frequently, when TylKR1 
reduced the more unnatural oxo-ester substrates, the enatioselectivity was reversed, 
resulting in the A2 product (the enantiomer of the natural stereoisomer) being the major 
product instead of the B1 product.[105] An approach that harnesses such observations of 
differences in stereochemical outcome with various substrates and/or point mutations are 
introduced is further explored in Chapter 3. 
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TRANS-AT PKSS: DEVIATIONS FROM CANONICAL CO-LINEARITY 
The majority of the work reviewed above corresponds to “canonical” PKSs, such 
as erythromycin and other PKSs from filamentous actinomyces bacteria, which are 
commonly found in the soil.[13] However, in recent years, there has been interest in 
pursuing a wider variety of taxa and bacterial habitats for the discovery of secondary 
metabolites. These investigations lead to the discovery of a new class of PKSs, which 
possess modular megasynthases that have distinctive architectural features that deviate 
from textbook colinearity.[51] The most notable feature of these PKSs is that each module 
receives its extender unit from the action of an AT domain that is present on a separate 
polypeptide. As such, these ATs are termed “trans-AT PKSs,” whereas textbook PKSs 
(such as DEBS, which harbor embedded ATs) are termed “cis-AT PKSs.” The same ATs, 
then, are used iteratively to acylate each module, and thus typically use the same building 
block throughout the synthase (malonyl-CoA).[51,106] While cis-AT PKSs have only eight 
different modular organizations (KS-AT-ACP, KS-AT-KR-ACP, KS-AT-DH-KR-ACP, 
KS-AT-ER-DH-KR-ACP, and their counterparts with methyltransferase domains), over 
50 modular organizations have been identified in trans-AT pathways.[107] These variant 
modular organizations frequently possess repeated or missing domains, unusual ordering 
of domains, or modules split in various ways between two proteins, which altogether 
serves to obfuscate the metabolite-structure colinearity. However, more recent 
biosynthetic and phylogenetic analysis has afforded some insights for determining new 
colinearity rules that are unique to trans-AT PKSs. [51] 
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Figure 1.8 An example of a trans AT PKS (the difficidin PKS) that contains two 
tandem split bimodules (a type B bimodule followed by a type A bimodule). 
B) Schematic of type A and type B bimodules. 
One of the interesting deviations from canonical colinearity arises from “split 
bimodules.” Because domains, which must collaboratively process the elongating 
polyketide chain, are located on separate polypeptides, split modular organizations 
necessitate protein-protein interactions that mediate chain transfer. Two “split bimodule” 
types that exemplify the deviant nature of trans-AT PKSs in comparison to cis AT PKSs 
are termed by Piel “type A” and “type B” bimodules (Figure1.8).[51] Type A bimodules 
harbor the following domain sequence: KS-KR-ACP-KS0 (where the KS0 denotes a KS 
that is catalytically inactive, identifiable by a lack of one of the active site histidines) on 
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one gene product, and a subsequent DH on the next polypeptide. In contrast, type B 
bimodules have a similar organization, except the C-terminal KS is catalytically active, 
and there is a KR following the N-terminal DH (KS-KR-ACP-KS then DH-KR). One of 
the clearest illustrations of “new” colinearity rules arising from trans-AT pathways is the 
action of the DH of type B bimodules, which performs two sequential dehydrations. First 
the hydroxyl arising from the KR from the downstream module is dehydrated, and 
subsequently the hydroxyl arising from the KR on the upstream module is dehydrated.[51] 
This likely suggests that the DH must visit two ACPs (one from the upstream module and 
one from the downstream module). In Chapter 4, the structure of a KR from a type A 
bimodule reveals several structural and sequence features that may explain some of these 
bridging interactions between the two polypeptides. 
OUTLOOK 
The colinear, assembly-line nature of PKSs renders them exciting platforms for 
synthetic biology and biocatalysis. As a more detailed understanding of individual 
domains interact in unnatural contexts has been uncovered, their applicability has 
improved in recent years. In addition to canonical systems (such as DEBS), a separate 
subclass of PKSs, the trans-AT PKSs have been recently identified and, even more 
recently, structurally and functionally dissected. The utility of the trans-ATs as a 
synthetic biology platform will undoubtedly increase, as we gain a better understanding 
of their unique colinearity rules and protein-protein bridging interactions. Encouragingly, 
the gap between applications we can envision for PKSs and the reality of their use as a 
synthetic biology platform has begun to narrow over recent years[69] due to advances in 
our knowledge, both in terms of their enzymology[108] and of structural features that 
mediate these protein-protein interactions.[14] The results presented within this dissertation 
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highlight a few incremental advances in terms of enzymatic mechanism, collaborative 
action of the domains in in vitro environments, and structural dissection that contribute to 
the ultimate goal of realizing the biocatalytic potential of these enzymes. 
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Chapter 2: Preparative Biocatalysis of Triketide Lactone Chiral 
Building Blocksiv 
INTRODUCTION 
Complex polyketides are structurally-diverse secondary metabolites 
biosynthesized through successive rounds of decarboxylative Claisen condensations and 
reductive processing by type I polyketide synthases (PKSs).[1,2] The broad medicinal 
utility of these compounds has generated intense interest in their production. The 
antibacterial erythromycin and the immunosuppressant rapamycin are accessed through 
fermentation; however, this strategy is not always a viable route to a complex polyketide 
as the producing organism may not be culturable and the biosynthetic pathway may not 
be amenable to heterologous production.[3]  Identifying efficient syntheses of such targets 
then becomes the bottleneck to their development as therapeutics.[4]  Medicinally-relevant 
marine natural products[5] such as bryostatin[6,7] and discodermolide,[8] are particularly 
notorious for these difficulties. Chiral precursors can simplify such syntheses, although 
the current chiral pool is largely limited to sugars, amino acids, and Roche esters.[8,9] 
PKSs themselves are accessible catalysts that synthesize complex chiral products at room 
temperature in aqueous conditions. As such, we envisioned harnessing this machinery to 
generate triketides that could be used as synthetic precursors to accelerate the total 
syntheses of natural products and their analogs. For example, one can envision 
constructing the anticancer agent discodermolide from triketide lactones  (Scheme 2.1).  
                                                
iv Portions of this chapter were reproduced from: Harper, A.D., Bailey, C.B., Edwards, A.D., and Detelich, 
J.F., and Keatinge-Clay, A.T. ChemBioChem. 2012, 13, 2200. ADH and CBB performed the majority of 
the experimental work. Specifically, ADH performed the HPLC-based assays and initial enzymatic screens, 
whereas CBB performed the biocatalytic reactions, isolation, and characterization of triketide lactones. 
ADE prepared proteins and assisted with initial enzymatic screens and JFD assisted with substrate 
synthesis. ADH, CBB, and ATK evaluated the experimental data and wrote the original text. 
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Isolated PKS modules C-terminally fused to a thioesterase (TE) domain 
(ModTEs) have been shown to generate triketide lactones harboring up to four 
contiguous stereogenic centers both in vivo[10-14] and in vitro.[15-18] Such compounds could 
be applied as synthetic precursors; however, in vivo titers rarely exceed a few milligrams 
per liter[10, 12-15] and, until recently, in vitro strategies have only yielded such compounds 
in trace quantities.[15-18] Herein, we report a versatile in vitro platform that combines 
enzymatic promiscuity and cofactor regeneration to afford a representative library of 
triketide lactones produced at unprecedented scales for in vitro PKS synthesis (up to 77 
mg). Six triketide lactones were generated in quantities amenable to rigorous 
characterization. Through the generation of the described library it became apparent that 
the biocatalytic platform also serves as a powerful strategy to study the activities and 
selectivities of PKS modules. 
 
 
Scheme 2.1.  Retrosynthetic analysis of the antitumorial agent, discodermolide using 
triketide lactone chiral synthons. 
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A MODTE PLATFORM FOR TRIKETIDE LACTONE BIOCATALYSIS 
The core of this biocatalytic strategy is the terminal module and TE of the 
erythromycin PKS (EryMod6TE), a module previously demonstrated to accept non-
natural substrates[19,20] (Scheme 2.2). We employed this miniature enzymatic assembly 
line to accept and extend a diketide, stereoselectively reduce the resulting triketide 
intermediate, and catalyze its cyclization.  
 
Scheme 2.2  Chemoenzymatic syntheses of triketide lactone chiral building blocks. In 
this biocatalytic platform extender units and chiral diketides are 
generated in separate reactions and then combined with EryMod6TE. 
The extension reaction is promoted by excess methylmalonyl-S-N-
acetylcysteamine (NAC) (2.1). This economical substitute for the natural extender unit, 
2S-methylmalonyl-S-CoA, was generated by incubating methylmalonate, NAC, and ATP 
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with the Streptomyces coelicolor malonyl-CoA ligase MatB.[21,22] β-Ketoacyl-S-NACs 
2.2-2.4 were obtained through facile syntheses, enabling the production of chiral 
diketide-S-NACs 2.5-2.7 through separate biocatalytic reactions.[23] (2S,3R)-3-Hydroxy-
2-methylpentanoyl-S-NAC (2.5) was generated through the reduction of α-substituted 
diketide 2 by the first ketoreductase (KR) of the erythromycin PKS (EryKR1), while both 
(3R)-hydroxypentanoyl-S-NAC (2.6) and (3R)-hydroxyhexanoyl-S-NAC (2.7) were 
generated through the reduction of α-unsubstituted diketides 2.3 and 2.4 by the first KR 
of the tylosin PKS (TylKR1). KRs were chosen according to prior studies that identified 
KRs with high activity and stereoselectivity toward NAC-based substrates.[23] Since 
purification of these KRs was demonstrated to be unnecessary for in vitro biocatalytic 
reactions, stereoselective reductions of achiral or racemic β-ketoacyl-S-NACs were 
performed in KR-containing dialyzed cell lysate that was supplemented with Bacillus 
subtilis glucose dehydrogenase (GDH), NADP+, and D-glucose (the NADPH-
regeneration system).[23] The extender unit generation and diketide reduction reactions 
were then combined with EryMod6TE-containing lysate from E. coli K207-3 cells, 
expressing the B. subtilis phosphopantetheinyl transferase Sfp that 
phosphopantetheinylates acyl carrier protein (ACP) domains in PKS modules.[20,24] After 
one day, EryMod6TE reactions were extracted and purified by flash chromatography to 
yield quantities of triketide lactone suitable for full characterization (4-77 mg). 
PREPARATIVE BIOCATALYTIC SYNTHESES 
Biocatalytic reactions initiated with diketides 2.2-2.4 (0.5 mmol scale) generated 
triketide lactones 2.8-2.10 (7%, 9%, and 10% isolated yields, respectively) (Table 2.1). 
While no isolable quantity of ketolactones 2.12 or 2.13 were produced in the reactions 
generating 2.9 and 2.10, ketolactone 2.11 was the major product in reactions generating 
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2.8 (13% vs. 7% isolated yield), resulting from TE operating before EryKR6 on the 
triketide-S-ACP intermediate. The significant amount of ketolactone product in reactions 
initiated with α-substituted diketide 2.2 suggests that α,γ-dimethyl, β-ketoacyl-S-ACP 
intermediates are better substrates for EryTE than EryKR6, while the small amounts of 
ketolactone product in reactions initiated with 2.3 and 2.4 suggest the opposite for α-
methyl, β-ketoacyl-S-ACP intermediates. The previously unmeasured differences in the 
reactivity of the EryTE and EryKR6 toward various polyketide intermediates demonstrate 
the utility of this biocatalytic platform to reveal subtle features of PKS enzymology even 
for a system as well-studied as the erythromycin PKS.  
We next examined the scalability of the biocatalytic platform. From a reaction 
initiated with 7 mmol of 2.4, 77 mg of 2.10 was readily isolated (6% isolated yield, a 
decrease from the 10% yield of the 0.5 mmol scale reaction). Triketide lactone 2.10 was 
easily separated from a small amount of the ketolactone side-product 2.13 (1% isolated 
yield) by flash chromatography. The scale of this in vitro synthesis of a complex 

































2.3 0.5 + 2.9 7.3 9 
2.3 0.5 - 2.12 5.6 7 
2.4 0.5 + 2.10 8.4 10 
2.4 0.5 - 2.13 3.4 4 






[a] In the EryMod6TE reaction. [b] Yields reflect quantities of triketide 
lactones (isolated by flash chromatography) generated from precursors 2.2-
2.4. 
 
MONITORING KETOLACTONE FORMATION  
We next sought to monitor the generation of triketide products by the biocatalytic 
platform. Chiral diketides, produced by KRs from β-ketoacyl-S-NACs, were ethyl 
acetate-extracted from reactions containing the NADPH-regeneration system. The 
incubation of chiral diketides 2.6 and 2.7 with EryMod6TE but without the NADPH-
regeneration system yielded ketolactones 2.12 and 2.13 (7% and 4% isolated yields on a 
0.5 mmol scale, respectively). Although the β-ketoesters of these ketolactones are weak 
chromophores (λmax = 248 nm), products were generated in sufficient concentrations for 
their synthesis to be monitored with an HPLC coupled to a photodiode array detector. 
Since β-hydroxyacyl-S-NACs and methylmalonyl-S-NAC are also UV-active (λmax = 233 
nm and λmax = 235 nm, respectively), all reactants and desired products were easily 
tracked throughout the biocatalytic reactions (Figures 2.1a and 2.1b; experimental 
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section). The quantities of ketolactone 2.11 generated from diketide 2.5 in this manner 
facilitated its structural determination by X-ray crystallography (Figure 2.1c). 
 
Figure 2.1.  A-B) Stacked HPLC chromatograms and a chart reveal the progress of the 
biocatalytic production of ketolactone 2.11. C) Oak Ridge Thermal Ellipsoid 
Plot (ORTEP) representation of the crystal structure of 2.11 (ellipsoids 
scaled at the 50% probability level). 
 
STEREOCHEMICAL CONSIDERATIONS IN MODTE PLATFORMS  
EryMod6TE was then examined for its ability to accept each of the α-methyl, β-
hydroxyacyl-S-NAC stereoisomers generated through the reduction of 2.2 by KRs that 
set different stereochemical combinations at the α- and β-carbons (AmpKR2, RifKR7, 
TylKR1, and EryKR1).[23,25,26] A strict stereochemical requirement for diketide 
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incorporation by EryMod6TE was observed in that ketolactone was only produced when 
EryMod6TE was supplied with 2.5, which possesses 2S and 3R stereochemistries. This 
result was unexpected as this stereoconfiguration is opposite to that of the natural 
substrate of EryKS6 during erythromycin biosynthesis (its hexaketide-S-ACP 
intermediate possesses 2R and 3S stereochemistries). Narrow specificity has been 
previously observed from ModTEs – 2.5 and each of its stereoisomers transthioesterified 
onto the KS of EryMod2TE but each of the stereoisomers rendered this KS condensation-
incompetent.[27] The exclusive incorporation by EryMod6TE of the non-natural (2S)-
methyl, (3R)-hydroxyl diketide into triketide lactones may either indicate differences in 
KS selectivity towards NAC-bound substrates versus ACP-bound substrates or an 
inability of EryTE to cyclize the other triketide stereoisomers.[27-30] The described 
biocatalytic platform will help in determining which domains control ModTE 
specificities. 
Enabling the general extension of diketide stereoisomers may represent the largest 
challenge to accessing stereochemically diverse libraries of triketide lactone building 
blocks. We are currently investigating other ModTE constructs such as the second 
module of the amphotericin PKS fused to the erythromycin TE (AmpMod2TE) since 
AmpKS2 naturally accepts a (2S)-methyl, (3S)-hydroxyl diketide. We are also exploring 
other TEs to address the possibility that EryTE may not be active toward all triketide 
stereoisomers[27-30 To obtain a ModTE with desired activities it may be necessary to 
construct chimeras containing KSs, ATs, KRs, and TEs from different modules and 
synthases.31  
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CONCLUSIONS AND OUTLOOK 
While the described biocatalytic system has already yielded a promising first step 
in accessing triketide lactone chiral building blocks from abundant achiral and racemic 
precursors, optimization is still necessary. We will attempt to improve the yields 
compromised by TE-mediated hydrolysis of diketide thioester substrates by employing a 
promiscuous acyl-CoA synthetase to regenerate hydrolyzed diketide-S-NACs in situ. We 
also seek to engineer ModTEs in which KR kinetically outcompetes TE to increase the 
efficiency of reduced triketide lactone production. Finally, we aim to incorporate 
chemical handles (e.g. terminal olefin, alkyne, chloride) into the building blocks to 
broaden their synthetic utility.[12,32] 
Polyketide synthesis from in vitro PKS reactions has been typically limited to the 
microgram scale by the cost of substrates and cofactors, particularly CoA-bound extender 
units and NADPH, and analysis of such in vitro reactions has typically been restricted to 
sensitive methods such as radio-TLC or mass spectrometry [15-18,26,33,34] The presented 
platform overcomes such restraints and renders more rigorous characterization techniques 
(e.g. HPLC, NMR, and crystallography) practical through the use of glucose-fueled 
NADPH regeneration[23] and truncated extender units.[20-22, 35] The increased scale of these 
in vitro reactions demonstrates that PKS enzymes can indeed be employed as 
biosynthetic biocatalysts.[36] In addition to helping generate chiral building blocks, the 
described biocatalytic platform will be  valuable in studying the activities and 
selectivities of enzymes within PKS modules. 
ABBREVIATIONS 
NAC, N-acetylcysteamine; PKS, modular polyketide synthase; KS, ketosynthase; 
AT, acyltransferase; KR, ketoreductase; ACP, acyl carrier protein; TE, thioesterase; 
GDH, Bacillus subtilis glucose dehydrogenase; NADPH, nicotinamide adenine 
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dinucleotide phosphate hydrogen; EryTE, erythromycin PKS thioesterase; ModTE, 
module+thioesterase; EryMod6TE, the 6th module of the erythromycin PKS fused to 
EryTE; EryMod2TE, the 2nd module of the erythromycin PKS fused to EryTE; 
AmpMod2TE, the 2nd module of the amphotericin PKS fused to EryTE; AmpKR2, KR 
from 2nd module of the amphotericin PKS; RifKR7, KR from 7th module of the rifamycin 
PKS; TylKR1, KR from 1st module of the tylosin PKS; EryKR1, KR from 1st module of 
the erythromycin PKS; EryKR6, KR from 6th module of the erythromycin PKS; EryKS2, 
KS from the 2nd module of the erythromycin PKS; AmpKS2, KS from the 2nd module of 
the amphotericin PKS. 
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Experimental Section for Chapter 2 
GENERAL CONSIDERATIONS 
N-acetylcysteamine (NAC),[1,2] and all β-ketoacyl-S-NAC substrates (2.2-2.4)[2] 
were synthesized according to literature procedures. Methylmalonic acid was purchased 
from TCI America, ATP was purchased from Meiya Pharmaceuticals, and NADP+ was 
purchased from CalBioChem. IPTG was purchased from either CarboSynth or Anatrace, 
and Ni-NTA agarose was purchased from Amintra. For purified proteins, final 
concentrations were determined using a Thermo Scientific Nanodrop 1000. Thin layer 
chromatography (TLC) was conducted with EMD gel 60 F254 pre-coated plates (0.25 
mM). Fisher scientific silica gel 60 (particle size 230-400 µm) was used for flash column 
chromatography. All HPLC monitoring was performed on a Waters 1525 binary HPLC 
pump connected to a Waters 2998 photodiode array detector using a Varian Microsorb-
MV C18 column (250 x 4.6 mm, 5 µm particle size, 100 Å pore size) with a matching 
Metaguard column and mobile phases consisting of water with 0.1% TFA (solvent A) 
and methanol with 0.1% TFA (solvent B) at a flow rate of 1 mL/min. 1H NMR data were 
acquired on a Varian Mercury 400 MHz instrument at ambient temperature and are 
reported in terms of chemical shift (δ ppm), multiplicity, coupling constant, and 
integration and are referenced downfield from (CH3)4Si to the residual solvent peak at 
7.26 ppm for CDCl3 as an internal standard. 13C NMR data were acquired on either a 
Varian Mercury 400 MHz instrument or a Varian Oxford 600 MHz instrument at ambient 
temperature and are reported in terms of chemical shift and referenced to the residual 
solvent peak at 77.16 ppm for CDCl3 as an internal standard. High-resolution mass 
spectrometry measurements were obtained by chemical ionization (CI) with a VG 
analytical ZAB2-E instrument. LC-MS analysis was performed on an Agilent 
Technologies 1200 Series HPLC with a Gemini C18 column (5 µm, 2 x 50 mm, 
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Phenomenex) coupled to an Agilent Technologies 6130 quadrupole mass spectrometer 
system equipped with an electrospray-ionization source. A 5- 95% B gradient over 12 
minutes at a flow rate of 0.7 mL/min was run in which the mobile phases were water with 
0.1% formic acid (solvent A) and acetonitrile with 0.1% formic acid (solvent B). Specific 
rotation measurements were made with an Atage AP-300 Automatic Polarimeter. 
PROTEIN EXPRESSION AND PURIFICATION 
Streptomyces coelicolor MatB,[1] TylKR1,[2] EryKR1,[2] AmpKR,[2] MycKR5,[2] 
RifKR7,[3] and Bacillus subtilis glucose dehydrogenase (GDH),[2] were expressed in E. 
coli BL21(DE3), and EryMod6TE1 was expressed in E.coli K207-3[4] (the expression 
plasmid for all proteins was pET28b, except RifKR7, which was pET28a). Starter 
cultures (50 mL) were grown to inoculate pre-warmed Luria broth supplemented with 25 
μg/mL kanamycin. When OD600=0.4, the media was cooled to 15 °C and then induced 
with 0.5 mM IPTG. After 16 hours, the protein was harvested by centrifugation (3,000 xg 
for 20 minutes), and the pellets of 6 L of cell growth were re-suspended in lysis buffer 
(100 mM HEPES, 500 mM NaCl, 10% v/v glycerol, pH 7.5). The cells were then lysed 
by sonication on ice and centrifuged (30,000 xg for 45 minutes) to remove cellular debris. 
For MatB and GDH, the proteins were purified by passing the crude lysate over a nickel-
NTA column equilibrated with lysis buffer. The column was washed with lysis buffer 
containing 15 mM imidazole, and the protein was eluted with lysis buffer containing 150 
mM imidazole. For isolated ketoreductases (EryKR1, TylKR1, AmpKR2, and RifKR7) 
and EryMod6TE, lysate was used. To generate lysate, cells from 6 L of cell growth were 
pelleted after expression (3,000 xg for 20 minutes), and the pellets of were resuspended 
in 50 mL lysis buffer before sonication and centrifugation (30,000 xg for 45 minutes). 
The crude lysate was then twice dialyzed at 4 °C in 10 kDa MWCO cellophane dialysis 
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tubing against dialysis buffer (30 mM HEPES, 200 mM NaCl, 10% v/v glycerol, pH 7.5), 
each time for 8 hours. 
BIOCATALYTIC SYNTHESES OF TRIKETIDE LACTONES 2.8-2.13 
General Considerations for Biocatalytic Syntheses: All biocatalytic reactions were 
performed at ambient temperature (~23 °C). Reaction progress for the ketoreductase 
reactions yielding 2.5-2.7 was monitored by TLC (15% MeOH:CHCl3) and HPLC 
absorbance at 235 nm (linear gradient of 15-35% B over 20 minutes).2 The progress of 
reactions yielding methylmalonyl-S-NAC (2.1) was monitored via HPLC at 235 nm 
(linear gradient of 0-50% B over 15 minutes). The progress of reactions yielding 2.8-2.13 





(2R, 3S, 4S, 5R)-3,5-Dihydroxy-2,4-dimethylheptanoic acid d-lactone (2.8) and (4S, 
5R)-2,4-dimethyl-3-oxoheptanoic acid d-lactone (2.11). Generation of methylmalonyl-
S-NAC (2.1) was performed in a 5 mL total volume containing 500 mM HEPES (pH 
7.5), 100 mM NaCl, 10% v/v glycerol, 120 mM methylmalonate, 120 mM ATP, 240 mM 
MgCl2, 100 mM NAC, and 0.5 mg/mL MatB and was reacted for 24 hours. Generation 
of reduced diketide 5 was performed in a 5 mL total volume containing 500 mM HEPES 
(pH 7.5), 100 mM NaCl, 15% v/v glycerol, 180 mM D-glucose, 2 mM NADP+, 100 mM 
2.2, 0.05 mg/mL GDH, and 1.3 mL EryKR1 lysate and went to completion after 16 





2.8, 7.3% yield 2.11, 7.3% yield
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EryMod6TE lysate and incubated in a 30 mL total reaction volume. After 24 hours the 
reaction was then extracted with EtOAc (3 x 150 mL), dried with MgSO4, filtered, and 
concentrated under vacuum. The crude extract was then extracted with chloroform (1 x 
100 mL) to remove remaining glycerol and concentrated under vacuum. The crude 
product was next purified via flash column chromatography (silica, 50% EtOAc:hexanes) 
to afford both triketide lactone 2.8 and ketolactone 2.11. Triketide lactone 2.8 was 
isolated as a yellow oil (6.3 mg, 7.3% yield from 2). Ketolactone 2.11 was isolated as a 
white solid (11.0 mg, 12.9% yield from 2.2). 
 
 
(2R, 3S, 5R)-3,5-Dihydroxy-2-methylheptanoic acid δ-lactone (2.9). Generation of 
methylmalonyl-S-NAC (2.1) was performed in a 5 mL total volume containing 500 mM 
HEPES (pH 7.5), 100 mM NaCl, 10% v/v glycerol, 120 mM methylmalonate, 120 mM 
ATP, 240 mM MgCl2, 100 mM NAC, and 0.5 mg/mL MatB and was reacted for 24 
hours. Generation of  reduced diketide 2.6 was performed in a 5 mL total volume 
containing 500 mM HEPES (pH 7.5), 100 mM NaCl, 15% v/v glycerol, 180 mM D-
glucose, 2 mM NADP+, 100 mM 2.3, 0.05 mg/mL GDH, and 1.3 mL TylKR1 lysate and 
went to completion after 16 hours. The reactions yielding 2.1 and 2.6 were then 
combined with 20 mL of EryMod6TE lysate and incubated in a 30 mL total reaction 
volume. After 24 hours the reaction was extracted with ethyl acetate (3 x 150 mL), dried 
with MgSO4, filtered, and concentrated under vacuum. The crude extract was extracted 






vacuum. The crude product was then purified via flash column chromatography (silica, 
60% EtOAc:hexanes) to afford triketide lactone 2.9 as a yellow oil (7.3 mg, 9.2% isolated 
yield from 2.3). No ketolactone side-product (2.12) was isolated. 
 
 
(2R, 3S, 5R)-3,5-Dihydroxy-2-methyloctanoic acid δ-lactone (2.10). Generation of 
methylmalonyl-S-NAC (2.1) was performed in a 5 mL total volume containing 500 mM 
HEPES (pH 7.5), 100 mM NaCl, 10% v/v glycerol, 120 mM methylmalonate, 120 mM 
ATP, 240 mM MgCl2, 100 mM NAC, and 0.5 mg/mL MatB and was reacted for 24 
hours. Generation of reduced diketide 2.7 was performed in a 5 mL total volume 
containing 500 mM HEPES (pH 7.5), 100 mM NaCl, 15% v/v glycerol, 5% v/v DMSO, 
180 mM D-glucose, 2 mM NADP+, 100 mM 2.4, 0.05 mg/mL GDH, and 1.3 mL TylKR1 
lysate. The reaction went to completion after 16 hours. The reactions yielding 2.1 and 2.7 
were then combined with 20 mL of EryMod6TE lysate to a 30 mL total reaction volume. 
After 24 hours the reaction was extracted with ethyl acetate (3 x 150 mL), dried with 
MgSO4, filtered, and concentrated under vacuum. The crude extract was then extracted 
with chloroform (1 x 100 mL) to remove remaining glycerol and concentrated under 
vacuum. The crude product was then purified via dry flash column chromatography 
(silica, 70% EtOAc:hexanes) to afford compound 2.10 as a yellow oil (8.4 mg, 9.6% 







Preparative Biocatalysis of (2R, 3S, 5R)-3,5-Dihydroxy-2-methyloctanoic acid δ-
lactone (2.10). Generation of methylmalonyl-S-NAC (2.1) was performed in a 70 mL 
total volume containing 500 mM HEPES (pH 7.5), 100 mM NaCl, 10% v/v glycerol, 120 
mM methylmalonate, 120 mM ATP, 240 mM MgCl2, 113 mM NAC, and 0.42 mg/mL 
MatB and went to completion in 36 hours. Generation of reduced diketide 2.7 was 
performed in a 70 mL total volume containing 500 mM HEPES (pH 7.5), 100 mM NaCl, 
15% v/v glycerol, 5% v/v DMSO, 180 mM D-glucose, 2 mM NADP+, 100 mM 2.4, 0.05 
mg/mL GDH, and 18.2 mL TylKR1 lysate and went to completion after 16 hours. The 
reactions yielding 2.1 and 2.7 were then combined with 190 mL EryMod6TE lysate and 
reacted in a total reaction volume of 330 mL. After two days the reactions were extracted 
with EtOAc (6 x 250 mL). The remaining emulsion was centrifuged (1000 xg for 1 
minute) and the organic phase was removed. The remaining aqueous phase was then 
extracted with EtOAc (2 x 250 mL), and the remaining emulsion was centrifuged again 
(1000 xg for 1 minute) and the organic phase was again removed. The combined organic 
phases were dried with MgSO4, filtered, and concentrated under vacuum. The crude 
extract was then extracted with chloroform (2 x 200 mL) to remove remaining glycerol 
and concentrated. The crude product was next purified via flash column chromatography 
(silica, 50% EtOAc:hexanes) to afford 2.10, a yellow oil (77 mg, 6.4% yield from 2.4). 
The ketolactone lactone side-product, 2.13, was also isolated as a grey solid (14.1 mg, 





2.10, 6.4% yield, 77 mg
52 
 
(5R)-2-methyl-3-oxoheptanoic acid δ-lactone (2.12). Generation of methylmalonyl-S-
NAC (2.1) was performed in a 5 mL total volume containing 500 mM HEPES (pH 7.5), 
100 mM NaCl, 10% v/v glycerol, 120 mM methylmalonate, 120 mM ATP, 240 mM 
MgCl2, 100 mM NAC, and 0.5 mg/mL MatB and was reacted for 24 hours. Generation of 
reduced diketide 2.6 was performed in a 5 mL total volume containing 500 mM HEPES 
(pH 7.5), 100 mM NaCl, 15% v/v glycerol, 5% v/v DMSO,180 mM D-glucose, 2 mM 
NADP+, 100 mM 2.3, 0.05 mg/mL GDH, and 1.3 mL TylKR1 lysate and went to 
completion after 16 hours. The reaction yielding reduced diketide 2.6 was then extracted 
with EtOAc (3 x 50 mL), dried with MgSO4, filtered, and concentrated under vacuum to 
isolate reduced diketide 2.6 from the NADPH regeneration system. Reduced diketide 2.6 
was diluted in 5 mL 500 mM HEPES (pH 7.5) and combined with the reaction yielding 
2.1 and 20 mL of EryMod6TE lysate. The reaction was incubated in a total volume of 30 
mL. After 24 hours, the reaction was extracted with EtOAc (3 x 150 mL), dried with 
MgSO4, filtered, and concentrated under vacuum. The crude extract was then extracted 
with chloroform (1 x 100 mL) to remove remaining glycerol and concentrated to afford 
the crude product. The crude product was next purified via dry flash column 
chromatography (silica, 50% EtOAc:hexanes) to afford ketolactone 2.12, a white solid 











(5R)-2-methyl-3-oxoheptanoic acid δ-lactone (2.12). Generation of methylmalonyl-S-
NAC (2.1) was performed in a 5 mL total volume containing 500 mM HEPES (pH 7.5), 
100 mM NaCl, 10% v/v glycerol, 120 mM methylmalonate, 120 mM ATP, 240 mM 
MgCl2, 100 mM NAC, and 0.5 mg/mL MatB and was reacted for 24 hours. Generation of 
reduced diketide 2.6 was performed in a 5 mL total volume containing 500 mM HEPES 
(pH 7.5), 100 mM NaCl, 15% v/v glycerol, 5% v/v DMSO,180 mM D-glucose, 2 mM 
NADP+, 100 mM 2.3, 0.05 mg/mL GDH, and 1.3 mL TylKR1 lysate and went to 
completion after 16 hours. The reaction yielding reduced diketide 2.6 was then extracted 
with EtOAc (3 x 50 mL), dried with MgSO4, filtered, and concentrated under vacuum to 
isolate reduced diketide 2.6 from the NADPH regeneration system. Reduced diketide 2.6 
was diluted in 5 mL 500 mM HEPES (pH 7.5) and combined with the reaction yielding 
2.1 and 20 mL of EryMod6TE lysate. The reaction was incubated in a total volume of 30 
mL. After 24 hours, the reaction was extracted with EtOAc (3 x 150 mL), dried with 
MgSO4, filtered, and concentrated under vacuum. The crude extract was then extracted 
with chloroform (1 x 100 mL) to remove remaining glycerol and concentrated to afford 
the crude product. The crude product was next purified via dry flash column 
chromatography (silica, 50% EtOAc:hexanes) to afford ketolactone 2.12, a white solid 









(5R)-2-methyl-3-oxooctanoic acid δ-lactone (2.13). Generation of methylmalonyl-S-
NAC (2.1) was performed in a 5 mL total volume containing 500 mM HEPES (pH 7.5), 
100 mM NaCl, 10% v/v glycerol, 120 mM methylmalonate, 120 mM ATP, 240 mM 
MgCl2, 100 mM NAC, and 0.5 mg/mL MatB and was reacted for 24 hours. Generation of 
reduced diketide 7 was performed in a 5 mL total volume containing 500 mM HEPES 
(pH 7.5), 100 mM NaCl, 15% v/v glycerol, 180 mM D-glucose, 5% v/v DMSO, 2 mM 
NADP+, 100 mM 2.4, 0.05 mg/mL GDH, and 1.3 mL TylKR1 lysate and went to 
completion after 16 hours. The reaction yielding reduced diketide 2.7 was then extracted 
with EtOAc (3 x 50 mL), dried with MgSO4, and concentrated under vacuum to isolate 
reduced diketide 7 from the NADPH regeneration system. Reduced diketide 2.7 was then 
diluted in 5 mL 500 mM HEPES (pH 7.5) and combined with the reaction yielding 2.1 
and 20 mL of EryMod6TE lysate. The reaction was incubated in a total volume of 30 mL. 
After 24 hours the reaction was extracted with EtOAc (3 x 150 mL), dried with MgSO4, 
filtered, and concentrated under vacuum. The crude extract was then extracted with 
chloroform (1 x 100 mL) to remove glycerol and concentrated to afford the crude 
product. The crude product was next purified via dry flash column chromatography 












(5R)-2-methyl-3-oxooctanoic acid δ-lactone (2.13). Generation of methylmalonyl-S-
NAC (2.1) was performed in a 5 mL total volume containing 500 mM HEPES (pH 7.5), 
100 mM NaCl, 10% v/v glycerol, 120 mM methylmalonate, 120 mM ATP, 240 mM 
MgCl2, 100 mM NAC, and 0.5 mg/mL MatB and was reacted for 24 hours. Generation of 
reduced diketide 2.7 was performed in a 5 mL total volume containing 500 mM HEPES 
(pH 7.5), 100 mM NaCl, 15% v/v glycerol, 180 mM D-glucose, 5% v/v DMSO, 2 mM 
NADP+, 100 mM 2.4, 0.05 mg/mL GDH, and 1.3 mL TylKR1 lysate and went to 
completion after 16 hours. The reaction yielding reduced diketide 2.7 was then extracted 
with EtOAc (3 x 50 mL), dried with MgSO4, and concentrated under vacuum to isolate 
reduced diketide 7 from the NADPH regeneration system. Reduced diketide 2.7 was then 
diluted in 5 mL 500 mM HEPES (pH 7.5) and combined with the reaction yielding 2.1 
and 20 mL of EryMod6TE lysate. The reaction was incubated in a total volume of 30 mL. 
After 24 hours the reaction was extracted with EtOAc (3 x 150 mL), dried with MgSO4, 
filtered, and concentrated under vacuum. The crude extract was then extracted with 
chloroform (1 x 100 mL) to remove glycerol and concentrated to afford the crude 
product. The crude product was next purified via dry flash column chromatography 
(silica, 50% EtOAc:hexanes) to afford ketolactone 2.13, a grey solid (3.4 mg, 4.0% yield 
from 2. 4). 
CHARACTERIZATION 
(2R, 3S, 4S, 5R)-3,5-Dihydroxy-2,4-dimethylheptanoic acid δ-lactone (8). 1H NMR 
(400 MHz, CDCl3) δ= 4.13 (m, 1H), 3.82 (dd, J=4.5 Hz, J=10 Hz, 1H), 2.47 (dq, J=4.5 
Hz, 7 Hz, 1H), 2.17 (m, 1H), 1.83 (m, 1H), 1.55 (m, 1H), 1.41 (d, J=7 Hz, 3H), 1.00 (t, 





39.84, 36.75, 25.26, 14.26, 9.86, 4.35. [α]D23 = +33 (c=0.21, CHCl3). HRMS (CI) (m/z) 
[M+H]+: calcd. for C9H16O3: 173.1178, found: 173.1176. This characterization is in 
agreement with literature reported data.[6] 
 
(2R, 3S, 5R)-3,5-Dihydroxy-2-methylheptanoic acid δ-lactone (2.9). 1H NMR (400 
MHz, CDCl3) δ= 4.16 (m, 1H), 3.76 (td, 10.5, 4.5 1H), 2.35 (m, 1H), 2.20 (m, 1H), 1.82-
1.62 (m, 3H), 1.41 (d, J=7 Hz, 3H), 1.00 (t, J=7 Hz, 3H). 13C NMR (100 MHz, CDCl3) 
173.53, 77.89, 70.48, 45.24, 37.84, 28.94, 13.63, 9.29. [α]D23= +31 (c=0.30, CHCl3). 
HRMS (CI) (m/z) [M+H]+: calcd. for C8H14: 159.1021, found: 159.1020. 
 
(2R, 3S, 5R)-3,5-Dihydroxy-2-methyloctanoic acid δ-lactone (2.10). 1H NMR (400 
MHz, CDCl3) δ= 4.24 (m, 1H), 3.76 (m, 1H), 2.35 (m, 1H), 2.20 (m, 1H), 1.78-1.46 (m, 
5H), 1.40 (d, J=7 Hz, 3H), 0.92 (t, J=7 Hz, 3H). 13C NMR (100 MHz, CDCl3). δ= 174.06, 
76.70, 70.15, 45.15, 38.26, 38.01, 18.12, 13.87, 13.62. [α]D21= +43 (c=1.01, CHCl3). 
HRMS (CI) (m/z) [M+H]+: calcd. for C9H16O3: 173.1178,  found 173.1178. 
 
(4S, 5R)-2,4-Dimethyl-3-oxoheptanoic acid δ-lactone (2.11). 1H NMR (400 MHz, 
CDCl3) δ= 4.65 (m, 1H), 3.61 (q, J=7 Hz, 1H), 2.62 (dq, J=7 Hz, J=3.2 Hz, 1H), 1.85 (m, 
1H), 1.65 (m, 1H), 1.36 (d, J=7 Hz, 3H), 1.12 (d, J=7 Hz, 3H), 1.07 (t, J=7 Hz, 3H).v 13C 
NMR (100 MHz, CDCl3) δ= 205.59, 170.23, 78.68, 50.55, 44.52, 24.18, 10.07, 9.88, 
8.39. HRMS (CI) (m/z):  calcd. for C9H14O3 [M+H]+: 171.1021, found: 171.1020. 
 
(5R)-2-Methyl-3-oxoheptanoic acid δ-lactone (2.12). 1H NMR (400 MHz, CDCl3) δ= 
4.64 (m, 1H), 3.57 (q, J=6.5 Hz, 1H), 2.74 (dd, J=2.8 Hz, J=19 Hz, 1H), 2.44 (dd, J=12 
Hz, J=19 Hz, 1H), 1.90-1.75 (m, 2H), 1.37 (d, J=6.5 Hz, 3H), 1.08 (t, J=7 Hz, 3H). 13C 
NMR (100 mHz, CDCl3) δ= 201.71, 170.07, 75.46, 51.80, 42.83, 27.65, 9.33, 7.93. 
                                                
v Note that the 1H splitting suggests that 2.11 is present as the keto tautomer in solution, which is in contrast 
to the solid-state (Figure C 6) where it is present as the enol tautomer. 
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HRMS (CI) (m/z) [M+H]+: calcd. for C8H12O3: 157.0865, found 157.0864. 
 
(5R)-2-Methyl-3-oxooctanoic acid δ-lactone (2.13). 1H NMR (400 MHz, CDCl3) δ= 
4.70 (m, 1H), 3.56 (q, J=6.5 Hz, 1H), 2.73 (dd, J=2.7 Hz, J=19 Hz, 1H), 2.47 (dd, J=12 
Hz, J=18 Hz, 1H), 1.6-1.4 (m, 3H), 1.36 (d, J=6.5 Hz, 3H), 0.99 (t, J=7 Hz, 3H). 13C 
NMR (100 MHz, CDCl3) δ=201.76, 170.13, 74.04, 51.82, 43.22, 36.47, 18.16, 13.79, 
7.83. HRMS (CI) (m/z) [M+H]+: cacld. for C9H14O3: 171.1021, found: 171.1021. 
MONITORING KETOLACTONE FORMATION VIA HPLC 
Generation of methylmalonyl-S-NAC (2.1) was performed in 500 mM HEPES (pH 8.0), 
100 mM NaCl, 10% v/v glycerol, 100 mM methylmalonate, 100 mM ATP, 200 mM 
MgCl2, 100 mM NAC, and 0.5 mg/mL MatB and was reacted for 48 hours. Generation of 
reduced diketides 2.5-2.7 was performed in 500 mM HEPES (pH 7.5), 100 mM NaCl, 
15% v/v glycerol, 5% v/v DMSO, 300 mM D-glucose, 1 mM NADP+, 100 mM β-
ketoacyl-S-NAC 2.2-2.4, 0.05 mg/mL GDH, and 20% v/v KR-containing lysate (EryKR1 
for 2.5, TylKR1 for 2.6-2.7) and went to completion after 16 hours. β-hydroxyacyl-S-
NACs 2.5-2.7 were extracted with ethyl acetate (3 x 100 mL), and concentrated under 
vacuum. Triplicate ketolactone reactions consisted of 250µL MatB reaction, 1 mL 
EryMod6TE lysate, an amount of extracted β-hydroxyacyl-S-NAC equivalent to that of 
methylmalonyl-S-NAC estimated by HPLC peak area in a total volume of 2.1 mL. 
Timepoints were taken at 0, 1, 2, 4, 8, 12, 22, and 24 hr by quenching 200 µL of the 
reaction with an equal volume of 2 M acetic acid in methanol and storing at -20 °C until 
analyzed. Before analysis, timepoint samples were centrifuged at 21,000 xg for 1 min (to 
pellet precipitate) and the supernatant was filtered through a 0.45 µm nylon membrane. 
For reactions yielding 2.11-2.13, 20-minute linear gradients (5-20% solvent B) were 
performed. For reactions yielding 2.12, an additional isocratic run (30% B) was necessary 
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to separate 2.6 from 2.12. 25 µL of the quenched reaction was injected for each timepoint 
and absorbance was monitored at 242 nm.vi Ketolactone formation was further confirmed 
via LC-MS (Table E2.1). Completion of KR reactions was judged by HPLC (15-minute 
gradient of 15-35% B, monitored at 234 nm). 
                                                
vi Note that when monitoring the disappearance of compound 1, the compound eluting directly before 1 
with a retention time of 9.3 minutes is residual acetyl-SNAC thioester, a minor impurity from the synthesis 
of N-acetylcysteamine. 
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Figure E2.1  Time course assays quantifying the formation of ketolactones 2.11-2.13 and 
the disappearance of both the reduced diketide priming unit (2.5-2.7) and 
extender unit 2.1 as monitored by HPLC peak area (in arbitrary units). A) 
Formation of ketolactone 2.11 primed with diketide 2.5. B) Formation of 
ketolactone 2.12 primed with diketide 2.6. C) Formation of ketolactone 2.13 
primed with diketide 2.7. 
Compound Formula Expected Found 
2.11 C9H14O3 171.09 171.4 
2.12 C8H12O3 157.08 157.2 
2.13 C9H14O3 171.09 171.2 
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Figure E2.2  Stacked HPLC plot of the disappearance of diketide 2.5 and extender unit 
2.1 and the formation of ketolactone 2.11 (monitored at 242 nm). 
 
 
Figure E2.3  Stacked HPLC plots of A) the disappearance of extender unit 2.1 and B) the 
disappearance of diketide 2.6 and the formation of ketolactone 2.12 
(monitored at 242 nm). 
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Figure E2.4  Stacked HPLC plot of the disappearance of diketide 2.7 and extender 
unit 2.1 and the formation of ketolactone 2.13 (monitored at 242 nm). 
THE 2S, 3R REQUIREMENT FOR DIKETIDE INCORPORATION BY MOD6TE 
 
Scheme E2.1  Schematic for the generation of all stereoisomers of diketide 5 by 
reducing with different types of isolated ketoreductases 
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Each of the stereoisomers of reduced diketide 2.5 were incubated with 
EryMod6TE; however, only reduced diketide 2.5 generated triketide lactone product. 
KR-containing lysate was employed to generate the diketide stereoisomers from diketide 
2.2 [AmpKR2(A1-type)[2] for the (2R, 3S)-diketide, RifKR7(A2-type)[2,3,5] for the (2S, 
3S)-diketide, TylKR1(B1-type)[2] for the (2R, 3R)-diketide, and EryKR1(B2-type)[2,5] for 
the (2S, 3R)-diketide] (Scheme E2.1). The reactions to form 2.5 and its stereoisomers 
were performed, extracted, and analyzed using the procedure detailed for the HPLC assay 
of ketolactone formation. Generation of 2.1 was also performed using the conditions 
described above. Triplicate ketolactone reactions consisted of 250 µL MatB reaction, 1 
mL EryMod6TE lysate, an amount of extracted β-hydroxyacyl-S-NAC equivalent to the 
methylmalonyl-S-NAC (as estimated by HPLC peak area), in a total volume of 2.1 mL.  
Timepoints taken at 0, 4, and 22 hr were quenched and assayed by HPLC as described 
above (Figure E2.5). 
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Figure E2.5  Time course plots of the incubation of methylmalonyl-S-NAC (2.1) and the 
stereoisomers of reduced diketide 5 (see Scheme E5.1) with EryMod6TE. 
Timepoints taken were at 0, 4, and 22 hours. All species were monitored by 
HPLC peak area (in arbitrary units). A) (2S,3R)-3-hydroxy-2-
methylpentanoyl-S-NAC (2.5), generated by incubating 2.5 with EryKR1 
(B2-type), yielded ketolactone 8. B) (2R,3R)-3-hydroxy-2-methylpentanoyl-
S-NAC, generated by incubating 2.5 with TylKR1 (B1-type), did not yield 
ketolactone. C) (2S,3R)-3-hydroxy-2-methylpentanoyl-S-NAC, generated 
by incubating 2.5 with AmpKR2 (A1-type), yielded trace quantities of 
ketolactone (consistent with the formation of the trace quantities of 2.5 as a 
side-product of the reduction of 2.5 by AmpKR2[2]). D) (2R,3R)-3-hydroxy-
2-methylpentanoyl-S-NAC, generated by incubating 2.5 with RifKR7 (A2-
type), did not yield ketolactone. 
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X-RAY EXPERIMENTAL  DATA FOR C9H14O3 (2.11) 
 
Figure E2.6 ORTEP diagram of 2.11 
Crystals grew as clusters of long, colorless needles by slow evaporation from 50% 
EtOAc:hexanes. The data crystal was cut from a larger crystal and had approximate 
dimensions; 0.48 x 0.12 x 0.10 mm. The data were collected on a Rigaku SCX-Mini 
diffractometer with a Mercury CCD using a graphite monochromator with Mo Kα 
radiation (λ = 0.71075 Å). A total of 540 frames of data were collected using ω-scans 
with a scan range of 1° and a counting time of 50 seconds per frame. The data were 
collected at 153 K using a Rigaku XStream temperature device. Details of crystal data, 
data collection and structure refinement are listed in Table 1. Data reduction were 
performed using the Rigaku Americas Corporation’s Crystal Clear version 1.40.[7[  The 
structure was solved by direct methods using SIR97[8[ and refined by full-matrix least-
squares on F2 with anisotropic displacement parameters for the non-H atoms using 
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SHELXL-97.9[8]  Structure analysis was aided by use of the programs PLATON98[10] and 
WinGX.[11]  The hydrogen atoms on carbon were calculated in ideal positions with 
isotropic displacement parameters set to 1.2xUeq of the attached atom (1.5xUeq for 
methyl hydrogen atoms). The function, Σw(|Fo|2 - |Fc|2)2, was minimized, where w = 
1/[(σ(Fo))2 + (0.0425*P)2] and P = (|Fo|2 + 2|Fc|2)/3. Rw(F2) refined to 0.114, with R(F) 
equal to 0.0599 and a goodness of fit, S, = 1.17. Definitions used for calculating R(F), 
Rw(F2) and the goodness of fit, S, are given below.vii The data were checked for 
secondary extinction effects but no correction was necessary. Neutral atom scattering 
factors and values used to calculate the linear absorption coefficient are from the 
International Tables for X-ray Crystallography (1992).[12]  All figures were generated 
using SHELXTL/PC.[13]  Tables of positional and thermal parameters, bond lengths and 
angles, torsion angles and figures are found elsewhere. CCDC number: 878292. 
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Chapter 3: Substrate Structure-Activity Relationships Guide Rational 
Stereochemical Engineering of Modular Polyketide Synthase 
Ketoreductasesviii 
INTRODUCTION 
Polyketides comprise a diverse class of natural products with intriguing carbon 
skeletons. Due to the stereochemical complexity of many polyketides, members of this 
class of natural products have been vibrant targets for developing and applying 
asymmetric methodologies.[1–4] In contrast to polyketides’ molecular complexity, 
polyketides are biosynthesized by multidomain megasynthase enzymes (termed 
polyketide synthases, PKSs) using remarkably simple biogenic precursors. PKSs perform 
extensions of malonyl-CoA or methylmalonyl-CoA through decarboxylative 
condensations followed by reductive processing by optional ß-carbon processing 
domains.[5] Of the ß-carbon processing domains, ketoreductase (KR) domains are 
responsible for the majority of the stereogenic centers in polyketides: KRs both 
stereoselectively reduce the ß-keto intermediates to a ß-hydroxy moiety and confer the 
stereochemical configuration of the α-substituent.[6] Additionally, KR domains possess 
sequence fingerprints, which enables prediction of the product stereochemistry. KRs that 
yield products with D-ß-hydroxyls are referred to as “A-type” and KRs that yield 
products with L-ß-hydroxyls are referred to as “B-type.”5 KRs that reduce D-α-substituted 
products are denoted as “1” and KRs that reduce L-α-substituted products are denoted as 
“2.”[6–9] 
                                                
viii Portions of this chapter are reproduced from the following publication: C. B. Bailey, M. E. Pasman and 
A. T. Keatinge-Clay, ChemComm, 2015, DOI: 10.1039/C5CC07315D. CBB performed the majority of the 
experimental work, and MEP helped with synthesis of standards. CBB and ATK evaluated the data and 
wrote the original text. 
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KRs’ natural substrates are ß-keto polyketide intermediates tethered to an 18Å 
phosphopantetheinyl prosthetic group (the phosphopantetheinyl arm”) of the acyl carrier 
protein. Frequently, KRs retain their stereochemical fidelity when reducing diketide N-
acetyl cysteamine (S-NAC) thioesters  (e.g. 3.1; Scheme 3.1), a common truncated mimic 
of the phosphopantetheinyl arm.[10] The relationship between the molecular similarity of 
the “handle” region of the substrate to the phosophopantheinyl arm and the 
stereochemical outcome of KR reductions is largely unexplored, as the majority of small 
molecule investigations of stereocontrol have been performed with S-NAC substrates.[10–
15] To date only one example is present in the literature wherein stereocontrol was 
examined with a small molecule substrate with a pantetheinyl handle. This report 
demonstrated that when the 1st KR of the erythromycin PKS (EryKR1) reduced 2-methyl-
3-oxopentanoyl-pantetheine, the kinetic parameters and stereochemical product 
distributions were virtually identical to EryKR1 reducing S-NAC substrate 3.1.[13] 
However, studies wherein the 1st KR from the tylosin PKS (TylKR1) was incubated with 
various oxo-ester substrates suggests that reversals in enatioselectivity may be correlated 
to unnatural handle structure.[16] To further dissect the interactions that mediate KR 
stereocontrol, we decided to systematically vary the stereoelectronic features of the KR 
handle. To this end, we synthesized congeneric thioester handles and evaluated the 
effects of structural alterations on KR stereoselectivity in a structure-activity relationship 
(SAR) fashion.  Here, we report the effects of altering thioester substrates in two key 
ways from canonical S-NAC substrates: atom substitution and truncation. 
USE OF A SUBSTRATE STRUCTURE-ACTIVITY RELATIONSHIP TO INTERROGATE 
STEREOCONTROL 
Four KRs were selected: EryKR1, TylKR1, the 2nd KR from the amphotericin 
PKS (AmpKR2), and the 7th KR from the rifamycin PKS (RifKR7) as representative B2, 
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B1, A1, and A2 type KRs, respectively. These KRs were chosen as they retain their 
stereochemical fidelity with 3.1, and are active in the presence of DMSO,[10,17] affording 
the ability to investigate hydrophobic substrate 3.3 (which required 20% v/v DMSO to 
solubilize enough substrate to observe activity). Biocatalytic screens combining KR, 3.1-
3.3, and an NADPH regeneration scheme (Scheme 3.1)[10] were incubated overnight, 
followed by analysis via chiral chromatography. To establish the elution order of the four 
stereoisomers for 3.3 and 3.2, we generated synthetic standards using a combination of 
stereospecific aldol reactions previously detailed by our laboratory[10,18] (experimental 
section).  The standards confirmed that each KR generated the predicted stereoisomer as 
the major product (experimental section). 
 
Scheme 3.1  KR-mediated reduction of 2-methyl-3-oxopentanoyl substrates with 
linkages to NAC (3.1), thioethylacetate (3.2), and ethanethiol (3.3) 
handles. GDH, glucose dehydrogenase. 






 71  
 
 
Figure 3.1. Percent conversion and stereoisomeric product ratios of (A) unmutated KRs 
and (B) EryKR1 point mutants and (C) AmpKR2, RifKR7, and TylK1 point 
mutants.  See experimental section for chromatograms and tables listing 
product ratios and percent conversions. The colors used correspond to those 
in Scheme 3.1. 
Given that stereocontrol is often observed with S-NAC substrates such as 3.1,[10]  
we sought to probe the role of the amide moiety.  As it has been shown that with 
EryKR1, the enzyme behaves identically toward 3.1 and the pantetheinyl analog (vide 
supra),[13] this suggests that longer mimics of the phosphopantetheinyl arm may not 
provide additional critical binding interactions. However, we hypothesized that the 
minimal polar feature retained between the pantetheine handle and the S-NAC handle 
(the amide moiety) might be a significant contributing element to stereocontrol, perhaps 
through hydrogen bonding interactions that guide substrate orientation. To test this 
hypothesis, we substituted the nitrogen atom of the amide to oxygen (3.2). Although this 
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atomic substitution is conservative, the ester linkage is distinct in a few ways: 1) it lacks a 
hydrogen bond donor, 2) it is a more flexible substrate, as it lacks hindered rotation 
arising from the amide C-N bond’s increased pi character and 3) it is far less polar. 
Surprisingly, the overall effects of this substitution on stereocontrol were relatively 
subtle. AmpKR2 generated the same minor products as it had with 3.1 (the B2 and A2 
products), however the stereoselectivity was significantly eroded: with 3.2, 31% of the 
overall products were non-A1 products, whereas for 3.1, only 6% of the products were 
unnatural stereoisomers (Figure 3.1A). TylKR1 produced the A2 stereoisomer (the 
enantiomer of its natural stereochemistry) as a minor product, which was also observed 
with 3.1.[10] EryKR1 was highly selective for the natural B2 stereochemistry with 
substrate 3.2, and RifKR7 generated its natural A2 product with perfect enatioselectivity 
(Figure 3.1A). We next decided to probe the role of this carbonyl via complete truncation 
to 3.3. Even more surprisingly, the results were similar to those with 3.2, except that 
stereoselectivity was further eroded for AmpKR2 and TylKR1 (Figure 3.1A). 
Additionally, EryKR1 appeared highly affected by the high DMSO concentration 
required to solubilize 3.3, whereas the other KRs were comparatively robust. 
A SAR-GUIDED POINT MUTANT 
Stereoselectivity with 3.3 demonstrates that no polar binding interactions from the 
handle are required to drive the formation of energetically favored transition states.  
Although this result was unexpected, it corroborates with a hypothesis presented by 
Leadlay and coworkers that KR stereocontrol is predominantly enforced by subtle 
stereoelectronic effects from active site residues.[11,14] To further probe this hypothesis, we 
generated point mutants of a representative KR, EryKR1. We chose a residue that is 
conserved in B2 type enzymes, leucine 1810, which is in close vicinity to both the 
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catalytic tyrosine and the cofactor[6,19] (Figure 3.2). L1810 is a fingerprint for predicting 
the stereochemistry of the α-methyl group: in B2 type KRs it is a usually leucine, in A2 
type KRs it is a histidine, and in B1 and A1 KRs, it is a glutamine[6] (experimental 
section). Furthermore, there is precedence for this residue being an important feature: the 
analogous residue in AmpKR2 was one of two residues mutated to completely reverse 
the stereocontrol of AmpKR2.[15] Thus, we generated the following point mutations to 
EryKR1: L1810H, and L1810Q, and L1810A. 
 
 
Figure 3.2  The active site of EryKR1 reveals the proximity of D1758 and L1810 to the 
catalytic tyrosine, Y1813, and NADPH (PDB code: 2FR1). 
The L1810H and L1810Q mutants were much less robust enzymes than wild type 
EryKR1: for all three substrates both mutants resulted in decreased activity and 
selectivity (Figure 3.1B). With 3.1, both mutants generated the natural B2 product 
whereas with 3.2, stereocontrol was significantly eroded (with 28% and 12% of and the 
A2 isomer for the L1810H and L1810Q, respectively). For 3.3, trace and no activity was 
observed with L1810H and L1810Q, respectively (Figure 3.1B). In contrast, the EryKR1 
L1810A mutant was both a highly active and highly stereoselective enzyme. Remarkably, 
however, the stereoselectivity, was entirely reversed from that of wild type, with selective 
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formation of the A2 product. By percent conversion, the EryKR1 L1810A mutant was 
more active than wild type. There was a subtle difference in product stereochemical 
distribution: as the handle became an increasingly poor mimic of the 
phosphopantetheinyl arm: for substrates 3.3, 3.2, and 3.1, the de values were 98%, 91%, 
and 69%, respectively (experimental section). Intriguingly, the enzyme generated the A2 
product with greater selectivity as the handle became increasingly unnatural. 
A SECOND RATIONAL MUTATION IS SYNERGISTIC 
A hypothesis for the function of the diagnostic fingerprint of B-type KRs, the 
LDD motif, is that these residues interact with the phosphopantetheinyl arm of the 
polyketide intermediate.[6,7,15,19–23] Structural characterizations have revealed that all KRs 
bind the NADPH cofactor in the same orientation (transferring the 4-pro-S-hydride). 
Thus, stereocontrol must arise from the substrate orientation. As such, in B-type KRs, the 
substrate must expose the si face, and in A-type KR the substrate must expose the re face 
to the cofactor.[7,20] The LDD motif is on a flexible loop that could interact with the 
substrate amide, thus positioning the diketide for reduction at the si face.[6,7,19,22] Indeed, in 
the crystal structure of a related enzyme, PhaB from Ralstonia eutropha H16 (a (R)-3-
hydroxybutyryl-CoA dehydrogenase), such an interaction is observed. A charged 
hydrogen bond is formed between an aspartate homologous to the second D of the LDD 
motif and the amide nearest the thioester in the bound acetoacetyl-CoA[24] (experimental 
section). Such an interaction with the LDD loop is consistent with the subtle differences 
in stereocontrol enforced by the EryKR1 L1810A mutant. For 3.1, hydrogen bonding 
with the aspartate residue can occur, which may account for the minor production of the 
B2 isomer. The enatioselectivity drastically increases as the atom is substituted to an ester 
in 3.2, thus unable to hydrogen bond with the aspartate in this fashion. With 3.3, near 
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perfect A2-enatioselectivity is observed, which is consistent with the handle structure 
completely precluding interaction with the aspartate. To further probe this hypothesis, we 
mutated the third D of the LDD motif (D1758) to generate both a D1758A single mutant 
and a L1810A/D1758A double mutant. 
The single D1758A mutation eroded B2 selectivity, however the B2 stereoisomer 
remained the major product for all three handles (Figure 3.1B). This indicates that L1810 
has a greater role in enforcing stereocontrol than hydrogen bonding with D1758. This 
result is consistent with the retention of stereocontrol in wild type EryKR1 with 
substrates 3.2 and 3.3, which are unable to hydrogen bond with D1758 (Figure 3.1B). 
Gratifyingly, for EryKR1 L1810A/D1758A, the two point mutations were synergistic: 
there was an enhancement of A2 selectivity over the L1810A single mutant for all 
substrates (99, 97, and 95% de for substrates 3.3, 3.2, and 3.1, respectively; Figure 3.1B, 
experimental section). Although the D1758A single mutant had diminished activity, the 
L1810A/D1758A had greater activity than wild type, just as had been observed with the 
L1810A single mutant (Figure 3.1B). Thus, through two point mutants an enzyme was 
designed that was both more active and more stereocontrolled than wild type. 
REVERSING STEREOCONTROL TO  FORM THE A2 STEREOISOMER IS GENERALLY 
ACCESSIBLE VIA ALANINE POINT MUTATIONS 
After determining that generating targeted point mutations was an effective 
strategy to reverse stereocontrol in EryKR1, we decided to probe how general this 
approach was. To this end, we generated analogous point mutations in RifKR7, TylKR1, 
and AmpKR2. In RifKR7, the residue appearing three residues N-terminal to the catalytic 
tyrosine is a serine (RifKR7 is unusual; as noted previously, typically this position is a 
histidine in A2 KRs), so thus we generated a RifKR7 S1474A mutant. The activity of 
RifKR7 S1474A was essentially identical to that of wild type, with only extremely subtle 
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differences in activity (Figure 3.1C). For substrates 3.2 and 3.3, the A1 stereosiomer was 
observed as a trace side product (1 and 0.4% of the overall product, respectively), which 
had not been observed in wild type RifKR7 (in wild type RifKR7, only the B1 product 
had been observed as a trace side product with substrate 3.1).  Additionally, the activity 
of RifKR7 toward substrate 3.3 was improved (80% conversion in wild type RifKR7 
versus 95% conversion with RifKR7 S1474A; Figure 3.1C, experimental section), 
perhaps suggesting that the alanine mutation confers enhanced DMSO tolerance relative 
to wild type enzyme. For AmpKR2 2292A, an increase in the amount of A2 product 
formed for all three substrates, however the reversals in stereochemistry were not as 
complete as they were for the EryKR1 L1810A mutant (Figure 3.1C). Although the 
major product in all cases was the A2 stereoisomer, for AmpKR2 2292A, significant 
formation of the natural A1 stereoisomer was observed (30, 22, and 40% of the overall 
products, for 3.1, 3.2, and 3.3, respectively). Interestingly, just has been observed with 
wild type, substrate 3.2 had significant formation of the B2 product compared to the other 
two thioesters (8, 14, and 2% of the overall products for 3.1, 3.2, and 3.3, respectively; 
Figure 3.1C, experimental section). 
For TylKR1, the residue appearing three residues N-terminal to the catalytic 
tyrosine is Q2341. Additionally, as TylKR1 is a B-type enzyme, it harbors an LDD motif. 
Thus, we generated three point mutations, just as we had with EryKR1: TylKR1 
Q2341A, TylKR1 D2288A, and TylKR1 D2288A/Q2341A (Figure 3.1C). For TylKR1 
Q2341A, in a similar fashion to EryKR1 L1810, increased formation of the A2 product 
occurred as the substrate became increasingly unnatural (42, 56, and 63% B1:A2 ee for 
substrates 3.1, 3.2, and 3.3, respectively; Figure 3.1C, experimental section). For 
TylKR1 D2288A, the mutation also increased the amount of A2 product formation, 
however not as effectively as TylKR1 Q2341A. Additionally, the TylKR1 D2288A 
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resulted in a less active enzyme when reducing substrate substrate 3.1 (41% conversion 
versus 97 and 69% conversion when reducing substrates 3.2 and 3.3, respectively; for 
wild type TylKR1, the conversions were 100, 93, and 82% for substrates 3.1, 3.2, and 
3.3, respectively; Figure 3.1C, experimental section). Although TylKR1 D2288A was 
completely anti diasteroselective when reducing substrate 3.1, there was an erosion of 
anti:syn diastereoselectivity for substrates 3.2 and 3.3 (76 and 80% anti:syn de, 
respectively; Figure 3.1C, experimental section). This suggests that in TylKR1 (like in 
EryKR1) the steric environment in the active site (i.e. Q2341) is a greater contributor to 
stereocontrol than hydrogen bonding interactions from the LDD motif (D2288). 
However, like the EryKR1 L1810/D1758 mutant, the two point mutations were 
synergistic: the TylKR1 D2288A/Q2341A double mutant had enhanced activity for all 
three substrates (100% conversion for substrates 3.1 and 3.2 and 96% conversion for 
substrate 3.3, Figure 3.1C, experimental section). The reversal to the A2 product with 
TylKR1 D2288A/Q3241A was similar, although not as complete as the analogous 
reversal of stereocontrol in EryKR1 (66, 63, and 71% ee for substrates 3.1, 3.2, and 3.3, 
respectively, Figure 3.1C, experimental section). Overall, the TylKR1 point mutants all 
behaved similarly to the analogous ones made in EryKR1. 
THE A2 STEREOISOMER IS THE “DEFAULT” STEREOCHEMICAL OUTCOME: 
BIOINFORMATIC AND PHYSICAL EXPLANATIONS 
Due to the chiral environment of the enzyme as well as the invariant orientation of 
the prochiral cofactor, there must be intrinsic facial selectivity. Empirically, it appears 
that A-type facial selectivity is favored. A few bioinformatic observations are consistent 
with this hypothesis. Although the first two L and D residues of the LDD motif found in 
cis AT KRs are not conserved in trans AT KRs, the second D of the LDD is invariant in 
all B-type KRs.[25–29] For A-type KRs, the analogous fingerprint is a conserved W.[8,9] 
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However, the W is entirely absent in trans AT A-type KRs (indeed, there are no 
identified fingerprints that correlate to trans-AT A type KRs).[25–29] Examples of cis AT A 
type KRs that lack the diagnostic W also exist.[30] The sequence variance in A-type KRs 
suggests that there may be many evolutionary solutions to A-type facial selectivity. In 
contrast, the D appears to be a significant contributing element to driving B-type 
reduction. Perhaps this sequence conservation is due to evolutionary pressure to retain 
features that guide the substrate to undergo the less intrinsically favorable facial 
selectivity (an energy diagram illustrating this putative facial bias is shown below; 
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Figure 3.3  Curtain-Hammet analysis of KR reductions (α-unsubtituted shown), 
demonstrating an energetic a facial bias for A-type ketoreduction. An 
energetic difference of ~3 kcal/mol would result in ~99% ee. 
The intrinsic preference for anti diasteroselectivity can be rationalized by the 
Felkin-Ahn model.[31] Under Felkin-Ahn selectivity, the nucleophile will approach in the 
least hindered fashion with the electrophile in the conformation that results to the least 
torsional strain (Scheme 3.2). Thus, interactions in the active site (e.g. steric clashes or 
hydrogen bonding) would be required to drive syn selectivity. Indeed, the effects of 
mutations on TylKR1 support this hypothesis: although they exhibited a similar reversal 
to the A2 product, the complete reversal of stereochemical outcome was not achieved to 
the same extent as with mutants of EryKR1, a naturally syn selective enzyme. A possible 
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explanation is that formation of the natural stereoisomer for TylKR1 (the B1 anti 
product) is a more intrinsically favored energetic pathway than formation of the natural 
stereoisomer for EryKR1 (the B2 syn product). Notably, anti selective (B1 and A2) KRs 
are found in modules harboring a DH.[6,9,22,30] Perhaps it makes evolutionary sense that in 
modules wherein stereochemical information is lost (i.e. the hydroxyl is dehydrated to an 
olefin), KRs have evolved to undergo more intrinsically energetically favorable 
reductions. Additionally, the hypothesis of an intrinsic preference for A-type facial 
selectivity and anti diastereoselectivity (resulting in an energetic “default” of the A2 
stereoisomer) is further supported by: 1) the activity of the RifKR7 S1474A mutant was 
essentially identical to that of wild type RifKR7 and 2) EryKR1, AmpKR2, and TylKR1 
all generated enhanced amounts of the A2 product with analogous active site mutations. 
With this rationalization in mind, the next challenge will be using a similar 
approach to engineer KR selective for a less intrinsically favored stereochemical outcome 
(e.g. a syn selective KR). This should be achievable, as kinetic data with 3.1 indicates that 
the energetic differences that lead to different stereoisomeric products in KRs are 
extremely small.[32] Indeed, with unnatural substrates such as 3.1-3.3, KRs are not acting 
as evolutionarily optimized catalysts; they are essentially relatively loosely bound chiral 
catalysts that aid asymmetric induction, and essentially follow the Curtain-Hammet 
principle (Figure 3.3). Energetic differences arising from asymmetric induction are 
notoriously small (95% ee typically results from an energetic difference of ~3 
kcal/mol[32]), which explains why minor perturbations to the active site yields drastic 
differences in stereochemical outcome. 
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Scheme 3.2  Felkin-Anh analysis the reduction of a diketide by NADPH, resulting in 
anti selectivity. 
FUTURE DIRECTIONS 
An exciting future direction is a collaboration that has been instigated with the 
group of Prof. Matthew Sigman at the University of Utah. Sigman and coworkers have 
used a “big data” Qsar approach to rationally predict and design asymmetric catalysts in 
the realm of synthetic organic chemistry.[33,34] Because KRs enforce stereocontrol with 
small molecule mimics through weak, non-colvalent interactions (e.g. hydrophobic 
interactions or hydrogen bonding), they may be an ideal model system for translating this 
approach to engineering enzymes. 
CONCLUSIONS AND OUTLOOK 
In summary, here we employ a substrate SAR approach to uncover the origins of 
KR selectivity, which, in turn can be used to guide mutagenesis. Through this method, we 
entirely reversed the stereoselectivity of EryKR1 through a mere two judicious point 
mutations. This approach was found to be general when similar mutations were 
introduced in RifKR7, TylKR1, and AmpKR2. These results demonstrate the utility of 
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applying simple physical organic models to both rationalize and engineer enzymatic 
stereocontrol. 
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Experimental Section for Chapter 3 
GENERAL CONSIDERATIONS 
Anhydrous tetrahydrofuran (THF) was distilled from sodium and benzophenone, 
and dichromethane (DCM) was distilled from calcium hydride. Thin layer 
chromatography (TLC) was conducted with EMD gel 60 F254 pre-coated plates (0.25 
mM). Fisher scientific silica gel 60 (particle size 230-400 µm) was used for flash column 
chromatography. 1H NMR data were acquired on a Varian Mercury 400 MHz instrument 
at ambient temperature and are reported in terms of chemical shift (δ ppm), multiplicity, 
coupling constant, and integration and are referenced downfield from (CH3)4Si to the 
residual solvent peak at 7.26 ppm for CDCl3 as an internal standard. 13C NMR data were 
acquired on either a Varian Mercury 400 MHz, 500 MHz, or 600 MHz instrument and 
are reported in terms of chemical shift and referenced to the residual solvent peak at 
77.16 ppm for CDCl3 as an internal standard. High-resolution mass spectrometry 
measurements were obtained by chemical ionization (CI) with a VG analytical ZAB2-E 
instrument. Characterization of 3.2,[1] (E)-4-ethylidene-3-methyloxetan-2-one,[2] 2-




methylpentanoyl)oxazolidin-2-one[6]) were in accordance with literature reported data. 
PROTEIN EXPRESSION AND PURIFICATION 
Bacillus subtillus glucose dehydrogenase (GDH),[1,9] TylKR1,[1,9] EryKR1,[1,9] 
AmpKR2,[1,9] RifKR7,[2,10] and all their respective point mutants were expressed in E. Coli 
BL21 (the expression plasmid for all proteins was pET28b, except RifKR7, which was in 
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pET28a). Starter cultures (50 mL) were grown to inoculate pre-warmed Luria broth 
supplemented with 25 mg/L kanamycin. 5 mL of starter culture was added to 1L of Luria 
broth supplemented with 25 mg/L kanamycin, and cultures were grown at 37°C until 
OD600=0.4. When OD600=0.4, the media was cooled to 15 °C and then induced with 0.5 
mM IPTG. After 16 hours, the proteins were harvested by centrifugation (3,000 xg for 20 
minutes), and the pellets were re-suspended in lysis buffer (100 mM HEPES, 500 mM 
NaCl, 10% v/v glycerol, pH 7.5). The cells were then lysed by sonication on ice and 
centrifuged (30,000 xg for 45 minutes) to remove cellular debris. The protein was 
purified by passing the crude lysate over a nickel-NTA column equilibrated with lysis 
buffer. The column was then washed with lysis buffer containing 15 mM imidazole, and 
the protein was eluted with lysis buffer containing 150 mM imidazole. Final protein 
concentrations were determined using a Thermo Scientific Nanodrop 1000. 
BIOCATALYTIC ASSAYS 
Reactions were modified from a method described previously[1] using the 
following conditions: 200 mL HEPES, 100 mM NaCl, 10% (v/v) glycerol, 200 mM D-
glucose, 5 mM NADP+, 5 mM diketide substrate (3.1-3.3), 0.1 μM Bacillus subtillus 
GDH, and 10 μM KR in a total volume of 1 mL. For reactions with substrate 3.3 20% 
(v/v) DMSO was added to solubilize the substrate.ix  After overnight incubation (18 
hours) at 23° C, the reactions were extracted with 2 volumes of ethyl acetate and 
evaporated to dryness. Subsequently, the reactions were diluted in ethanol (for substrate 
1) or running buffer (for substrates 3.2-3.3) and analyzed via chiral chromatography. All 
                                                
ix Screens were performed with less DMSO for substrate 2.3, however activity was not observed without a 
minimum of 20% (v/v) DMSO because an insufficient amount of the substrate was solubilized. Screens 
with varying amounts of DMSO were also performed with substrates 1-2, however because the DMSO 
interacted with the more polar atoms of the amide and ester and was difficult to remove, it interfered with 
the resolution on the chiral HPLC. 
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reactions were performed in duplicate.  Product ratios and percent conversions were 
determined via HPLC integration. 
 
Figure E3.1  Chiral chromatograms of reactions with 3.1, 3.2 and 3.3 and synthetic 
standards (see synthetic methods section). Standards were spiked with 
substrates 3.2 and 3.3 confirm the peak alignment. The elution order of the 
reduction products of 3.1 was reported previously.[1] 
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Figure E3.2  Chiral chromatograms of EryKR1 mutant assays. Wild type EryKR1 and 
RifKR7 are shown for reference 
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Figure E3.3  Chiral chromatograms of TylKR1, RifKR7, and AmpKR2 alanine mutant 
assays. 
Table E3.1 HPLC conditions for substrates 3.1-3.3. 
Substrate Solvent Flow Rate Column 
(Chiracel) 
3.1 7% ethanol:hexanes 0.8 mL/min OCH 
3.2 2% ethanol:hexanes 0.8 mL/min OJH 
3.3[1] 0.25% isopropanol:hexanes 0.8 mL/min OJH 
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 [a] Integrations are reported in arbitrary units. 
Table E3.3 Product Ratios (averaged over duplicate runs) 
KR (Substrate) % B1 
(2R, 3R) 
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There were deviations from previously published results1 with 3.1: [a] Product ratio reported previously: 
100% B2 product. [b] Product ratio reported previously: 89% B1 product, 7.9% A2 product, 2.7% A1 
product. [c] Product ratio reported previously: 1.3% A2 product, 93.2% A1 product, 5.5% B2 product. 
Table E3.4 Summary of Ketoreductase Assays 





























































































































































































































































[a] Conversion of total reduced product. [b] syn: anti or anti:syn  de depends on the major product. For 
wild type EryKR1, AmpKR2, EryKR1 L1810Q, EryKR1 L1810H (with 3.1 and 3.2), and EryKR1 D1758A 
the syn: anti de was calculated. For RifkR7, TylKR1, EryKR1 L1810H (with 3.3), EryKR1 D1758A, and 
EryKR1 L1810A/D1758A, RifKR7 S1474A, AmpKR2 Q2292A, TylKR1 Q2341A, TylKR1 D2288A, and 
TylKR1 D2288A/Q2341A, the anti:syn de was calculated. [c] Enatiomeric excess is calculated for the 
excess of the major product stereoisomer over all four stereosiomers. [d] Absolute configuration of the 
major product. [e] Reported previously as 66% conversion.1 [f] Reported previously as 78% conversion.1 
SITE DIRECTED MUTAGENESIS 
Site directed mutagenesis of EryKR1 used EryKR1 cloned into vector pET28b1 as 
a template and used the quickchange method. The following primers were used 
(mutagenesis sequence indicated in red): 
1) For L1810A 5’- gcctttggtgcaccgggtgccggcgggtatgcgccaggcaac-3’ and 5’-
gttgcctggcgcatacccgccggcacccggtgcaccaaaggc-3’ 
2) for L1810Q 5’- gcctttggtgcaccgggtcagggcgggtatgcgccaggcaac-3’ and 5’-
gttgcctggcgcatacccgccctgacccggtgcaccaaaggc-3’ and 
3) for L1810H 5’- gcctttggtgcaccgggtcacggcgggtatgcgccaggcaac-3’ and 5’- 
gttgcctggcgcatacccgccgtgacccggtgcaccaaaggc-3’ and 
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4) for D1758A 5’ gcggcggcaaccttggatgccggcaccgtcgatactctg-3’ and 5’ 
cagagtatcgacggtgccggcatccaaggttgccgccgc-3’. For the double mutant D1758A/L1810A, 
EryKR1 L1810A in pET28b was used as template. 
 
Site directed mutagenesis of TylKR1 used TylKR1 cloned into vector pET28b1 as 
template and used the quickchange method. The following primers were used: 
1) for Q380A: 5'-acatggggcaacgccggcgcgggtgcgtacgccgccgccaa-3' and  
5'-ttggcggcggcgtacgcacccgcgccggcgttgccccatgt-3' 
2) for D327A: 5'-ttccacaccgccgggattctggacgccgcggtgatcgacacgctg-3' and  
5'- cagcgtgtcgatcaccgcggcgtccagaatcccggcggtgtggaa 
For the double mutant D327A/Q380A, the TylKR1 Q280A in pET28b was used 
as template. 
 
Site directed mutagenesis of RifKR7 used RifKR7 cloned into vector pET28a10,11 
as template and used the quickchange method. The following primers were used 
(mutagenesis sequence indicated in red): 
1) for S296A: 5'-agcatcttcatgggtgccggcgccggtggttacgcggcagcgaat-3' and  
5'-attcgctgccgcgtaaccaccggcgccggcacccatgaagatgct-3' 
 
Site directed mutagenesis of AmpKR2 used AmpKR2 cloned into vector pET28b 
as template and used the quickchange method. The following primers were used 
(mutagenesis sequence indicated in red): 
for Q380A: 5'-tctggggcagcggtggcgcgcccggctacgccgccgccaa-3' and 
5'- ttggcggcggcgtagccgggcgcgccaccgctgccccaga-3' 
All mutations were confirmed by DNA sequencing. 







Figure E3.4  Image of the homologous aspartate residue hydrogen bonding with the first 
amide of the phosphopantetheinyl moiety of acetylacetyl-CoA (analogous to 
the amide in substrate 3) in the structure of (R)-3-hydroxybutyryl-coa 
dehydrogenase From Ralstonia Eutropha (pdb code 4N5M).[11] 
 
Figure E3.5  Sequence alignment of KRs indicating conserved fingerprint residues. 
Residues corresponding to hydroxyl stereochemistry (the conserved W of A-
type KRs and the LDD of B-type KRs)[12-14] are highlighted in magenta. 
Residues corresponding to α-substituent stereochemistry are highlighted in 
cyan.[14] 





(E)-4-ethylidene-3-methyloxetan-2-one. Dichloromethane (150 mL) and triethylamine 
(18.72 mL, 66 mmol, 1 eq) were added over 3Å molecular sieves to a flame-dried flask 
and cooled to 0°C.  Propionyl chloride (19.02 mL, 66 mmol, 1 eq) was added dropwise at 
0°C over a period of 90 minutes.  The reaction was then stirred at room temperature for 
16 hours, concentrated under vacuum, and filtered over celite to remove the 
triethylammonium chloride salt, affording a yellow oil (2.5 g, 33%). The characterization 
was in agreement with reported literature data.[2] 
 
 
2-mercaptoethylacetate. According to a modified literature procedure,5 2-
mercaptoethanol (0.65 mL, 7.6  mmol, 1 eq) and potassium flouride (0.93 g, 7.6 mmol, 1 
eq) were dissolved in acetic acid (15 mL) and heated at 80˚C for 16 hours. The reaction 
was diluted with water (50 mL), and extracted with ethyl acetate (2x 100 mL). The 
organic layer was then washed with saturated NaHCO3 (50 mL) and brine (50 mL), dried 
over Na2SO4, evaporated to dryness, and filtered over a plug of silica with 20% ethyl 
acetate: hexanes to afford a yellow oil (312 mg, 28%). The characterization was in 
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General Synthetic Route for 2-Methyl β-Keto Thioester Substrates (1-3): To a flame 
dried flask, methyl diketene dimer (427 mg, 3.8 mmol, 1 eq) and thiol (3.8 mmol, 1 eq) 
were added to dichloromethane (30 mL) at 0°C.  Catalytic triethylamine was added, and 
the reaction warmed to room temperature and stirred for 16 hours.  The reaction was then 
washed with saturated NaCl (1 x 30 mL), extracted in ethylacetate (2 x 50 mL) and 
concentrated under vacuum to afford the crude product.  The crude products were 
purified via dry flash column chromatography (silica, for 1 50% EtOAC:Hex, for 2 30% 
EtOAc:Hex, and for 3 EtOAc). An additional semi-preparative HPLC purification step 
was required for 3 to remove co-eluting impurities: Varian  
Microsorb-MV C18 column (250 x 4.6 mm, 5 µm particle size, 100 Å pore size) 
with a matching Metaguard column, 15-35% B over 30 minutes at 1 mL/min, with 
mobile phases consisting of water with 0.1% TFA (solvent A) and methanol with 0.1% 
TFA (solvent B). 
 
(R,S)-ethyl 2-methyl-3-oxopentanethioate (1). 1H NMR (400 MHz, CDCl3) δ 3.74 (q, 
J=7, 1H), 2.91 (q, J=7, 3H), 2.68-2.43 (m, 2H), 1.37 (d, J=7, 3H), 1.26 (t, J=7, 3H), 1.05 
(t, J=7, 3H). 13C NMR (100 MHz, CDCl3) δ 205.30, 196.71, 61.14, 35.70, 23.66, 14.44, 
13.54, 7.57. HRMS (CI) (m/z) [M+H]+: calcd. for C8H14O2S: 175.0793, found 175.0792. 
 
(R,S) 2-methyl((2-methyl-3-oxopentanoyl)thio)ethyl acetate (2). 1H NMR (400 MHz, 
CDCl3) δ 4.18 (td, J=6.5 Hz, J=1.3 Hz, 2H), 3.73 (q, J=7 Hz, 1H), 3.14 (t, J=6.5Hz, 2H), 








DCM, 0˚ to rt
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CDCl3) δ 204.79, 195.80, 170.45, 62.27, 60.91, 34.63, 27.81, 20.57, 13.43, 7.49. HRMS 




Scheme E3.1 Route for synthetic standards. 
General Synthetic Route for 2-Methyl β-Hydroxy Standards: Standards were 
synthesized using the method detailed previously by Piasecki et al.1 Briefly, the (2S, 3R)-
S-methyl 3-hydroxy thioester standards were synthesized via an Evans syn selective aldol 
reaction with (4,S)-Benzyl-3-propionyl-2-oxozolinone and propionaldehyde.4,5 The  (2R, 
3R)-S-methyl 3-hydroxy and (2R, 3S)-S-methyl 3-hydroxy thioester standards were 
synthesized as a mixture of diasteromers via the anti selective aldol reaction described by 
Heathcock et al with (4,S)-benzyl-3-propionyl-2-oxozolinone and propionaldehyde. The 
Heathcock adol uses conditions identical to the classic Evans syn selective aldol, except 
that two equivalents of dibutylboron triflate are added, and results in a mixture of 
diasteromers: an anti product with the same hydroxyl stereochemistry the Evans syn 
product and the non-Evans syn product.[7] Subsequently, the chiral auxiliary was cleaved 
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the appropriate thiol as described by Boddy et al.[6] The characterizations of the acyl 
oxazolinone intermediates were in agreement with literature reported data.[1, 4-8] 
 
(2R,3S)-S-ethyl 3-hydroxy-2-methylpentanethioate. 1H NMR (400 MHz, CDCl3) δ 
3.83 (m, 1H), 2.88 (q, J=7, 2H), 2.72-2.66 (m, 1H), 2.38 (br s, 1H), 1.52-1.39 (m, 2H), 
1.26 (t, J=7, 3H), 1.21 (d, J=7, 3H), 0.97 (t, J=7, 3H). 13C NMR (100 MHz, CDCl3 δ 
204.54, 73.58, 52.69, 27.15, 23.36, 14.79, 11.45, 10.51. 13C (500 MHz, CDCl3): 204.22, 
73.43, 52.63, 26.98, 23.14, 14.56, 11.25, 10.29 HRMS (CI) (m/z) [M+H]+ calcd. for 
C8H17O2S: 177.0949, found 177.0952. 
 
(2S,3R)-S-ethyl 3-hydroxy-2-methylpentanethioate  and (2R,3R)-S-ethyl 3-hydroxy-2-
methylpentanethioate were isolated as an inseparable mixture of diasteromers (4:3 
syn:anti dr). 1H NMR (400 MHz, CDCl3) δ syn diasteromer: 3.82 (m, 1H), 2.89 (q, J=7, 
2H), 2.72-2.66 (m, 1H), 1.52-1.39 (m, 2H), 1.26 (t, J=7, 3H), 1.21 (d, J=7, 3H), 0.97 (t, 
J=7, 3H). 13C (100 MHz, CDCl3): 204.26, 75.20, 52.80, 27.10, 24.00, 13.52, 11.54, 9.99δ 
anti diasteromer: 3.61 (m, 1H), 2.87 (q, J=7, 2H), 2.72-2.66 (m. 1H), 1.57-1.46 (m, 2H), 
1.26 (t, J=7, 3H), 1.23 (d, J=3, 2H), 0.98 (t, J=7, 3H). 13C (100 MHz, CDCl3): 204.22, 
75.57, 53.32, 27.77, 25.95, 13.11, 10.40. 9.89. HRMS (CI) (m/z) [M+H]+: calcd. for 
C8H17O2S: 177.0949, found 177.0954. 
 
 2-(((2R,3S)-3-hydroxy-2-methylpentanoyl)thio)ethyl acetate. 1H NMR (400 MHz, 
CDCl3) δ 4.32 (t, J=7, 2H), 3.88-3.81 (m, 1H), 3.15 (t, J=7, 2H), 2.76-2.69 (m, 1H), 2.08 
(s, 3H), 1.54-1.40 (m, 2H), 1.22 (2, J=7, 3H), 0.98 (t, J=7, 3H). 13C (150 MHz, CDCl3): 
202.78, 170.54, 73.34, 62.41, 53.40, 27.41, 29.56, 20.59, 13.70, 10.12. HRMS (CI) (m/z) 
[M+H]+: calcd. For C10H18O4S: 235.1104, found 235.1106. 
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2-(((2S,3R)-3-hydroxy-2-methylpentanoyl)thio)ethyl acetate and 2-(((2R,3R)-3-
hydroxy-2-methylpentanoyl)thio)ethyl acetate were isolated as an inseparable mixture 
of diasteromers (3:4 syn: anti dr). (400 MHz, CDCl3) δ syn diasteromer 4.32 (t, J=7, 2H), 
3.86-3.81 (m, 1H), 3.15 (t, J=7, 2H), 2.76-2.69 (m, 1H), 2.29 (br d, J=4 HZ, 1H), 2.08 (s, 
3H), 1.54-1.40 (m, 2H), 1.22 (d J=7, 3H), 0.98 (t, J=7, 3H). 13C (100 MHz, CDCl3): 
204.48, 170.37, 73.20, 62.25, 53.45, 29.39, 27.50, 20.38, 14.44, 9.90 (400 MHz, CDCl3). 
δ anti diasteromer: 4.18 (t, J=7, 3H), 3.68-3.61 (m, 1H), 3.13 (t, J=7, 2H), 2.78-2.69 (m, 
1H), 2.24 (br d, J=7.6), 2.06 (s, 3H), 1.63-1.51 (m, 2H), 1.23 (d J=7, 3H), 0.98 (t, J=7, 
3H). 13C (100 MHz, CDCl3): 204.48, 170.34, 74.64, 62.25, 53.70, 28.14, 27.24, 20.34, 
14.55, 9.33. HRMS (CI) (m/z) [M+Na]+: calcd. for C10H18O4S: 257.08180, found 
257.0821. 
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Chapter 4: A Trans-Acyltransferase Ketoreductase Reveals 
Architectural Features and Sequence Elements Unique to Split 
Bimodulesx 
INTRODUCTION 
Complex polyketides comprise a large, pharmaceutically relevant class of natural 
products biosynthesized by the multienzyme assembly lines, polyketide synthases 
(PKSs). Modular type I PKSs are comprised of a series of repeating enzymatic domains 
that each perform a discrete enzymatic function. These domains organize into “modules” 
that correspond to one round of elongation and reductive processing of a keto group. 
Type I PKSs are further subdivided into two evolutionarily distinct classes based on 
whether their acyltransferases (ATs) are embedded within the PKS or exist as free 
standing protein domains.[1] Of these two PKS classes, the “textbook” rules of polyketide 
assembly (wherein there is a one-to-one correspondence between protein sequence and 
metabolite structure, termed “colinearity”) are largely based on the dissection of cis-AT 
PKSs, such as the well studied erythromycin PKS.[2,3] In contrast, the biosynthetic logic 
of the trans-AT systems remains far more elusive, both because trans-AT PKSs have 
been identified more recently, and because of their much higher degree of modular 
variation which frequently incorporates aberrant domain order, inactive domains and 
repeating domains, which altogether serves to obfuscate the colinear relationship between 
synthase and product.[2] 
 
                                                
x Portions of this chapter are based on a manuscript in preparation for publication with the coauthors Drew 
T. Wagner, Darren C. Gay, Hannah R. Manion, and Adrian T. Keatinge-Clay. DTW and CBB are equally 
contributing co-first authors. DTW solved the PksKR2 crystal structure with the assistance of DCG, CBB 
performed the functional analysis, and HRM assisted with protein purification. The majority of the 
structural and bioinformatic analysis was performed by CBB and DTW. DTW, CBB, and ATK analyzed 
the data and are in the process of writing the manuscript. 
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Of the more common structural deviations exemplifying the peculiar architecture 
of trans-AT PKSs are modules “split” between two polypeptides (i.e. domains that 
process the same keto group are appear on separate gene products). One of the most 
prevalent forms of this “splitting” arises when the dehydratase domain (DH) appears on 
the N-terminus of a downstream polypeptide. These split bimodules conform to one of 
two domain orderings, denoted by Piel as type A and type B bimodules.[2] Type A split 
bimodules, correlated with the addition of two carbons in the form of a cis-olefin, are 
comprised of a ketosynthase, ketoreductase, acyl carrier protein, and inactive 
ketosynthase (KS+KR+ACP+KS0) at the C-terminal end of the upstream polypeptide and 
a dehydratase and acyl carrier protein (DH+ACP) at the N-terminal end of the 
downstream polypeptide. Type B split bimodules, though similar to type A bimodules, 
are correlated with the addition of four carbons in the form of an α,β-trans γ,δ-cis-diene 
and consist of a ketosynthase, ketoreductase, acyl carrier protein, and a second active 
ketosynthase (KS+KR+ACP+KS) at the C-terminal end of one polypeptide and a 
dehydratase, acyl carrier protein, and KR (DH+ACP+KR) at the N-terminal end of the 
subsequent polypeptide (Figure 4.1A).[2] 
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Figure 4.1  A) PksX biosynthetic gene cluster from Bacillus subtilis. Two type A 
bimodules are found, one between the C-terminus of PKSJ and the N-
terminus of PkSL and a second between the C-terminus of PkSL and the N-
terminus of PkSM. B) Schematic of the two types of split bimodules, the 
type A bimodule (featuring a non-elogating KS0 and yielding a cis double 
bond), and the type B bimodule (featuring an elongating KS and yielding an 
 α,β-trans γ,δ-cis-diene). The timing of the dehydrations is unknown. In 
type A bimodules, the dehydration could occur on the ACP of the upstream 
module or the downstream module. For type B bimodules, it is likely that 
the DH acts twice, once to form a cis double bond and once to form a trans 
double bond. 
Because there has been little experimental interrogation of split bimodules, their 
mechanistic features and modular organizations are poorly understood. Indeed, only a 
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few reported experimental results have uncovered any mechanistic aspects of type A 
bimodules.  Piel and coworkers demonstrated that for both of the type A bimodules in the 
bacillaene pathway, there was an accumulation of intermediates with mass differences 
corresponding to the hydrated and dehydrated products on the two ACPs of the 
bimodules. This result indicates the N-terminal DH as the most likely candidate for 
catalyzing the dehydration, despite its presence in the downstream polypeptide.[4] A 
second investigation demonstrated that for type A bimodules, the condensation-inactive 
KS0 motif is a crucial feature[5] for polyketide production. Even fewer experimental 
details regarding the mechanistic aspects of type B bimodules exist. However, chemical 
and biosynthetic logic suggests that the N-terminal DH likely operates twice: once on the 
intermediate bound to the ACP of the preceding module and a second time on the 
intermediate bound to the ACP of the module in which it is located. With regard to 
chemical logic, the activation of the proton α to the keto moiety is far greater than the 
proton α to a hydroxy moiety that would result from two sequential dehydrations on the 
second ACP. With regard to biosynthetic logic, α, β processing seems far more in line 
with typical keto processing than γ,δ processing. 
The polyketide, bacillaene, is produced by a prototypical trans-AT PKS, a non-
ribosomal peptide synthetase (NRPS)-PKS hybrid endogenous to B. subtilis and B. 
amyloqiufaciens FZB42.[2,6–8] Bacillene’s polyene structure (Figure 4.1) is an example of 
the collaborative action of tandem pairs of KR and DH domains (two of which are 
installed by type A split bimodules). In polyketide biosynthesis, cis olefins are installed 
by the syn-coplanar dehydration of L-β-hydroxyacyl intermediates, whereas trans-olefins 
arise from D-β-hydroxyacyl intermediates.[9–18] PKS KRs are classified by their 
stereoselectivity: A-type KRs catalyze the formation of L-β-hydroxyacyl intermediates, 
whereas B-type KRs catalyze the formation of D-β-hydroxyacyl intermediates. In cis-AT 
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pathways, the KR domains possess signature sequence fingerprints that enable the 
prediction of the hydroxyl configuration (and thus the olefin geometry installed by the 
DH). A type KRs contain a conserved tryptophan, whereas B-type KRs contain and a 
leucine-aspartate-aspartate motif.[11,19,20] The fingerprints found in KRs from trans-AT 
pathways, however, are far less robust. Currently, the only sequence fingerprint 
correlated with stereochemical outcome in trans-AT PKSs is a single aspartate residue, 
which corresponds to the second D of the “LDD” motif. For trans-AT A-type KRs, no 
sequence fingerprints have been identified; thus assignment of KRs as A-type arises 
solely from the absence of this diagnostic aspartate.[21–25] As the only crystal structure of a 
KR from a trans-AT pathway is a B-type KR (PksKR1),[25] no structural clues are 
available that illuminate A-type stereocontrol in trans AT pathways. 
Here we report the first structural analysis of an A-type KR from a trans-AT 
pathway, the KR from the second module of the bacillaene synthase. In addition, it is the 
first KR solved that resides within a split bimodule (a type A split bimodule). The 1.98 
Å-resolution structure reveals several features that are absent in other structurally 
characterized KRs. An active site loop reveals an ordered hydrogen-bonding network that 
may contribute to enforcing A-type stereocontrol. Most strikingly, the structure reveals 
an exposed hydrophobic helix, which is associated exclusively with the first KRs of split 
bimodules. Because this helix is present in every type A and B split bimodule KR, we 
hypothesize that it may be involved in protein-protein recognition events to recruit the 
upstream DH. Bioinformatic analysis indicates that this helix corresponds to an insertion 
within the protein sequence, as well as several other diagnostic sequence motifs. Based 
on the analysis of the KR types present within split bimodules, it appears that type A split 
bimodules always generate α,β-cis olefins, whereas type B split bimodules always 
generate α,β-trans- and γ,δ-cis dienes, which has implications for the reassignment of 
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biosynthetic intermediates in known pathways. We also envision that several of these 
notable sequence elements will have diagnostic utility in future genome mining 
applications. 
OVERALL STRUCTURE   
The crystal structure of PksKR2 was solved to 1.98 Å using molecular 
replacement with PksKR1 (PDB code 4J1Q) from the bacillaene synthase (from B. 
subtilis sp. 168) as a search model.[25] The construct encoding the polypeptide fragment, 
PksKR2, spanned residues 3954–4459 of the PksJ protein, with the first 14 and final 33 
residues absent in the X-ray structure. The remainder of the structure, aside from the 
omission of residues 69-73 and 207-210 due to poor electron density, was complete. 
PksKR2 crystallized in a complex with an NADP+ cofactor in space group P212121, with a 
single monomer in the asymmetric unit (Table 4.1). 
Like previous KR structures, PksKR2 is comprised of two domains: an N-
terminal structural subdomain and a C-terminal catalytic subdomain. Both domains 
contain the Rossmann fold common to short-chain dehydrogenase/reductase (SDR) 
enzymes, however the structural subdomain lacks the NADP+ cofactor. Clear density was 
observed for the entire NADP+ cofactor, which makes multiple contacts with the enzyme 
(Figure 4.2c). The active site of the catalytic subdomain includes the critical tyrosine, 
Y386, which acts as a general acid, as well as the conserved lysine and serine residues 
(S347 and K371).   When comparing the structure to PksKR1 (PDB code: 4J1Q), a high 
degree of structural similarity between the two proteins is observed with an almost 
complete overlay of secondary structure (aside from a few structural elements; Figure 
4.2A), as exemplified by an overall R.M.S.D. of 1.9 Å. 
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Table 4.1 Data collection and refinement statistics. 
Data collection PksKR2  
Wavelength (Å) 1.0332 
Space group P212121 
Cell dimensions,  a, b, c (Å) 46.1, 84.9, 134.3 
Resolution (Å) 50.00–1.98 
Rmerge 0.082 (0.681) 
I/σ(I) 21.8 (1.76) 
No. of reflections 34894 
Completeness (%) 97.1 (87.2) 
Redundancy 6.4 (5.6) 
Wilson B value (Å2) 40.1 
Refinement   
Resolution (Å) 71.74–1.98 
No. of reflections 34894 
Rwork/Rfree 0.204/0.236 
No. of atoms  
   Protein 3565 
   Water 16 
Average B factors (Å2)  
   Protein 40.52 
   Water 30.18 
RMS deviations  
   Bond lengths (Å) 0.024 
   Bond angles (°) 1.766 
Ramachandran Statistics (%)  
   Preferred Regions 97.76 
   Allowed Regions 2.24 
   Outliers 0 
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Figure 4.2  New structural elements of PksKR2. A) Structural overlay of PksKR2 and 
PksKR1 (4j1q). New structural features (including the insertion helix, an 
additional β-strand, and a new ordered loop) are shown in gold. B) The 
hydrogen bonding network found in the new active site ordered loop region 
preceding to the catalytic tyrosine, featuring Q383 and various backbone 
carbonyls, including L379. C) The NADPH binding region has a new ionic 
interaction with R228. D) Overlay of PksKR1 and PksKR2 in the “LDD 
loop” region, indicating that in PksKR1, the diagnostic D275 is poised to 
interact with the elongating intermediate, whereas in PksKR2 M327 is in 
this position. Additionally, the LDD loop of PksKR1 is larger by 
approximately 3 residues, which orients the flexible loop to interact with the 
substrate in a different fashion. 
DEVIATIONS FROM OTHER KETOREDUCTASE STRUCTURES 
The structure of PksKR2 reveals several features not observed in other KR 
structures. The conserved motif of the dinucleotide binding site present in both A and B 
type KRs from cis and trans-AT pathways, is altered in these KRs compared to all other 
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types (typical consensus sequence: GGTGGTGxLG; split bimodule KR consensus 
sequence: GGTRGLG[A,L]). In particular, this conserved arginine (R228) makes ionic 
interactions with both the 5’ and 2’ phosphates of the NADP+ cofactor (Figure 4.2c). 
Additionally, PksKR2 contains an extra β-sheet in comparison to PksKR1 in the 
structural subdomain and a new ordered loop in the active site region appears in PksKR2, 
which, by sequence, appears to be absent trans-AT KRs that are not embedded within 
split bimodules (Figure 4.2A-B, Figure 4.3). The most striking difference between 
PksKR2 and PksKR1 is the presence of an additional surface helix of approximately 15 
residues located approximately 20 residues downstream of the dinucleotide-binding site 
within the C-terminal catalytic subdomain of PksKR2.  This inserted helical region 
sharply protrudes from structure and is not present in any of the other nine KRs solved to 
date (Figure 4.2A). 
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Figure 4.3  Sequence alignment of the catalytic subdomain of trans-AT KRs. Split 
bimodule KRs are denoted as A’. The diagnostic B-type D is indicated by a 
red asterisk. 
  TT                                                        PksKR2_A’_splitA  
1       10        20        30        40        50          
PksKR2_A’_splitA            GG    G                   G                       V LIT  GI L A A G KLVL  R LFPKDH L TR L C RHF ECY VK T EQ PPREEWARF...KTSNTSL
BonKR5_A’_splitA            GG    G                   G                       V LIT  GI A V R G RLVL  R LFPDAH L TR YRC QHF R H VR T EA PPRHEWQAR...RDEPGAT
EtnKR09_A’_splitA           GG    G                   G                       V VT  GI L A V G KLVL  R LYPPAE LW TR M C KHF DAH VR M EA PERDAWDAYLT.SGSDEIC
ThalKR6_A’_splitA           GG    G                   G                       IT  GL A LV R G RLLL  R LLGPDDCVW TR LTC RH S H VR T TA PPRSEWDAL...GARDADF
DifKR9_A   _splitB           GG    G                   G                       V MIT  GI I A AV R G KLVI  R LFPKDA L SR A A EH S . CR M EP PDSSEWADM....KKDGIL
MlnKR10_A’_splitB           GG    G                   G                       A VIT  GI A A LV R G KLVL  LFPADK I TG R I ED K . VK T TRP PLRSEWDHLLKEGRQDEKT
ChiKR11_A’_splitB           GG    G                   G                       LVS  GL A LV R G RLAL  R LIAAGRPI MQ AEV RH R . AR L KP PPRERWRALVADPARDPLT
LeiKR2_A’_splitB            GG    G                   G                       A LVT  GI A LV R G RIAL  PAVDR Y TR ARV RL R . AR T ARPQPPRADWPLL....SPGTPE
ThalKR1_A                   GG    G                   G                       LLT  GL L A LM R RVVA  RLRTGGCY LG R F VR R .YGA L SAHDAGVQ..............
DifKR5_A                    GG    G                   G                       LIT  GL L A K G LIL  R AIKSGKTY CG L F GYFSG . PVT T SA DGSVL..............
EtnKR19_A                   GG    G                   G                       V VIT  GL V LA R RIAL  RLRDGG Y AG Q FGEH R .CAG V RRRDERIE..............
EtnKR10_B                   GG    G                   G                       V LT  GL I A IA VVL  R LFEAGG YW LG R F RH GT.AGAT T SP SEESR..............
MlnKR7_B                    GG    G                   G                       V LIT  GL L A LA KLIL  R AVKKNG Y AG Y F EY KQ.AEV T SP SRETA..............
PksKR1_B                    GG    G                   G                       V LIT  L L A IA R G IVL  R LWKDEG Y AGS L F KE N T RST T SV SEDKE..............
                                              ..............PksKR1_B          
          .                                                 PksKR2_A’_splitA  
 60         70         80        90        100       110    
PksKR2_A’_splitA                G                                    H AG     V L  V V L L D V L I G I GVI   AEKIQA RE .EAK .Q EMLS T S DAQ EQT QH KRT.L P G C LTDMD
BonKR5_A’_splitA                G                                    H AG     V L  A V V L D L L V G I GVL   GDKIRD LA .EAE .Q EVLA P S PAA RAA RE TAT.L P G C RVDAE
EtnKR09_A’_splitA               G                                    H AG     I L  A V L D M V V G A GVV   KRKIED LY .EAR .Q RVSTTP T EAR ASE AR RRE.M E L C NTDFT
ThalKR6_A’_splitA               G                                    H AG     L L  A I V L D V L V G V LV   ARRAAG RA .EAM .R EYSA A D ARA AAE AR RPT.L A TA C AVDWS
DifKR9_A   _splitB               G                                    H AG     M L  A I V L D I I G I GV    PEKAER QR .AER .E RYYS S T QKG RKMTDS RGT.M P T F C AMG.E
MlnKR10_A’_splitB               G                                    H AG      V L L V I GVI   VSNIKLFQSF.EEK .NYLYYSGS TNEEK RSFFHQ SLE.FKD S C LHSGG
ChiKR11_A’_splitB               G                                    H AG     V L  A V L D L L L G L GVV   AARVAL LD .EAS .E RIYVGS T REA QGF GG ERD.L P G C EMRTS
LeiKR2_A’_splitB                G                                    H AG     V L  A V L E L V G I GVV   AETASL AE .EAQ .R LVHSGP S RERTDRF RE REV.L P G C RGPVG
ThalKR1_A                       G                                    H AG     V L  A L A V D M L I G L GVI   ....AS AA CAEA GT RYLQ D C AAA AAV DD GRH.E R N A CE..D
DifKR5_A                        G                                    H AG     I L  A V A A D M L V G I GVI   ....NK KR .EES .K FYVQ D A QAQ EKG QE KEKGC P H A LQ..G
EtnKR19_A                       G                                    H AG     L L  A A A V D M V I G I GVL   ....AQ GR .REA TE EYFE D A AAQ SGA AA EAR.W A H A VE..S
EtnKR10_B                       G                                    H AG     L L  A I A V D L L I G L GIL   ....AW DA RATT .T DYLP D A ERR RTV AD KER.H R T G VL..R
MlnKR7_B                        G                                    H AG     L L  A A A I I I G L GIL   ....QK SA .ENL .E LYVP D SKEKETDAL KY KQT.F E N S LV..K
PksKR1_B                        G                                    H AG     L L  A V A V D V L I G L GII   ....NE EA .RSI .E VYRE D S QHA RHL EE KER.Y T N G SS..K
....      .                                                 PksKR1_B          
                                                            PksKR2_A’_splitA  
   120       130       140       150       160       170    
PksKR2_A’_splitA                V   K                     FSS          G   Y  I K I  L P V GL L PL F VL   V AIIP A Q D AMTLAF R TSDD QR E S TT YRHVCNE Q F S ELS A
BonKR5_A’_splitA                V   K                     FSS          G   Y  L K M  L P M GL L PL F VL   V AAVP V Q D AMQPAL R RAHT QP E A DT LACLDPA R V S ALA S
EtnKR09_A’_splitA               V   K                     FSS          G   Y  V K I  P I GV L V PL F LL   V AAVP V Q E AMNPAF R TRAG EG SA R DV RQ FADV R V A RLA S
ThalKR6_A’_splitA               V   K                     FSS          G   Y  K M  L P GL V A PV VL   V AAIP A Q D AEPAFFA SRES RA Q TA AT VD LAGA KRI A ALG A T
DifKR9_A   _splitB               V   K                     FSS          G   Y  K I  P V GL L A PL F IL   V LIP A Q D AMHPAFYN TETE ES CK T RG YE VQNE S F SG SLA S
MlnKR10_A’_splitB               V   K                     FSS          G   Y  I K  P V GL L I PL F IL   I A P  D ANPAF H RMSEFKT YG T QN ER FNNR D F A QS KLSK MT S
ChiKR11_A’_splitB               V   K                     FSS          G   Y  I K I  L P V GL V L PL F V    V ALIP A D AATPAF H DIAD AA S D QL HE TSTS D F T A RLS IL
LeiKR2_A’_splitB                V   K                     FSS          G   Y  I K  L P GL L L F VL   L AVAP A D AARPSF G ELADFDP E TT EV DE CAGDRPE F S GLA VL
ThalKR1_A                       V   K                     FSS          G   Y  A K V  L P L A L L PL F L   L IVG   ALRASL D SLDD HA A AA TV DR TAGL D VC AG D..F CGA
DifKR5_A                        V   K                     FSS          G   Y  L K  L P A G L V PL F    AILG  S D AMTESI E DLQTFQQ S D TAV DQ LSRE D FCC SS D..F C
EtnKR19_A                       V   K                     FSS          G   Y  V R V  A P V G I V PL F L   AVLG  S D ASGAV D SWEQ AA R E TRV DE TARQ D MC TA D..G C T
EtnKR10_B                       V   K                     FSS          G   Y  A K L   A GL I A L F VL   A AV G A Q D VADSTI K TAAE EA FAA L LA DE TRHED D L S W N.. A
MlnKR7_B                        V   K                     FSS          G   Y  I K I  I P V G L A PL F VM   L AVLP A Q D ADAFI K TKES EE A F TVW DK AEEE D F S N.. S F
PksKR1_B                        V   K                     FSS          G   Y  I K  L P V GL V PL F I    V LG A Q D AADRFI H TNEEFQE Q S LH DECSKDF D F F SGC N.. A
                                                            PksKR1_B          
           .......                                          PksKR2_A’_splitA  
   180              190       200           210       220   
PksKR2_A’_splitA   N                           W  W    M                      A YMD FA ISVQ P  KE G GL IS Y EA.......HQKHAPI N T GE....VTNQAYRDS LS TN
BonKR5_A’_splitA   N                           W  W    M                      A YMD A LSIQ P  RD G GA YV QA.......QAARLPI S S GE....SRSAVYQGL FLSHGD
EtnKR09_A’_splitA  N                           W  W    M                      A YLD A ASIQ P  KD G GLA YV AAG.....FGPKVAHC S T GA....ASSAAYRST QTCAD
ThalKR6_A’_splitA  N                           W  W    M                      A WLD FA VSVQ P  R G GL LA Y RA.......YARALPV N GA GE....VRSRAYAQS SA DD
DifKR9_A   _splitB  N                           W  W    M                      A FMD FA VQ P  KE G GL LS S NHQ.....AGKGNVFVKA V T AEGL..PETPAYQKS SR SA
MlnKR10_A’_splitB  N                           W  W    M                      A YMD FA SIN P  KE G GL LA Y AYH.....FQKGRTYFT S V GT....VTSPLYDEL DS ST
ChiKR11_A’_splitB  N                           W  W    M                      A FMD FA SIQ  G LA V AQR.....AAAGERHVR SR QGG AG....EGTRRFEEWD PTYST
LeiKR2_A’_splitB   N                           W  W    M                      A FLD YA SV  P  E G GV LA C DHQ.....VRSGRPWFR A T S S GA....DRPDSCAPV GP GD
ThalKR1_A          N                           W  W    M                       L YA V I  P  RD  G LG RL MS QRADGRVDAHGRRRRV A A L GA GFDDPVKRDRYLAAS QRM DA
DifKR5_A           N                           W  W    M                       F FV L IN P  KE G G LG R QMA RHRDKLVSLGLRSGKS A L G HVGTAESTDMYLKSS QRY YT
EtnKR19_A          N                           W  W    M                      A F YA V V  P  RD G G LR QVA QHREQLRRRGERSGAT A C L G GAVGSEGIEMYLRTS QRY ER
EtnKR10_B          N                           W  W    M                      A LD FA LSI  P  R G GL LAL E VHRNELVKAGRRSGRT D L SG KVDDA.NERLVERAY VP DE
MlnKR7_B           N                           W  W    M                      A MD F LSIN P   GL LGC G TQYR....SMKGRPGKT L DAGN TVGP..GELQALRHA EL SA
PksKR1_B           N                           W  W    M                      A FMD FA IS N P  E G GM MS A EYRRSLAASKKRFGST F L E G QVGAE.DEKRMLKTT VP PT
                                 TT                         PksKR1_B          
                  .       TT                                PksKR2_A’_splitA  
    230       240        250                                
PksKR2_A’_splitA    G                                                         E L D IV VL LS RFL Q SKKFGPV. PAMANQTN.WEPEL MK....
BonKR5_A’_splitA    G                                                         D L M D L VL LA R L AQ ARRYGPV. PAQVDGSR.WQPEV MR....
EtnKR09_A’_splitA   G                                                         E L D IL VM LD RFL E ARRLGPV. PLVIDEAR.FDTRA LR....
ThalKR6_A’_splitA   G                                                          L L D AL VLAQ A F W ERMPAPV. PAFVRDGE....RPWLDWLG.
DifKR9_A   _splitB   G                                                         D L D II I LE KFL Y LNGQSC..G PCVPEDSE.PDFGD LK....
MlnKR10_A’_splitB   G                                                         E L I AL II LR A LYH ERKSSN.. PIVKKGTV.FHADS LN....
ChiKR11_A’_splitB   G                                                         E L L D AV V AA S L Q RLHGAPC. FAGRKLPEE....AA ERWLQ.
LeiKR2_A’_splitB    G                                                         E L V E IL IV LE R L R ALPAEQAR PCPPIDGIAADPAA LG....
ThalKR1_A           G                                                         E E LL VL ID FAWF R ASPSAAPV AGER........AR VSWLG.
DifKR5_A            G                                                         E L A E LL VL AE E F T VQPSSQYL AGFP........SR KRFLQ.
EtnKR19_A           G                                                         E L A E AM VL VA A W R GAGVSPRL AGQP........RR HGFLS.
EtnKR10_B           G                                                          L A E AM VL LAA W F V RSSLAQVV SGQA........EK RSKVI.
MlnKR7_B            G                                                          L A M VI IQA A FQDS SRSASQLA SGDK........DR SELLST
PksKR1_B            G                                                          L A I VM MDS K FYQG VSDKPQVF EGQL........QK KQKLL.
                         ........                           PksKR1_B          
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STRUCTURAL FEATURES THAT MAY CONTRIBUTE TO A-TYPE STEREOCONTROL 
Several structural features of PksKR2 illuminate how A-type stereocontrol may 
be enforced. The structural dissection of PKS KRs has revealed that all reductase-
competent KRs bind NADPH in the same orientation, transferring the 4-pro-S-hydride to 
the β-carbonyl of the polyketide intermediate.[11,12,25–29] Thus, KR stereocontrol arises 
solely from the substrate orientation, which is dictated by the stereoelectronic 
environment of the active site. One of the residues hypothesized to interact with the β-
keto moiety is the third D of the LDD motif. This D is located on a loop that appears 
directly above the catalytic tyrosine, termed the “LDD loop.[11,30,31] It has been suggested 
that this conserved D hydrogen bonds with the phosphopantetheinyl arm,[11,12] thus 
guiding the intermediate to expose the appropriate face to the NADPH for B-type 
ketoreduction. In support of this hypothesis, this hydrogen-bonding interaction was 
observed between an aspartate homologous to the invariant aspartate of the LDD loop 
and the first pantetheinyl amide in a structure of a related enzyme, PhaB from Ralstonia 
eutropha H16.[32] As PksKR1 is a B-type KR, it possesses this conserved aspartate 
(D275). In contrast to PksKR1, the LDD loop region of PksKR2 appears to be expanded 
by approximately three residues (Figure 4.2D, Figure 4.3). Indeed, by sequence analysis, 
KRs associated with split bimodules are always A-type and typically appear to have 
about 3-4 additional residues in the LDD loop region in comparison to other KRs from 
trans-AT pathways (Figure 4.3). The residue M327 of PksKR2 roughly overlays with 
D275 of PksKR1 in PksKR2 suggesting the possibility that the combination of additional 
residues and the steric bulk of M327 positions this loop such that it precludes the facial 
orientation that leads to B-type ketoreduction in split bimodules. 
PksKR2 also possesses a conserved glutamine residue (Q383) three residues prior 
to the catalytic tyrosine, which appears roughly analogous to a conserved glutamine 
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residue observed in two solved cis AT A-type KRs (the second KR from the 
amphotericin PKS, AmpKR2 and the first KR from the phospholactomycin PKS, 
Plm1).[28,30] Mutagenesis and modeling studies with AmpKR2 suggest that this conserved 
glutamine residue interacts with the substrate, impacting stereocontrol.[28,33,34] Directly 
preceding the catalytic tyrosine is a new structured loop with an ordered hydrogen-
bonding network that appears to position both Y386 and Q383. This structured loop 
provides numerous hydrogen bonding interactions with the backbone carbonyls and 
appears to be dependent on an invariant proline that precedes the glutamine by 6 residues 
(P377 in PksKR2; Figure 4.2B, Figure 4.3). Of particular note, the backbone carbonyl of 
L379 (which is a highly conserved residue in split bimodule KRs; Figure 4.3) appears to 
play a critical role orienting Q383 in this hydrogen-bonding network. Thus, the 
conformation of Q383 is likely stabilized in such a way where it is primed to interact with 
the β-keto substrate, guiding the substrate to adopt the correct facial orientation for A-
type ketoreduction. Oddly, by inspection of the sequence alignment, the residues 
correlating to this ordered loop are absent in A-type KRs that are not harbored within 
split bimodules (Figure 4.3), further highlighting the evolutionary divergence. 
STEREOCHEMICAL ASSAY 
To further confirm the assignment of PksKR2 as an A-type KR, we incubated 
PksKR2 with a common substrate for KR activity assays (β-keto N-acetyl cysteamine 
thioester, 4.1) in the presence of an NADPH regeneration system (B. subtilis glucose 
dehydrogenase and glucose) and analyzed the products via chiral HPLC  (Figure 
4.4).[25,35] Although it is possible to observe results that are artifactual due to the truncated 
nature of N-acetyl cysteamine substrates,[36] typically the ketoreduction products of these 
analogs corroborate with the reduction observed on their natural substrates (this trend 
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appears to hold in particular with KRs that are found early in the pathway and naturally 
reduce smaller substrates such as PksKR2).[37] For comparison, identical ketoreduction 
assays were performed with two characterized cis-AT KRs: the first KR from the tylosin 
synthase (TylKR1), which has been shown generate the R stereoisomer (4.1A) with 100% 
ee on substrate 4.1, and the fifth KR from the mycolactone synthase (MycKR5), which 
has been shown to generate the S stereoisomer (4.1B) with 93% ee on substrate 4.1.[37]  In 
agreement with the bioinformatic identification of PksKR2 as an A-type KR, the major 
product of PksKR2 co-eluted with the major ketoreduction product of MycKR5, 
revealing its identity to be the S stereoisomer (1b), whereas the minor product of PksKR2 
co-eluted with TylKR1 revealing its identity to be the R stereoisomer (1a) (the ee for 
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Figure 4.4  Stereochemical characterization of PKSJKR2 with an N-acetyl cysteamine-
bound substrate analog. Red corresponds to the reduction of 4.1 by 
PKSJKR2, cyan to the reduction of 4.1 by TylKR1 (a B type KR), and 
magenta to the reduction of 4.1 by MycKR5 (an A type KR). 
BIOINFORMATIC ANALYSIS REVEALS SEQUENCE SIGNATURES OF SPLIT BIMODULE 
KRS 
In light of the unique structural features of PksKR2 compared to PksKR1 and 
previous cis-AT structures, we began a focused bioinformatic investigation to compare 
these novel features to KRs from other trans-AT pathways. An extended multiple 
sequence alignment revealed that these split bimodule KRs are well distributed across 
trans-AT systems, occurring in most of the better characterized pathways including 
difficidin, leinamycin, etnangien, the thailandamides, macrolactin, oxazolamycin, 
kirromycin, bongkrekic acid and pederin. The alignment also revealed that all A-type 
KRs fall into one of two distinct groups, with one is generally found in the context of 
canonical PKS module organization reminiscent of cis-AT pathways and the other almost 
always found in modules that are split or structurally anomalous in some other fashion. 
The traditional subclass of A-type KR shows a high degree of sequence similarity to B-
type trans-AT KRs (Figure 4.3), with the only clear distinguishing residue being the 
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previously mentioned diagnostic aspartate residue.[21–25]  Aside from this single residue, 
the consensus sequences of B type and the majority of A type KRs are essentially 
identical (Figure 4.3), rendering the sequence dissimilarity of split bimodule A type KRs 
all the more remarkable. 
Several of the deviations found in this unusual KR class are conserved enough at 
the sequence level to be diagnostically important. Included among these distinguishing 
elements is the ~15-residue insertion helix lying approximately 25 residues C-terminal to 
the NADPH binding motif with the consensus sequence LPPRxEW (in PksKR2, the 
insertion corresponds to residues L255-L271) (Figure 4.2A). Additionally, there is a 
diagnostic fingerprint that appears directly above the LDD loop region with consensus 
sequence [P,L]AF[L,I,V,A]RK (residues A331-K335 in PksKR2) (Figure 4.3). Also, the 
aforementioned nicotinamide-binding motif has a G to R substitution (Figure 4.2C, 
Figure 4.4) and although noted previously in the literature, it has not to our knowledge 
been associated with type A and type B split bimodules.[38]  
EXCEPTIONS: KRS HARBORING THESE MOTIFS THAT APPEAR OUTSIDE THE CONTEXT 
OF A SPLIT BIMODULE 
We uncovered no example of a type A or type B bimodule not containing a KR 
with these motifs as the penultimate domain (excluding ACPs) in the upstream protein. 
However, a few examples of KRs harboring these atypical motifs were found outside the 
context of type A and type B bimodules. The eighth KR from the oxazolomycin pathway 
(OzmKR8) contains the motifs detailed above, even though it falls within a canonical 
modular organization wherein the DH is present within the same polypeptide.[39] The 
second KR from the myxovirescin pathway (TAKR2) also possesses these motifs, despite 
being outside the context of a split bimodule. However, TAKR2 has an unusual modular 
organization as it appears C-terminal to an enoyl-CoA hydratase (ECH) and N-terminal 
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to a KS0, which are both domains associated with the isoprenoid-like β-branching 
activity.[2,40–42] However, the functions of these domains remain mysterious, as 
β-branching does not occur in TA_Mod2.[2,38,42] The second KR from the pederin pathway 
(PedKR2), also possesses the features described above and occurs C-terminal to an 
uncommon pyran synthase domain, which cyclizes the polyketide to form a pyran 
moiety.[43] In both of these cases, then, it is possible that the structural features of split 
bimodule KRs have been co-opted to mediate uncommon domain activities. The 
chivosazol PKS also harbors a KR with these unique features, outside of the context of a 
split bimodule (ChiKR14 in ChiF). However, it appears that ChiDH15 performs two 
dehydrations, dehydrating the hydroxyls installed by ChiKR14 and ChiKR15, yielding an 
 α,β-trans- γ,δ-cis-diene.[44] Given the presence of the sequence signatures in ChiKR14 
and the double dehydrating activity of ChiDH15, it is tempting to hypothesize that this 
ChiF bimodule may be a recent descendant from a type B split bimodule that evolved to 
merge the two polypeptides. 
PROTEIN-PROTEIN INTERACTIONS IN SPLIT BIMODULES 
Split modules necessitate inter-protein interactions to bridge the vertically 
adjacent polypeptides. Given the strict inclusion of these unprecedented KR features in 
both bimodule types, one hypothesis for their distinct structural and sequence features 
may be their involvement in protein-protein recognition. Since trans-AT systems lack the 
N- and C-terminal docking domains (NDD and CDD regions) that link adjacent PKS 
polypeptides in the cis-AT systems,[45–47] adjacent proteins must rely on inter-domain 
binding contacts as the sole mediators of synthase assembly. As the insertion helix 
sequence is a conserved element and contains several surface-exposed hydrophobic 
residues, we hypothesize that it may have a role in mediating protein-protein interactions.  
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One hypothesis is that the exposed helix may be involved in recruiting the DH from the 
next polypeptide. In type B bimodules, such an interaction would be necessary, as the DH 
is likely visited by the ACP from both the downstream and upstream polypeptides. In 
type A bimodules, it is unknown whether the DH performs the dehydration on the 
upstream or downstream ACP.  Regardless of the timing of the dehydration events, 
clearly these two bimodular organizations are evolutionarily related, and thus likely rely 
on similar inter-peptide interactions to ensure chain transfer to the next polypeptide. 
Notably, the structure of N-terminal DH from a type B bimodule from the difficidin PKS, 
Dif10 (unpublished results, Dr. Jia Zeng) reveals that N-terminal DHs from split 
bimodules are truncated relative to embedded DHs. This truncation exposes a 
hydrophobic region along the surface that is a plausible binding partner for the insertion 
helix. 
REASSIGNMENT OF INTERMEDIATES IN KNOWN PATHWAYS 
In our bioinformatic investigations we discovered an invariant pattern in type B 
bimodules with regard to the KR types present. In the first module of the bimodule, the 
KR is invariantly A-type and possesses the unique features associated with split bimodule 
A-type KRs. The KR of the second module always possesses the signature aspartate 
residue, indicative of B-type reduction. With the biosynthetic logic detailed earlier, the 
resultant dehydration products would be an  α,β-trans- γ,δ-cis-diene. Although the 
majority of annotated trans-AT metabolites and their corresponding intermediates are in 
agreement with this prediction,[2] there are a few examples for which the intermediates 
resulting from type B bimodules are annotated as having α,β-cis, γ,δ-cis or α,β-trans, 
γ,δ-trans intermediates. We believe that these cases wherein α,β-trans-γ,δ-cis are not 
annotated as such in the literature are likely the result of either misannotation, unstable 
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polyene structures, or the action of a downstream isomerase. For example, in both the 
difficidin and macrolactin pathways, there are intermediates arising from type B 
bimodules which are typically denoted in the literature as having  α,β-cis- γ,δ-cis-dienes 
(in difficidin, the type B bimodule is present between DifI and DifJ, and in macrolactin, 
the type B bimodule is present between MlnF and MlnH).[2,48–50]  
For each of these cases, inspection of the KR sequences harbored within the type 
B bimodule yielded the aforementioned pattern of an A-type KR with the distinctive 
sequence motifs detailed above followed by a B-type KR suggesting that the 
intermediates would have  α,β-trans- γ,δ-cis-diene geometries rather than the variant 
diene geometries denoted in the literature.[2]  The difficidin PKS presents an interesting 
case wherein a type B bimodule (between DifI and DifJ, modules 10 and 11) is 
immediately followed by a type A bimodule (between DifJ and DifK, module 12). DifK 
also harbors an unusual DH following the N-terminal DH of module 12, which currently 
has no annotated function (Figure 4.5A). Presumably, the double bond geometries 
assigned in the literature of difficidin intermediates in modules 10-12 are inferred from 
the geometry of the triene in the final metabolite. However, in addition to the 
bioinformatic discordance of a α,β-cis- γ,δ-cis-diene in the type B bimodule, the type A 
bimodule present between DifJ and DifK is annotated as a trans olefin (as mentioned 
previously, type A bimodules are believed to always generate cis olefins[2]). The disparity 
between the triene geometry present in the final metabolite and the preceding 
intermediate triene geometry can be explained by the presence the additional DH domain 
in DifK. Inspection of the sequence of the second consecutive DH of DifK revealed that 
in place of the active site aspartate, there is an asparagine. This aspartate to asparagine 
substitution is associated with isomerase activity: this sequence signature is found both in 
DH-like domains that have pyran synthase activity[43] as well as “shift” enoyl isomerases 
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which isomerize olefins from the α,β position to the β,δ position (Gay et al, 2014; 
Mouldenhauer, 2010; Kusebach et al, 2010). Thus the disparity between the final triene 
geometry in the metabolite and the bioinformatic predictions is explainable by this DH-
like isomerizing domain (Figure 4.5B). 
Macrolactin, at first inspection presents a similar case, in that the intermediates 
annotated as having α,β-cis, γ,δ-cis geometry,  along with the presence of an additional 
dehydratase present on the C-terminus of MlnF.[2] The C-terminal dehydratase also 
possesses the diagnostic aspartate to asparagine mutation. However, inspection of the 
final metabolite corroborates with the bioinformatic prediction of the diene geometries 
from a type B bimodule (α,β-trans- γ,δ-cis-diene), suggesting that the intermediate 
structure was misannotated in the literature (Figure 4.5C-D). Thus, it is possible that the 
additional dehydratase in this case is present for structural reasons, perhaps providing a 
bridging interaction with the N-terminal KR of the upstream polypeptide, rather than 
isomerase activity. Thus, in all three cases detailed above, it is likely that the diene 
geometry forms as α,β-trans- γ,δ-cis,  from the type B bimodule as opposed to the variant 
geometries shown in the literature (Figure 4.5). 
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Figure 4.5  A) Current assignment of intermediates in the difficidin pathway B) 
Reassignment of intermediates in the difficidin pathway using sequence 
motifs. 
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Figure 4.5  C) Current assignment of the macrolactin pathway D) Reassignment of the 
macrolactin pathway using sequence motifs. [2] 
In addition to the reassignment of PKS intermediates, our bioinformatic analysis 
of split bimodules revealed an example of reassigning the domain ordering of an entire 
PKS based on these new sequence elements. Specifically, our efforts uncovered a 
polypeptide from the basiliskamide PKS, a pathway reported by Cichewicz and 
coworkers from the genome of B. laterosporus strain PE36 isolated from a feral pig 
nostril. Chichewicz and co-workers’ proposed domain order appears to us to lack a DH 
domain in module one along with a product requiring 3 dehydrations when only 2 are 
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present (experimental section).  Due to the presence of the split module KR sequence 
motifs, and the presence of an active C-terminal KS and N-terminal DH, we believe it 
more likely that the basiliskamide PKS type B bimodule perform a double dehydration in 
its terminal module to account for all dehydrations observed in the final product. This 
would explain why there is one fewer DH than one would expect from the sequence-
structure colinear relationship, which was missed in the initial assignment of the 
biosynthetic pathway (experimental section). [51] 
GENOME MINING APPLICATIONS OF KR SEQUENCE SIGNATURES 
To test the predictive power of these KR sequence fingerprints and evaluate their 
prevalence within the bacterial kingdom, we performed a BLAST search using a 148 
consensus sequence spanning the C-terminal catalytic domain of the KR.  Several new 
protein sequences were returned from uncharacterized systems of under-studied bacteria 
including Brevibacillus laterosporus (PE36), Paenibacillus taiwanensis, and 
Salinibacillus aidingensis MSP4 (experimental section).  The sequences encoding these 
split bimodule KRs were obtained and submitted for analysis using the protein homology 
algorithm, antiSMASH.[52–54] The resulting predicted domain order of these orphan 
sequences was indicative of a modular structure consistent with either type A or type B 
bimodules, characterized by a C-terminal KS or KS0 and bridging N-terminal DH. Thus 
one might envision that the novel sequence features presented in this report might be 
useful diagnostic regions for software programs that aid in the identification of orphan 
gene clusters.  This may be particularly useful in the identification of the double 
dehydrations of type B bimodules, as such DH activity deviates from canonical PKS 
colinearity. 
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CONCLUSIONS AND OUTLOOK 
The recent crystallographic dissection of trans-AT PKSs has revealed a great deal 
about the complex, peculiar architecture seen at both the domain and modular level that 
further illustrates the divergent nature of these systems. The structure of PksKR2 contains 
several unprecedented structural elements and conserved sequence motifs that strongly 
correspond to the unique modular architectures of split bimodules.  The near invariant 
inclusion of these KR sequence and structural elements in split bimodules suggests a role 
in mediating the docking of adjacent PKS polypeptides (possibly to the upstream DH), a 
process that remains a lingering mystery for the trans-AT systems. Additionally, we 
suggest that the fingerprints presented herein will be useful in the characterization of PKS 
gene clusters and their corresponding metabolites. 
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Experimental Section for Chapter 4 
CLONGING, PROTEIN EXPRESSION, AND PURIFICATION 
The DNA encoding PKSKR2 (from pksJ, accession number NP_389598) was 
amplified from B. subtilis str. 168 gDNA with primers:  
5’-	   GCGGCCTGGTGCCGCGCGGCTCTAGCTCAGAAAGAGACAAAAAAGAACTG -3’ 
and  
5’-	   GTGGTGGTGGTGGTGGTGATGTTATCCATCACATTTGGAAACTTC-3’ (black 
corresponds to the annealing region, and red corresponds to the junction for ligation 
independent cloning) and cloned into expression plasmid pGAY28b.[1] The plasmid was 
then transformed into E. coli BL21(DE3). The cells were grown to an OD600 of 0.5 in 
Luria broth containing 50 mg/L kanamycin at 37 °C. The temperature was then dropped 
to 15 °C prior to inducing protein expression with 0.5 mM IPTG, and grown for an 
additional 16 hr. Cells were collected via centrifugation at 4,000 x g for 15 min, 
resuspended in lysis buffer (400 mM NaCl, 50 mM HEPES pH 7.5, 10% glycerol), and 
lysed by sonication. Cellular debris was removed by centrifugation at 30,000 x g for 30 
min and the cell lysate was then poured over Ni-NTA resin (Qiagen) pre-equilibrated 
with lysis buffer. Bound protein was washed in 40 ml of lysis buffer containing 15 mM 
imidazole and eluted with lysis buffer containing 150 mM imidazole. An equilibrated 
Superdex 200 gel filtration column was used to buffer exchange the protein solution into 
150 mM NaCl and 10 mM HEPES pH 7.5 and the protein was concentrated to 11 mg/mL 
prior to crystallization trials. 
KETOREDUCTASE STEREOCHEMICAL ASSAYS 
Ketoreduction assays were modified from a method described previously,[2,3] with 
5 mM substrate 3.1, 125 mM HEPES pH 7.5, 250 mM NaCl, 200 mM D-glucose, 10% 
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v/v glycerol, 200 μM NADP+, 1 μM glucose dehydrogenase (from B. subtilis), and 5 μM 
ketoreductase to a total volume of 500 μL The reactions were incubated overnight at 
room temperature (25 °C), extracted with ethyl acetate (3 x 500 μL) and dried in a 
speedvac. All samples were re-suspended in ethanol prior to chromatographic analysis. 
Chiral chromatography was performed with a ChiraCel OC-H column (250 x 4.6 mm) 
with a Beckman Coulter System Gold 126 pump and a System Gold 166 PDA detector 
equipped with a 20 μL loop. Absorbance was monitored at 235 nm. The solvent system 
used was 7% ethanol in hexanes (measured using volumetric flasks) at 0.8 mL/min. 
Substrate 3.1 was synthesized as described previously.[4] Enantiomeric excess was 
determined using peak area integrations. 
CRYSTALLIZATION AND STRUCTURE DETERMINATION 
Crystals of PksKR2 grew in 2 days by sitting drop vapor diffusion at 22 °C. 
Drops were formed by mixing 2 μL protein solution (9 mg/mL PksKR2, 150 mM NaCl, 
10 mM HEPES, pH 7.5) with 1 μL crystallization buffer (sodium citrate, 0.1 M HEPES 
pH 7.0). Crystals were frozen in liquid nitrogen after a 20-min soak in the crystallization 
buffer modified with 10% (v/v) ethylene glycol. Diffraction data, collected at ALS 
Beamline 5.0.3, were processed by HKL2000.[5] The structure was solved to 1.98 Å 
resolution by molecular replacement with PhaserMR[6] in the CCP4 suite,[7] using the 
KR1 monomer from the PksX synthase of B. subtilis (PDB code: 4J1Q)[3] as the search 
model. The model generated from the molecular replacement solution was used to 
iteratively build into the remaining electron density map with Coot[8] and was refined 
with Refmac5.[9] 
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Figure E4.1  Structural overlay of PKSJKR2 (red), PKSJKR1 (dark purple; pdb code 
4j1q), PlmKR1 (green; pdb code 4hxy), TylKR1 (light pink; pdb code 2fr1), 
EryKR1 (blue; 2z5L), and AmpKR2 (magenta; 3mjv). The insertion helix 
unique to A’ KRs is indicated by brackets. 
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Figure E4.2  Multiple Sequence Alignment of KR domains from split 
bimodules. SplitA and splitB indicates type A and type B bimodule KRs 
respectively.  A or B indicates A type or B type ketoreduction respectively.  Etn 
= etnangien PKS, Bat = batumin PKS, Bon = bongkrecic acid PKS, Pks = 
bacillaene PKS (B. subtilis), Bae = bacillaene PKS (B. amyloliquefaciens), Dif = 
difficidin PKS, Ozm = oxazolomycin PKS, Rhi = rhizoxin PKS,  Mln = 
macrolatin PKS, Lei = leinamycin PKS,  Ped = pederin PKS, TA = antibiotic TA 
PKS, Thal = thailandamide PKS, Kir = kirromycin PKS, Chi = chivosazol PKS, 
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Gura = Geobacter uraniumreducens polyketide PKS.  Sporo, atroph, latero, ehim 
& himasta represent uncharacterized synthases. 
Figure E4.3 Sequence LOGOS of catalytic subdomains show sequence dissimilarity 
between A’ KRs and all other trans-AT keteoreductases. Sequence logos for PksKR2’s A 
type subclass (A’), regular A type (A) and B type trans-AT KRs.  Logos comprise KR 
domains from the bacillaene, bongkrekic acid, chivosazol, difficidin, etnangien, 
oxazolomycin, rhizoxin and thailandamide synthases.  The asterisk indicates conserved 
aspartate fingerprint associated with B type reduction. 
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Figure E4.4  Orphan cluster from Salinibacillus aidingensis MSP4 (NCBI accession 
code: APIS01000007) anti-SMASH output.[10–12]  The KR present in 
ctg_1_131 is an A’ type KR. The KS present in ctg1_131 has sequence 
motifs indicating that it is condensation-incompetent (the HGTG motif is 
absent).[13] Taken together, this indicates that it is a type A bimodule (no 
double dehydration occurs). 
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Figure E4.5  Orphan cluster from Paenibacillus taiwanensis (NCBI accession code: 
KE384307) anti-SMASH output.  The KR present in ctg1_44 is an A’ KR 
type, and the KS present has sequence motifs indicating that it is 
condensation-competent (the HGTG motif is present).[13]  The KR in ctg 
1_45 is a B-type KR by sequence.  Taken together, this indicates that a type 
B bimodule is present, and that a double dehydration should be assigned to 
this module. 
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Figure E4.6 C) Anti-SMASH interpretation suggested by Chichewitz and co-workers, 











KS KS KS KS KS
KR
ER
MT KR MT KR DH KR KRDH















sation Mod 4b Mod 2,3,4a Mod 5 AT
Adenyl-
ation
Mod 1 Mod 2 Mod 3 Mod 4 Mod 5
Mod 1




Figure E4.6  Revised analysis of the anti-SMASH analysis of Brevibacillus laterosporus 
(NCBI accession code NZ_CAGD00000000) GI-9 type B bimodule (PKS genes: 
WP_035319071.1,WP_035319075.1,WP_035319073.1,WP_003344916.1), 
suggested by Chichewiz and coworkers[14] to be the putative biogenic origins of 
basiliskamides and B. D) Revised anti-SMASH interpretation based on the 
presence of the double dehydrating type B bimodule (highlighted in green).  
 
Corroborating our assignment is the presence of an A’ type KR in Mod 4, as well 
as a B-type KR in Mod5, suggesting cis followed by trans dehydration (Figure E4.6). 
The active KS of the split Mod5 is also diagnostic of a double-dehydrating type B 
bimodule. Additional features that we believe are supportive of our assignment are a) that 
the genes of the operon are not scrambled in terms of modular order, b) and DH activity 
from module 1 (which is necessary for ER activity) is missing in the previous 
assignment. Indeed, this pathway has three putative dehydrations, but only two DHs 
present, which is further evidence for a double dehydrating DH. Our assignment has a 
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couple features that are not accounted for: the final metabolites’ structures suggest a 
ketoreduction step in what would putatively occur module 2. We believe this is explained 
either via non-colinear action of KR3 (which is an A-type KR, consistent with the 
structure of the final metabolite), or by a downstream tailoring enzyme. Consistent with 
the latter hypothesis, an uncharacterized NADPH utilizing oxidoreductase appears in the 
cluster after the PKS. The other feature is that the double bond geometry deviates from 
the final metabolite, possibly also explained by downstream tailoring enzymes. 
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Chapter 5: Mechanically Modulating the Photophysical Properties of 
Fluorescent Proteins Using Mechanical Forcexi 
INTRODUCTION 
Polymer mechanochemistry[1–4] is a rapidly growing field of study wherein 
mechanical energy is harnessed to drive useful chemical transformations,[5–10] many of 
which are otherwise inaccessible. Apart from their fundamental interest, 
mechanochemical phenomena can be applied toward the development of novel stress-
sensing materials with the capacity to report damage quantitatively and qualitatively. 
Salient examples of mechanically facilitated transformations that have been exploited 
within such materials include the electrocyclic ring opening of spiropyran derivatives,[11–
13] formal [4+2] cycloreversions of anthracene derived Diels-Alder adducts,[14,15] and 
formal [2+2] cycloreversions of 1,2-dioxetanes.[16] Collectively, these systems report 
stress either through mechanochromism[11–13] or mechanoluminscence,[14,15] which enables 
quantification of mechanical damage using standard optical spectroscopies. 
Unfortunately, such stimulus responsive materials typically require tedious chemical 
syntheses; consequently, tuning their mechanochemical reactivity (e.g., through chemical 
diversification of mechanically labile scaffolds) can present a significant impediment to 
the development of new force-responsive sensors.  
   Recently, attention has been directed toward harnessing the biosynthetic 
machinery of living organisms to access mechanically sensitive biomolecules (i.e., 
                                                
xi Portions of this chapter were reproduced from: Brantley, J. N.; Bailey, C. B.; Cannon, J. R.; Clark, K. A.; 
Vanden Bout, D. A.; Brodbelt, J. S.; Keatinge-Clay, A. T.; Bielawski, C. W. Angew. Chem. Int. Ed. 2014, 
20, 5188. DOI: 10.1002/anie.201306988. JNB and CBB prepared and tested the protein composites. JRC 
and JSB performed the mass spectrometry studies. KAC and DAVB assisted with fluorescence microscopy. 
ATKC and CWB helped design and evaluate the experimental results. All authors contributed to the 
writing of the original text and figure preparation. The majority of the text was written by JNB, CBB, 
AKC, and CWB. 
 145  
 
“biomechanophores”).[18] While nature is replete with examples of force responsive 
systems,[20] there is a relative dearth of reports wherein biomolecules are used for 
mechanochemical applications. Indeed, although the modulation of enzymatic activity 
through mechanical stress has been reported,[18–21] few efforts have been directed toward 
developing biomechanophores that report mechanical stress through optical output. We 
envisioned that polymeric materials containing fluorescent proteins could serve as useful 
classes of stress-sensing biocomposites. Fluorescent proteins,[22] which are ubiquitous 
within the purview of the biochemical sciences, can be modified via site-selective 
mutagenesis[24] to precisely alter their structural and photophysical properties. 
Additionally, fluorescent proteins have been extensively optimized to achieve high 
stability and high levels of recombinant overexpression.  
The photophysical properties of the canonical fluorescent protein, green 
fluorescent protein (GFP), stem from a 4-(p-hydroxybenzylidene)imidazolidin-5-one 
chromophore located in the center of the protein's β-barrel structure.[22] Genetic mutations 
that alter the structure of the chromophore (as in the case of cyan fluorescent protein or 
blue fluorescent protein) or local residues that impact the stereoelectronic environment 
surrounding the chromophore (as in the case of yellow fluorescent protein) give rise to a 
vibrant array of proteins with unique emissive properties.[22] The fluorescence of all 
photoemissive protein variants is highly dependent on proper folding of the protein;[22,24,25] 
as such, mechanical perturbation of the β-barrel structure results in modulation of any 
associated photophysical properties.[26–28] Yellow fluorescent protein (YFP) is particularly 
attractive for use as a biomechanophore, as the yellow fluorescence results from a weak 
arene interaction between the chromophore and tyrosine 203 (mutated from threonine in 
the parent GFP).[25] Gruner and colleagues reported that pressurized crystals of the YFP 
variant, citrine, exhibited a gradual hypsochromic shift in fluorescence as the pressure 
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was increased from 0 to 360 MPa at low temperatures (77 K).[29,30] The fluorescence was 
subsequently found to bathochromically shift upon reducing the pressure and warming 
the crystals to 180 K. While this work clearly revealed the potential to develop YFP as a 
mechanosensor, there have been no reports to date wherein an analogous modulation of 
YFP fluorescence was harnessed for applications in mechanically responsive materials.  
In addition, surprisingly few efforts have been directed toward developing stress-sensing 
materials that employ fluorescent proteins. For example, Clark and colleagues utilized 
Förster resonance energy transfer (FRET) between YFP and cyan fluorescent protein 
(CFP) to develop stress reporting poly(acrylamide) composites.[30,32] Stretching these 
materials under uniaxial strain resulted in increased FRET interactions between YFP and 
CFP near micro-cracks that formed within the material, as determined by fluorescence 
confocal microscopy and fluorescence lifetime imaging (FLIM).[32] Bruns and colleagues 
more recently reported that eYFP could serve as a mechanically sensitive link between 
glass substrates and epoxy resins, where delamination of the resin resulted in 
denaturation of the protein and subsequent fluorescence quenching.[33] While these 
examples elegantly demonstrated that fluorescent proteins could be adapted for 
applications in stress reporting, there have been no reports showcasing diverse and 
tunable mechanochemical responses from biocomposite materials containing fluorescent 
proteins, which are features that are expected to be valuable for the design of precisely 
tailored force-sensing materials. Here, we report the facile preparation of biocomposite 
materials containing either: 1) an enhanced YFP (eYFP[34]) that exhibits shifts in λem 
under mechanical stress, or 2) a genetically modified GFP (GFPuv[35,36]) that exhibits 
fluorescence quenching under the action of mechanical force. 
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MECHANICAL ACTIVATION OF EYFP BIOCOMPOSITES 
As eYFP was predicted to exhibit greater mechanical sensitivity than GFPuv,[26] 
our initial efforts were directed toward the development of eYFP-containing 
biocomposites. We reasoned that embedding eYFP within a polymeric matrix and 
subjecting the resulting material to bulk compression would elicit the desired 
photophysical modulation, as local areas of high pressure generated during material 
compression could disrupt the arene interaction responsible for yellow fluorescence via 




Scheme 5.1 Schematic representations of proposed mechanical activations of 
fluorescent proteins. (A) Compression of composite materials containing 
eYFP distorts the arene interaction between the chromophore and 
tyrosine 203. (B) The incorporation of cysteine residues at strategic sites 
in GFPuv facilitates the covalent attachment of polymer chains to the 
protein; subsequent compression of the composite mechanically 
denatures GFPuv and quenches the protein’s fluorescence. 
To test the aforementioned hypothesis, we overexpressed hexahistidine-tagged 
eYFP in E. coli BL21 (DE3) and subsequently purified the isolated protein by nickel 
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affinity chromatography. As shown in Scheme 5.2, poly(methyl methacrylate) (PMMA) 
composites were prepared by adding eYFP (5.2) directly to a mixture of methyl 
methacrylate (A.2), azobisisobutyronitrile (AIBN, 5.3), and the plasticizer, 1-butyl-3-
methylimidazolium hexafluorophosphate (BMIM-PF6, 5.4), at 40 °C (see experimental 
section for additional details). The stability of eYFP under these relatively harsh 
conditions was remarkable, and the composite materials isolated following consumption 
of the free monomer exhibited strong fluorescence (λex = 485 nm; λem = 540 nm; Φ = 
0.64) and relatively uniform protein distribution. Although significant denaturation of 
eYFP was observed upon dissolution of the isolated biocomposites in tetrahydrofuran (as 
evidenced by fluorescence quenching), this obstacle to material processing was 
circumvented by cutting and polishing the composites to afford specimens with defined 
geometries. The BMIM-PF6 additive, which is known to serve as a highly effective 
plasticizer of acrylate derived polymers,[37] allowed precise modulation of the physical 
properties exhibited by the composites. Specifically, the addition of BMIM-PF6 enabled 
the glass transition (Tg) of PMMA to be reduced to approximately 40 °C (as determined 




Scheme 5.5 Synthesis of eYFP-containing biocomposites. General conditions: eYFP 
(5.1; 1.0 equiv), MMA (5.2; 2.6 x 105 equiv), AIBN (5.3; 1.3 x 103 
equiv), and BMIM-PF6 (5.4; 3.1 x 104 equiv) were combined in a single 
vessel under N2 and heated to 40 °C. 
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To test the mechanical sensitivity of our composite materials, a 50 mg sample was 
mounted in a hydraulic press and subjected to compression at incrementally increasing 
pressures (0 – 360 MPa) for periods of 45 s, after which time the solid state fluorescence 
was measured. As shown in Figure 5.1 (left), the λem of the sample gradually shifted from 
539 nm at 0 MPa to approximately 534 nm at 360 MPa (a hypsochromic shift 
commensurate with that previously reported by Gruner[30]). Frictional heating during 
compression appeared to contribute to the overall response of the material through 
thermal denaturation of the protein (as evidenced by a reduction in fluorescence intensity; 
see experimental section for additional details). Importantly, though, the observed change 
in λem correlated monotonically with the applied force and was, thus, consistent with a 
mechanical process.[1-4] Compressing the composites for 1 h did not cause their λem to 
shift beyond what was measured after compression for 45 s at the same pressure. 
Collectively, these data suggested to us that mechanical forces generated upon 
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Figure 5.1 (Left) Compression of PMMA composites containing eYFP caused the λem 
to gradually undergo a hypsochromic shift. Normalized fluorescence 
intensities are shown. (Right) The fluorescence maxima of the compressed 
PMMA composite containing eYFP plotted as a function of applied 
pressure. 
  MECHANICAL ACTIVATION OF GFPUV BIOCOMPOSITES 
Having established a straightforward preparation of ratiometric stress sensors, we 
sought to explore the mechanochromism of another fluorescent protein to realize an 
intensiometric stress reporter. Such reporters are particularly valuable because they 
exhibit changes in their optical properties as a function of applied load that facilitate rapid 
assessment of mechanical damage. As mechanical unfolding of GFP has previously been 
shown to quench the protein’s fluorescence,[26] efforts were directed toward expanding 
the results of these atomic force microscope (AFM) pulling experiments to bulk 
materials. While the mechanical response of eYFP presumably resulted from the 
distortion of a weak, local interaction, we reasoned that modulation of GFP’s 
photophysical properties would involve more global phenomena (i.e., complete 
denaturing of the protein); thus, we surmised that significantly higher forces would be 
required to mechanically denature the protein. As such, we hypothesized that GFP would 
need to be chemically cross-linked to the polymer matrix to sufficiently harness the 
mechanical forces generated during compression to achieve the desired fluorescence 
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quenching. Guided by the work of Dietz, Rief, and Lorimer,[26] which revealed that the N-
terminal β-sheet in GFP is mechanically labile, we concluded that polymeric appendages 
should be introduced on opposing sides of the aforementioned β-sheet in order to direct 
mechanical forces to this putative “Achilles’ heel” (i.e., the most mechanically labile 
structural element within the protein). The strategic incorporation of cysteine residues 
within the polypeptide backbone was predicted to facilitate the desired polymer ligation, 
as Bowman and Cramer have shown that thiyl radicals (which can be generated from 
thiols under free radical polymerization conditions) react efficiently with propagating 




Scheme 5.3 Synthesis of mechanically active GFPuv-containing biocomposites. 
General conditions: GFPuv(Y39C/D103C) (A.5; 1.0 equiv), MMA (A.2; 
2.6 x 105 equiv), and AIBN (A.3; 1.3 x 103 equiv) were combined in a 
single vessel under N2 and heated to 40 °C. 
Site-directed mutagenesis was performed to incorporate cysteine residues on 
opposing sides of the β-barrel (replacing tyrosine 39 and aspartate 103) in GFPuv, as the 
attachment of polymer chains at these sites could direct mechanical forces to the 
aforementioned β-sheet and induce mechanical denaturation (and, consequently, 
fluorescence quenching). GFPuv was selected due to its high stability in bacterial 
expression systems and its stronger fluorescence signal than wild-type GFP.[34,36] The 
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resultant hexahistidine-tagged GFPuv(Y39C/D103C) double mutant was overexpressed 
in E. coli BL21 (DE3) and purified by nickel affinity chromatography. As shown in 
Scheme 5.3, PMMA composites were prepared by polymerizing methyl methacrylate 
(5.2) in the presence of GFPuv(Y39C/D103C) (5.5; see experimental section for 
additional details). Gel-permeation chromatography (GPC) visualized with ultraviolet-
visible detection at 280 nm (a λmax of tyrosine) revealed that the resulting polymeric 
material displayed an increased absorbance at this wavelength relative to a PMMA 
homopolymer that was prepared in the absence of GFPuv(Y39C/D103C) at the same 
concentration (see experimental section for additional details). Moreover, mass 
spectrometry studies revealed that GFPuv(Y39C/D103C) was coupled to methyl 
methacrylate under the polymerization conditions, which confirmed that the cysteine 
residues were solvent exposed. Taken together, these results were consistent with the 
covalent attachment of GFPuv(Y39C/D103C) to the growing polymer chains during the 
preparation of the aforementioned composites. As shown in Figure 5.2, the solid state 
fluorescence of the composites (λem = 507 nm; λex = 420 nm) was in agreement with the 
successful incorporation of GFPuv(Y39C/D103C) into the polymeric matrix. 
Compression of these materials in a hydraulic press (41 MPa; 45 s) resulted in a 
significant reduction in fluorescence intensity (Figure 5.2A). Moreover, the fluorescence 
intensity was found to decrease monotonically with increasing pressure (0 – 41 MPa), 
which is a hallmark of mechanical phenomena (Figure 5.2A).[1-4] Compression of the 
materials for 1 h did not cause their fluorescence intensity to change beyond what was 
measured after 45 s at the same pressure. As such, these results suggested to us that 
mechanical forces were indeed denaturing the GFPuv(Y39C/D103C) upon compression 
of the composites (Scheme 5.1). 
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To further demonstrate the mechanical origin of the observed activity, we also 
explored the mechanophoricity of the Y39C and D103C single mutants, wherein only one 
attachment site was present on the surface of the protein. Presumably, these mutants 
would function in a manner analogous to semi-telechelic derivatives of chemical 
mechanophores (i.e., the mutants would not exhibit the same modulation in fluorescence 
as the Y39C/D103C double mutant).[1–4] Overexpression in E. coli and subsequent 
purification via nickel affinity chromatography afforded the desired semi-telechelic 
biomechanophores, which were subsequently added to the polymerization of poly(methyl 
methacrylate) as described above. As shown in Figure 5.2, compression of the resulting 
composites did not significantly alter their photophysical properties. Similarly, 
compression of composites containing unmodified GFPuv did not result in modulation of 
their associated photophysical properties, and mass spectrometry confirmed that GFPuv 
was not coupled to methyl methacrylate under the polymerization conditions (see 
Appendix D for additional details). Collectively, these data supported the conclusion that 
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Figure 5.2 (Top) Compressing PMMA composites (0 – 41 MPa) containing double 
mutant GFPuv(Y39C/D103C) resulted in a monotonic decrease in the 
fluorescence intensity of the material. The fluorescence intensities at λem = 
507 nm are plotted for clarity. (Bottom) Compression of PMMA composites 
containing GFPuv (left), GFPuv(Y39C) (center), or GFPuv(D103C) (right) 
did not significantly alter the fluorescence intensities of the materials. 
CONCLUSIONS 
In summary, we have demonstrated that mechanical forces may be used to 
modulate the photophysical properties of fluorescent proteins embedded within 
polymeric matrices. Our work constitutes the first example of modulating the λem of 
eYFP-containing polymer composite materials through the action of mechanical forces, 
as well as the first example of mechanically modulating the photophysical properties of 
GFPuv in a bulk material. Moreover, we have shown that mechanical perturbation of 
various fluorescent proteins alters their photophysical properties in distinct and tunable 
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manners (i.e., the reported systems exhibited either ratiometric or intensiometric 
responses to mechanical stress). The ability to precisely manipulate the optical output of 
composite materials containing biomechanophores through targeted mutations could 
afford new opportunities for the facile development of stress-responsive materials with 
tailored sensitivities. Moreover, we have demonstrated that single-molecule experiments 
can guide the rational design of biomechanophores, and insight garnered from 
mechanochemical studies involving chemical systems can be translated to those 
involving force-sensitive biomolecules. Indeed, the technical simplicity associated with 
preparing the mechanically responsive biocomposites described herein holds promise for 
their development and utility as new classes of force responsive materials. 
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Experimental Section for Chapter 5 
EXPERIMENTAL CONSIDERATIONS 
1-Butyl-3-methylimidazolium hexafluorophosphtae (BMIM-PF6) was prepared 
according to literature procedure.[1] All other reagents and materials were commercially 
available. Methyl methacrylate (MMA) was passed over a plug of basic alumina to 
remove any stabilizer prior to use. Azobisisobutyronitrile (AIBN) was recrystallized from 
acetone prior to use. Isopropyl β-D-1-thiogalactopyranoside (IPTG) and nickel-
nitrilotriacetic acid agarose (Ni-NTA) were used without further purification. GFPuv (A. 
victoria green fluorescent protein exhibiting the following mutations: Q24H, A76S, 
L79V, A83S, Q91R, F99S, Y100F, M141L, M153T, P105Q, V163A, K173E, and 
I219V) was expressed from plasmid pNGFP-BC[2] (generous gift of Prof. Eric Gouaux, 
Oregon Health Science University). eYFP (A. victoria green fluorescent protein with the 
following mutations: S61G, S68A, R86Q, S98F, T154M, A164V, T204Y, and K207A)3 
was expressed from plasmid pET21a (generous gift of Prof. Andrew Ellington, 
University of Texas at Austin). Mechanical tests were performed using a standard 
benchtop Carver hydraulic press. Dynamic mechanical analysis (DMA) was performed 
using a TA Instruments Q800 series DMA outfitted with a compression clamp. 
Differential scanning calorimetry (DSC) was performed using a Metler Toledo 823e DSC. 
Fluorescence spectra were acquired using a QuantaMaster Photon Technology 
International fluorometer. Gel permeation chromatography (GPC) was performed on a 
Viscotek GPCmax Solvent/Sample Module. Two fluorinated polystyrene columns 
(IMBHW-3078 and I-MBLMW-3078) were used in series and maintained at 24 °C. THF 
was used as the eluent at a flow rate of 1.0 mL min–1. Detection was performed using a 
Viscotek VE 3580 Refractive Index Detector or a Viscotek 2600 Photodiode Array 
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Detector (tuned at 370 nm). Molecular weight and dispersity data are reported relative to 
polystyrene standards. 
SITE DIRECTED MUTAGENESIS  
Site directed mutagenesis of GFPuv was performed using pNGFP-BC as a 
template according to the quickchange method. To prepare GFPuv(D103C), the 
following primers were used (altered sequences are bold and red):  
1) 5’-CGCACTATATCTTTCAAATGTGACGGGAACTACAAGACG-3’  
2) 5’-CGTCTTGTAGTTCCCGTCACATTTGAAAGATATAGTGCG-3’.  
The following primers were used to prepare GFPuv(Y39C):  
1) 5’-GAAGGTGATGCAACATGCGGAAAACTTACCCTT-3’  
2) 5’-AAGGGTAAGTTTTCCGCATGTTGCATCACCTTC-3’  
The GFPuv(Y39C/D103C) double mutant was generated using the GFPuv(Y39C) 
plasmid as a template and the above primers for GFPuv(D103C). All mutations were 
confirmed by DNA sequencing, and the mutants were expressed and purified using the 
same procedure as that described for the isolation of GFPuv (vide infra). 
PROTEIN EXPRESSION AND PURIFICATION  
Both GFPuv and eYFP were transformed into E. coli BL21 (DE3). Starter 
cultures (50 mL) were grown to inoculate pre-warmed Luria Broth supplemented with 50 
μg/mL ampicillin. When OD600 = 0.4, the media was cooled to 15 °C and induced with 
0.5 mM IPTG. After 16 h, the cells were harvested by centrifugation (3,000 relative 
centrifugal force for 20 minutes) and re-suspended in lysis buffer (10% glycerol v/v, 0.5 
M NaCl, 100 mM HEPES pH 7.5), sonicated, and centrifuged (30,000 relative centrifugal 
force for 45 minutes) to remove cellular debris. The lysate was passed over a Ni-NTA 
agarose column equilibrated with lysis buffer. The column was washed with lysis buffer 
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containing 15 mM imidazole and protein was eluted with lysis buffer containing 150 mM 
imidazole. GFPuv was further purified using a Superdex 200 column equilibrated in 10 
mM HEPES, pH 7.5, 150 mM NaCl. Final protein concentrations were determined using 
a Thermo Scientific Nanodrop 100 (absorbance at 280 nm). 
PROCEDURE FOR THE PREPARATION OF EYFP COMPOSITES  
An 8 mL Teflon capped vial was charged with a stir bar, eYFP (64 μL 9.4 mg mL-
1 solution in lysis buffer; 1.8 × 10-8 mmol), MMA (0.5 mL; 4.7 mmol), BMIM-PF6 (160 
mg; 0.56 mmol) and AIBN (4.0 mg; 2.4 × 10-2 mmol). The vial was purged with nitrogen, 
sealed, and heated at 40 °C for 19 h with vigorous stirring. The resulting polymeric 
material was removed from the vial, washed with acetone (5 mL) and dried under 
reduced pressure. Cuboidal specimens for mechanical testing were prepared by cutting 
approximately 50 mg samples from the bulk material and polishing with ultrafine sanding 
paper. 
REPRESENTATIVE PROCEDURE FOR THE PREPARATION OF GFP COMPOSITES: 
PREPARATION OF GFPUV(Y39C/D103C) COMPOSITES  
An 8 mL Teflon capped vial was charged with a stir bar, GFPuv(Y39C/D103C) 
(0.35 mL 1.7 mg mL-1 solution in lysis buffer; 1.8 x 10-8 mmol), MMA (0.5 mL; 4.7 
mmol), and AIBN (4.0 mg; 2.4 x 10-2 mmol). The vial was purged with nitrogen, sealed, 
and heated at 40 °C for 19 h with vigorous stirring. The resulting polymeric material was 
removed from the vial, washed with acetone (5 mL) and dried under reduce pressure. The 
resulting material was dissolved in tetrahydofuran (THF; 10 mg mL-1) and analyzed with 
gel-permeation chromatography (Figure E5.1). Cuboidal specimens for mechanical 
testing were prepared by cutting approximately 50 mg samples from the bulk material 
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and polishing with ultrafine sanding paper. GFPuv, GFPuv(Y39C), and GFPuv(D103C) 
composites were prepared using an analogous procedure. 
PREPARATION OF POLY(METHYL METHACRYLATE)  
An 8 mL Teflon capped vial was charged with a stir bar, methyl methacrylate 
(MMA) (0.5 mL; 4.7 mmol), ethylene glycol dimethyacrylate (44 μL; 2.3 × 10-1 mmol) 
and AIBN (4.0 mg; 2.4 × 10-2 mmol). The vial was purged with nitrogen, sealed, and 
heated at 40 °C for 19 h with vigorous stirring. The resulting polymeric material was 
removed from the vial, washed with acetone (5 mL) and dried under reduced pressure. 
The resulting material was dissolved in tetrahydofuran (THF; 10 mg mL-1) and analyzed 
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Figure E5.1 (A) Gel-permeation chromatograph of the GFPuv(Y39C/D103C) composite 
material (see section 1.5 for additional details). (B) Gel-permeation 
chromatograph of the GFPuv(Y39C/D103C) composite material visualized 
with ultraviolet-visible detection at 280 nm. (C) Gel-permeation 
chromatograph of poly(methyl methacrylate). (D) Gel-permeation 
chromatograph of poly(methyl methacrylate) visualized with ultraviolet-
visible detection at 280 nm. 
GENERAL PROCEDURE FOR MECHANICAL ACTIVATION OF EYFP COMPOSITES  
A 50 mg sample of the eYFP composite was cut from the bulk material (vide 
supra), and the fluorescence of the material was recorded. The sample was then 
compressed (30, 110, 180, or 360 MPa) in a Carver hydraulic benchtop press for 45 s. 
The pressure exerted on the sample was determined using the relationship P = FA-1, 
where F is the applied load, A is the cross-sectional area of the sample, and P is the 
applied pressure. As the Carver press employed two disk-shaped plates, the samples were 
found to compress into disks during the experimental studies. As such, A was 
approximated as the area of the disk following compression (DMA studies involving 
GFPuv composites validated this approximation; vide infra). Figure 5.1 in Chapter 5 
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shows representative fluorescence spectra (normalized) of the material compressed at 0, 
30,110, 180, and 360 MPa. Increasing the compression time to 1 h did not cause the λem 
of the material to shift beyond what was measured after compression for 45 s (see Figure 
E5.2). A decrease in fluorescence intensity, which was attributed to frictional denaturing 
(vide infra), was also observed (Figure E5.3 and Figure E5.4). 
 
 
Figure E5.2 Normalized fluorescence spectra of eYFP composite (black) following 
compression (110 MPa) for 45 s (red) and 1 h (blue). 
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Figure E5.3 Fluorescence spectra of an eYFP composite (black) following compression 
at 30 MPa (red), 110 MPa (blue), and 360 MPa (green).  
 
 
Figure E5.4  An eYFP-containing composite before (left) and after (right) compression at 
110 MPa.  
COMPRESSION OF LYOPHILIZED EYFP 
Lyophilized eYFP (0.6 mg; 1.8 × 10-8 mmol) was loaded onto a Carver benchtop 
press and subjected to compression (external load of 3000 psi) for 45 s. The solid-state 
fluorescence of the sample was recorded (Figure E5.5), and the reduction in fluorescence 
intensity was attributed to thermal denaturation through frictional heating (a phenomenon 
previously observed4 by Bruns et al.) 
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Figure E5.5 Fluorescence spectra of lyophilized eYFP (black) following compression 
(external load of 3000 psi; red). 
PREPARATION AND MECHANICAL ACTIVATION OF MIXED 
EYFP/GFPUV(Y39C/D103C) COMPOSITES 
A Teflon capped 8 mL vial was charged with eYFP (64 μL 9.4 mg mL-1 solution 
in lysis buffer; 1.8 × 10-5 mmol), GFPuv(Y39C/D103C) (0.24 mL 1.7 mg mL-1 solution in 
lysis buffer; 1.2 × 10-8 mmol), MMA (0.5 mL; 4.7 mmol), BMIM-PF6 (160 mg; 0.56 
mmol) and AIBN (4.0 mg; 2.4 × 10-2 mmol). The vial was purged with nitrogen, sealed, 
and heated at 40 °C for 19 h with vigorous stirring. The resulting polymeric material was 
removed from the vial, washed with acetone (5 mL) and dried under reduced pressure. A 
cuboidal specimen for mechanical testing was prepared by cutting an approximately 50 
mg sample from the bulk material and polishing with ultrafine sanding paper. The sample 
was then compressed at 30 MPa for 45 s. Figure E5.6 shows that the λem of eYFP was 
hypsochromically shifted following compression, whereas the λem of 
GFPuv(Y39C/D103C) did not shift following compression (the fluorescence intensity 
did, however, decrease). 
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Figure E5.6 Normalized fluorescence spectra of mixed eYFP/GFPuv(Y39C/D103C) 
composite (green) following compression (30 MPa; 45 s). Dashed blue lines 
are drawn from the λem associated with eYFP. A dashed black line is drawn 
from the λem associated with GFPuv(Y39C/D103C).  
GENERAL PROCEDURE FOR COMPRESSION OF GFP COMPOSITES 
A 50 mg sample of the GFP composite was cut from the bulk material (vide 
supra), and the fluorescence of the material was recorded. The sample was then 
compressed (21, 31, or 41 MPa) in a Carver hydraulic benchtop press for 45 s. The 
pressure exerted on the sample was determined using the relationship P = FA-1, where F 
is the applied load, A is the cross-sectional area of the sample, and P is the applied 
pressure. As the Carver press employed two disk-shaped plates, the samples were found 
to compress into disks during the experimental studies. As such, A was approximated as 
the area of the disk following compression. Figure 5.2 in Chapter 5 shows 
representative fluorescence spectra of the GFP materials following compression at 
various pressures (see also Figure E5.9). Increasing the compression time to 1 h did not 
cause the fluorescence intensity of the GFPuv(Y39C/D103C) material to decrease beyond 
what was measured after compression for 45 s at the same pressure (see Figure E5.7). 
Moreover, increasing the compression time to 1 h did not cause the fluorescence intensity 
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of the control materials (e.g., the GFPuv composite) to alter significantly from that 
measured following compression for 45 s at the same pressure (Figure E5.8). 
 
 
Figure E5.7 Fluorescence spectra of GFPuv(Y39C/D103C) composite (black) following 
compression (31 MPa) for 45 s (red) and 1 h (blue). 
 
 
Figure E5.8 Fluorescence spectra of GFPuv composite (black) following compression 
(31 MPa) for 45 s (red) and 1 h (blue). 
 




Figure E5.9 A GFPuv(Y39C/D103C)-containing composite before (left) and after (right) 
compression (external load of 7000 psi). 
REPRESENTATIVE PROCEDURE FOR DMA ANALYSIS OF GFPUV(Y39C/D103C) 
COMPOSITE  
A cuboidal specimen of the GFPuv(Y39C/D103C) composite (1.14 mm × 1.14 
mm × 0.72 mm) was mounted in a TA Instruments Q800 series DMA outfitted with a 
compression clamp and subjected to controlled force compression (pre-load force of 
0.001 N; force ramp rate of 1 N min-1). The applied stress and resultant material strain 
were recorded until a maximal stress of approximately 10.4 MPa was exerted on the 
sample (Figure E5.10). The fluorescence intensity of the material following DMA 
analysis was found to decrease relative to the fluorescence intensity of the material prior 
to DMA analysis (Figure E5.10). 
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Figure E5.10 Stress/strain curve for DMA analysis of GFPuv(Y39C/D103C) composite. 
Inset shows the fluorescence of the composite prior to (green) and following 
(red) DMA analysis. 
REPRESENTATIVE PROCEDURE FOR DMA ANALYSIS OF GFP CONTROL MATERIALS: 
DMA ANALYSIS OF GFPUV COMPOSITE.  
A cuboidal specimen of GFPuv composite (1.18 mm × 1.18 mm × 0.71 mm) was 
mounted in a TA Instruments Q800 series DMA outfitted with a compression clamp and 
subjected to controlled force compression (pre-load force of 0.001 N; force ramp rate of 1 
N min-1). The applied stress and resultant material strain were recorded until a maximal 
stress of approximately 10.4 MPa was exerted on the sample (Figure E5.11). The 
fluorescence intensities of the material prior to and following DMA analysis are shown in 
Figure E5.11. 
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Figure E5.11 Stress/strain curve for DMA analysis of GFPuv composite. Inset shows 
the fluorescence of the composite prior to (black) and following (red) DMA 
analysis. 
GFPUV MASS SPECTROMETRY STUDIES: GENERAL CONSIDERATIONS 
Proteins were infused into an Orbitrap Elite mass spectrometer (ThermoFisher, 
San Jose, CA) at 5 μL/min. Intact protein spectra were collected in positive mode and 
were a composite of 50 averaged scans acquired at maximum resolution (240,000 at m/z 
400). Neutral masses were then extrapolated using the Xtract algorithm (ThermoFisher, 
San Jose, CA) with a signal to noise ratio of 5:1. 
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PROCEDURE FOR EVALUATING THE REACTIVITY OF GFPUV(Y39C/D103C) WITH 
METHYL METHACRYLATE UNDER POLYMERIZATION CONDITIONS 
An 8 mL Teflon capped vial was charged with a stir bar, GFPuv(Y39C/D103C) 
(0.35 mL 1.7 mg mL-1 solution in lysis buffer; 1.8 × 10-8 mmol), MMA (0.5 mL; 4.7 
mmol), and AIBN (4.0 mg; 2.4 × 10-2 mmol). The vial was purged with nitrogen, sealed, 
and heated at 40 °C for 10 minutes with vigorous stirring. The vial was exposed to the 
ambient atmosphere, and the reaction mixture was subsequently desalted and buffer 
exchanged via 5 sequential exchanges using a 10 kDa molecular weight cutoff filter into 
LC-MS grade water. The resulting protein solution was diluted to 10 µM in 49/50/1 
water/acetonitrile/formic acid, and infused into an Orbitrap Elite mass spectrometer. As 
shown in Figure E5.12, both cysteine mutations were reactive with methyl methacrylate 
under these conditions. 
PROCEDURE FOR EVALUATING THE REACTIVITY OF GFPUV(Y39C/D103C) WITH 
METHYL METHACRYLATE IN THE ABSENCE OF RADICAL INITIATORS 
An 8 mL Teflon capped vial was charged with a stir bar, GFPuv(Y39C/D103C) 
(0.35 mL 1.7 mg mL-1 solution in lysis buffer; 1.8 × 10-8 mmol), and MMA (0.5 mL; 4.7 
mmol). The vial was purged with nitrogen, sealed, and heated at 40 °C for 10 minutes 
with vigorous stirring. The vial was exposed to the ambient atmosphere, and the reaction 
mixture was subsequently desalted and buffer exchanged via 5 sequential exchanges 
using a 10 kDa molecular weight cutoff filter into LC-MS grade water. The resulting 
protein solution was diluted to 10 μM in 49/50/1 water/acetonitrile/formic acid, and 
infused into an Orbitrap Elite mass spectrometer. As shown in Figure E5.12, both 
cysteine mutations were not reactive with methyl methacrylate under these conditions. 
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PROCEDURE FOR EVALUATING THE REACTIVITY OF GFPUV WITH METHYL 
METHACRYLATE UNDER POLYMERIZATION CONDITIONS 
An 8 mL Teflon capped vial was charged with a stir bar, GFPuv (0.14 mL 4.2 mg 
mL-1 solution in lysis buffer; 1.8 × 10-8 mmol), MMA (0.5 mL; 4.7 mmol), and AIBN 
(4.0 mg; 2.4 × 10-2 mmol). The vial was purged with nitrogen, sealed, and heated at 40 °C 
for 10 minutes with vigorous stirring. The vial was exposed to the ambient atmosphere, 
and the reaction mixture was subsequently desalted and buffer exchanged via 5 sequential 
exchanges using a 10 kDa molecular weight cutoff filter into LC-MS grade water. The 
resulting protein solution was diluted to 10µM in 49/50/1 water/acetonitrile/formic acid, 
and infused into an Orbitrap Elite mass spectrometer. Figure E5.12 shows that no change 




Figure E5.12 (a, b) Deconvoluted intact mass spectra of GFPuv (a) and 
GFPuv(Y39C/D103C) (b). The expected 72 Da mass shift associated with 
both mutations is observed. (c) Deconvoluted intact mass spectrum of 
GFPuv following reaction with methyl methacrylate in the presence of 
AIBN. (d) Deconvoluted intact mass spectrum of GFPuv(Y39C/D103C) 
following reaction with methyl methacrylate in the presence of AIBN. (e) 
Deconvoluted intact mass spectrum of GFPuv(Y39C/D103C) following 
reaction with methyl methacrylate in the absence of AIBN.  
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WIDE FIELD FLUORESCENCE MICROSCOPY GENERAL CONSIDERATIONS 
Fluorescence images were collected at room temperature using an upright 
microscope (Olympus BX60) with high-pressure mercury lamp excitation and a dichroic 
mirror (Olympus WB filter cube) combined with a digital camera (SPOT). The 
microscope objective lens used was a 5 X, 0.12 N.A., dry, CP-Achromat (Zeiss, 440920). 
All fluorescence images are false-colored (ImageJ thallium filter). 
PREPARATION OF GFPUV(Y39C/D103C) COMPOSITE FOR WIDE FIELD 
FLUORESCENCE MICROSCOPY ANALYSIS 
An 8 mL Teflon capped vial was charged with a stir bar, GFPuv(Y39C/D103C) 
(0.35 mL 1.7 mg mL-1 solution in lysis buffer; 1.8 × 10-8 mmol), MMA (0.5 mL; 4.7 
mmol), and AIBN (4.0 mg; 2.4 × 10-2 mmol). The vial was purged with nitrogen, sealed, 
and heated at 40 °C for 19 h with vigorous stirring. The resulting polymeric material was 
removed from the vial, washed with acetone (5 mL) and dried under reduced pressure. A 
cuboidal specimen was prepared by cutting an approximately 50 mg sample from the 
bulk material and polishing with ultrafine sanding paper. The specimen was mounted into 
a Carver benchtop hydraulic press, and a square plate (2.41 mm × 2.41 mm) was 
compressed into the material. The area of the plate and the applied load were used to 
calculate the pressure exerted on the sample (approximately 10.3 MPa). The sample was 
then analyzed using a wide field fluorescence microscope, which revealed decreased 
fluorescence intensity in the compressed area relative to the uncompressed material 
(Figure 5E.13).  
PREPARATION OF GFPUV COMPOSITE FOR WIDE FIELD FLUORESCENCE MICROSCOPY 
ANALYSIS 
An 8 mL Teflon capped vial was charged with a stir bar, GFPuv (0.14 mL 4.2 mg 
mL-1 solution in lysis buffer; 1.8 × 10-8 mmol), MMA (0.5 mL; 4.7 mmol), and AIBN 
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(4.0 mg; 2.4 × 10-2 mmol). The vial was purged with nitrogen, sealed, and heated at 40 °C 
for 19 h with vigorous stirring. The resulting polymeric material was removed from the 
vial, washed with acetone (5 mL) and dried under reduced pressure. A cuboidal specimen 
was prepared by cutting an approximately 50 mg sample from the bulk material and 
polishing with ultrafine sanding paper. The specimen was mounted into a Carver 
benchtop hydraulic press, and a square plate (2.41 mm × 2.41 mm) was compressed into 
the material. The area of the plate and the applied load were used to calculate the pressure 
exerted on the sample (approximately 10.3 MPa). The sample was then analyzed using a 
wide field fluorescence microscope, which revealed negligible changes in the 
fluorescence intensity in the compressed area relative to the uncompressed material 




Figure E5.13 Wide field fluorescence micrograph of GFPuv(Y39C/D103C) composite 
following compression. The yellow dashed line outlines the edge of the 
square compression site (see text for additional details). 




Figure E5.14 Wide field fluorescence micrograph of GFPuv composite following 
compression. The yellow dashed line outlines the edge of the square 
compression site (see text for additional details). 
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Chapter 6:  Conclusions and Outlook 
This dissertation presents a few incremental advances in deciphering enzymatic 
mechanisms, understanding the collaborative actions of the various domains within a 
module in in vitro environments, and structural dissection that contribute to the ultimate 
goal of realizing the biocatalytic potential of PKSs. For PKSs to be a useful and rationally 
reprogrammable platform for synthetic biology and biocatalysis, several enzymatic 
features must be understood.  First, we must understand how the domains work at a 
mechanistic level, and how to reprogram their selectivities (e.g. changing the AT’s 
extender unit selectivity as was described in Chapter 1, or changing the stereocontrol 
that the KR confers, as was experimentally demonstrated in Chapter 3). Second, we 
must understand the downstream effects of such structural changes in terms of the 
interacting kinetics and selectivities of the various domains.  In Chapter 2, a platform 
that examines a miniaturized system—a ModTE construct—evaluates how the various 
domains within a module interact in unnatural environments.  Finally, we must 
understand bridging protein-protein interactions that facilitate chain transfer and afford 
different gene products to operate in concert with one another.  Chapter 4 illuminates 
one of these potential protein-protein interactions in a relatively uncharacterized class of 
polyketide synthases, the trans-AT PKSs. 
Polyketide synthases have potential for developing of facile strategies to generate 
chiral building blocks. ModTE systems like the one described in Chapter 2 have the 
potential to generate libraries of stereoisomeric products such as the triketide lactones 
highlighted in Chapter 1. Chapter 2 explores a robust platform to generate one of these 
triketide lactones.  In the future, steps will be taken to optimize the biocatalytic scheme 
including exploring the use of promiscuous acyl-CoA ligases as well as directed 
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evolution approaches to attenuate the thioesterase activity towards diketide substrates to 
improve yields. Furthermore, other ModTE systems that have 1) different selectivities for 
the stereoisomeric configurations of the starter units and 2) different KR types harbored 
within the module will be explored to build a library of stereoisomeric chiral building 
blocks (as was described in Chapter 1). Additionally, the substrate scope of ModTE 
systems needs to be further elucidated, including exploring the incorporation of synthetic 
handles such as terminal olefins, terminal alkynes, halides, or azides. This has been 
explored somewhat by the Keatinge-Clay laboratory to develop of chemical biology 
tools. One such study explored the use of triflouromethyl groups as a 19F probe to detect 
reactions performed in cell lysate.[1] A second explored the use of terminal alkynes for 
use in attaching a fluorescent tag via CuAAC, which resulted in the detection of minor 
PKS products from a ModTE platform.[2] In the future, however, we hope to use this 
demonstrated substrate promiscuity to incorporate synthetic handles to construct 
complex, polyketide scaffolds. Future studies will include collaborations with total 
synthesis groups to demonstrate that concise, chemoenzymatic syntheses can be realized 
with these chiral building blocks. 
In addition to their role in generating chiral building blocks, although this was not 
our intention when we embarked upon this project, the ModTE system described in 
Chapter 2 has received some notice from the “cell free” biocatalysis/synthetic biology 
community.[3,4] The triketide lactones described in Chapter 2 generated through the 
multi-enzyme cascades (utilizing MatB, the KR, the GDH-based cofactor-recycling 
scheme in addition to the multi-domain Mod6TE protein) presents one of the early 
examples forming complex small molecules from cell lysate.  The goals of the “cell free” 
biocatalysis/synthetic biology movement are to generate the most minimal systems 
required to generate molecules of interest through biological methods. Thus, this work 
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presents incremental advancements in terms of the molecular complexity that can be 
generated outside of the context of a cell. Perhaps this work will assist in the 
development of cell free “chassis” platforms to enable powerful transformations in 
synthetic biology in the future. 
In Chapter 3, a number of insights regarding the intrinsic reactivities of 
polyketide synthase ketoreductases were obtained.  Most notably, that the energetic 
default pathway for PKS KRs is the one that forms the A2 stereoisomer, which is 
partially explained by the Felkin-Anh model to rationalize the intrinsic preference for anti 
diastereoselectivity. Interestingly, we demonstrate that polar “orienting” interactions from 
hydrogen bonding residues play a small role in enforcing KR stereocontrol.  Indeed, with 
truncated mimics, the KRs are very much acting as loosely bound catalysts that aid 
asymmetric induction. With that insight, then, there are a lot of potential future directions 
to improve the utility of KRs as biocatalysts, as well as engineer specific enzymatic 
outcomes. Because the energetic differences are small, it appears that drastic differences 
in stereochemical outcome can be achieved by a very constrained set of residues that 
surround the active site and comprise the active site stereoelectronic environment. 
These weak binding interactions in KRs may seem like a shortcoming in terms of 
their power as biocatalysts, but in reality there is an element of engineerability in weak 
non-covalent interactions, as minor structural changes can be harnessed to effect large 
changes. A saturation mutagenesis approach would likely be fruitful in terms of 
designing specific mutants that are active and stereocontrolled when reducing specific 
substrates. Moreover, the quantitative structure-activity relationships and “Big Data” 
approaches harnessed effectively by the group of Matthew Sigman at University of Utah 
could be a powerful way to explore engineering KRs. Indeed, the robust chemical models 
of carbonyl nucleophilic attack, the small substrates (resulting in the ability to use 
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computational chemistry to determine chemical parameters), and the stereochemical 
distribution of products (which correlates to ΔΔG‡) taken together render PKS KRs an 
ideal system to translate this approach to a biological system. While the “big data” 
approach has been successful in providing useful predictive information that affords the 
rational design of catalysts for assymetric transformations in chemical systems, it has yet 
to be applied to an enzymatic system.[5,6] Perhaps these approaches in the future will 
afford the ability to design mutant enzymes to selectively reduce a broad range of desired 
substrates in a stereocontrolled fashion. 
In Chapter 4, a domain from a trans-acyltransferase PKS is investigated 
structurally, functionally, and bioinformatically. Trans-AT PKSs have remained elusive 
due to their more recent identification and biochemical investigation as well as their truly 
bizarre modular organizations. One of the organizations, termed “split bimodules” by 
Piel, is a paradigm of the unusual biosynthetic strategies found in trans-AT PKSs.[7] Our 
structural characterization has revealed some potential clues regarding how these unusual 
modules assemble.  Notably, new helical regions and sequence truncations are revealed 
through structural characterization and examination of sequence trends. Future functional 
experiments need to be explored to examine the fundamental reactivity of some of the 
strange biosynthetic strategies described in Chapter 4. To further explore the 
mechanistic details of split bimodules, one approach might be performing alanine 
scanning along the new helical region of the A’ KRs, or deleting this helical region 
entirely and then determining if there is a buildup of intermediates on one or both ACPs 
via mass spectrometry. Also, deuterium-labeling experiments, elucidating the exact 
nature of the double dehydration, might be informative.  
In Chapter 5, an additional project unrelated to the main work of this dissertation 
is described. This project explores the use of mechanical force in the context of biological 
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systems through using fluorescent proteins as reporter molecules. In the case of a green 
fluorescent protein, a ratiometric response was observed, whereas in the case of yellow 
fluorescent protein an intensiometric response was observed. Work that has built on our 
findings from Jierry and coworkers has established that similar responses can be observed 
with much weaker mechanical compressions than those reported by us.[8] Additionally, 
Jierry and coworkers developed a reversible system building on the work presented in our 
irreversible system. Thus, the work described in this dissertation demonstrates a key 
example of harnessing alternate reactivity pathways in biological systems. 
In summary, this dissertation demonstrates that PKS domains can be harnessed to 
effect chemical complex transformations. As we continue to decipher the mechanistic 
details of these systems, polyketide synthases will certainly become a more powerful 
platform for applications synthetic biology and biocatalysis. 
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